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Résumé 
Nous avons utilisé une approche ethnobotanique pour identifier des espèces 
de plantes utilisées par les Cris afin de traiter les symptômes du diabète de type 2. 
Larix laricina du Roi (L. laricina) a récemment été identifiée comme une des 
meilleures plantes qui a stimulé le transport de glucose dans les cellules C2C12 et 
fortement potentialisé la différenciation des 3T3-L1 en indiquant une sensibilité 
potentiellement accrue à l’insuline. Ensuite, ces études de criblage ont été effectuées 
sur des extraits éthanolique (EE) en utilisant une série de bioessais in vitro. 
Cependant, les préparations traditionnelles des plantes sont souvent faites avec l’eau 
chaude. Le but de cette thèse de doctorat était d’isoler les principes actifs de L. 
laricina par un fractionnement guidé par l’adipogenèse; d’évaluer et de comparer 
l’activité et les mécanismes  antidiabétiques des EE et des extraits aqueux (HWE) de 
ces 17 plantes. 
Pour le fractionnement de L. laricina, on a isolé plusieurs composés connus et  
identifié un nouveau composé actif  cycloartane triterpene, qui a amélioré fortement 
l’adipogenèse et a été responsable en partie de l’activité adipogénique 
(potentiellement similaire à l’effet sensibilisateur à l’insuline des glitazone) de 
l’extrait éthanolique issu de l’écorce de L. laricina. 
Pour le métabolisme lipidique, nos résultats ont confirmé que 10 parmi les 17 
EE ont augmenté la différenciation des adipocytes alors que 2 extraits seulement 
l’ont inhibée. Les HWE ont montré une faible activité adipogénique ou 
antiadipogénique. Les EE de R. groenlandicum et K. angustifolia ont le PPAR γ 
(peroxisome proliferator-activated receptor γ), le SREBP-1 (sterol regulatory element 
binding protein-1) et le C/EBP (CCAAT-enhancer binding proteins) α, alors que ceux 
de P. balsamifera et A. incana les ont inhibés. L’effet inhibiteur de P. balsamifera a 
également été prouvé d’avoir impliqué l’activation de la protéine kinase activée par 
l’AMP (AMPK). Les EE et HWE de R. groenlandicum ont stimulé les mêmes 
facteurs de transcription alors que les extraits aqueux d’autres plantes sélectionnées 
ont perdu ces effets en comparaison avec leurs extraits éthanoliques respectifs. 
L’analyse phytochimique a également identifié le groupe des espèces actives et 
inactives, notamment lorsque les espèces ont été séparées par famille de plante. 
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Finalement concernant l’homéostasie de glucose, nos résultats ont confirmé 
que plusieurs EE ont stimulé le transport de glucose musculaire et inhibé l’activité de 
la glucose-6-phosphatase (G6Pase) hépatique. Certains des HWE ont partiellement 
ou complètement perdu ces activités antidiabétiques par rapport aux EE, tandis 
qu’une seule plante (R.groenlandicum) a juste conservé un potentiel similaire entre 
les EE et HWE dans les deux essais. Dans les cellules musculaires, les EE de 
R.groenlandicum, A. incana et S. purpurea ont stimulé le transport de glucose en 
activant la voie de signalisation de l’AMPK et en augmentant le niveau d’expression 
des GLUT4. En comparaison avec les EE, les HWE de R.groenlandicum ont montré 
des activités similaires; les HWE de A. incana ont complètement perdu leur effet sur 
tous les paramètres étudiés; les HWE de S. purpurea ont activé la voie de l’insuline 
au lieu de celle de l’AMPK pour augmenter le transport de glucose. Dans les cellules 
H4IIE, les EE et HWE des 5 plantes ont activé la voie de l’AMPK, et en plus les EE 
et HWE de 2 plantes ont activé la voie de l’insuline.  La quercétine-3-O-galactoside 
et la quercétine 3-O-α-L-arabinopyranoside ont été identifiées comme  des composés 
ayant un fort potentiel  antidiabétique et donc responsables de l'activité biologique 
des plantes HWE actifs avec le transport du glucose. 
En conclusion, on a isolé plusieurs composés connus et identifié un nouveau 
triterpène actif à partir du fractionnement de L. laricina. Nous avons fourni 
également une preuve directe pour l'évaluation et la comparaison d'une action 
analogue à l'insuline ou insulino-sensibilisateur des EE et HWE de plantes 
médicinales Cris au niveau de muscle, de foie et de tissus adipeux. Une partie de leur 
action peut être liée à la stimulation des voies de signalisation intracellulaire insulino-
dépendante et non-insulino-dépendante, ainsi que l’activation de PPARγ. Nos 
résultats indiquent que les espèces de plantes, les tissus ou les cellules cibles, ainsi 
que les méthodes d'extraction sont tous des déterminants significatifs de l'activité 
biologique de plantes médicinales Cris sur le métabolisme glucidique et lipidique. 
Mots-clés: Le diabète de type 2, l'AMPK, l’Akt, le PPAR γ, le SREBP-1, le C / EBP 
α, la G6Pase, la médecine traditionnelle, l'homéostasie du lipidique et du glucose.  
  
v 
Abstract 
We have used a collaborative ethnobotanical approach to identify plant 
species used by the Cree of Eeyou Istchee (CEI) to treat symptoms of type 2 diabetes. 
Several screening studies were performed on 17 species identified in a survey of the 
Cree Nation. Firstly, Larix laricina du Roi (L. laricina) was recently identified as one 
of the top plants, which stimulated glucose uptake in C2C12 muscle cells and 
strongly potentiated the differentiation of 3T3-L1 pre-adipocytes suggesting 
enhanced insulin sensitivity. Secondly, these screening studies were performed on 
ethanol extracts (EE) using an in vitro bioassay platform, however, traditional 
preparations are often based on hot water. So the purpose of this PhD thesis was to 
isolate the active principles from L. laricina through adipogenesis-guided 
fractionation, and to evaluate and compare the antidiabetic activity and mechanisms 
of EE and hot water extracts (HWE) of these 17 Cree plants. 
For the fractionation of L. laricina, we isolated several known compounds and 
identified a new active cycloartane triterpene, which strongly enhanced adipogenesis 
in 3T3-L1 cells and was responsible partly for the adipogenic (potentially glitazone-
like insulin sensitizing) activity of the ethanol extract of the bark of L. laricina. 
In the adipocyte lipid metabolism course, the results confirmed that 10 of the 
17 EE stimulated adipocyte differentiation and adipogenesis, whereas 2 had 
inhibitory effects. Corresponding HWE exhibited partial or complete loss of such 
adipogenic or anti-adipogenic activity. R. groenlandicum and K. angustifolia EEs 
activated Peroxisome proliferator-activated receptor γ (PPAR γ), sterol regulatory 
element binding protein-1 (SREBP-1) and CCAAT-enhancer binding protein 
(C/EBP) α, whereas P. balsamifera and A. incana decreased these transcription 
factors. P. balsamifera’s inhibitory effect was also found to involve AMP-activated 
protein kinase (AMPK) activation. R. groenlandicum HWE and EE stimulated 
similar transcription factors, but HWE of other selected plants lost such effects 
compared to their respective EE. Phytochemical analysis also uncovered clustering of 
active versus inactive species, notably when species were segregated by plant family. 
The results showed that several EE stimulated muscle glucose uptake and 
inhibited hepatic glucose-6-phosphatase (G6Pase) activity. Some of the HWE 
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partially or completely lost these antidiabetic activities in comparison to EE; while 
one plant (R.groenlandicum) retained similar potential between EE and HWE in both 
assays. In C2C12 muscle cells, EE of R.groenlandicum, A. incana and S. purpurea 
stimulated glucose uptake by activating AMPK pathway and increasing GLUT4 
expression level. In comparison to EE, HWE of R.groenlandicum exhibited similar 
activities; HWE of A. incana completely lost its effect on all parameters; 
interestingly, HWE of S. purpurea activated insulin pathway instead of AMPK 
pathway to increase glucose uptake. In the H4IIE cells, all selected 5 plants HWE 
and EE activated AMPK pathway, and in addition, 2 plants EE and HWE also 
activated insulin pathways. Quercetin-3-O-galactoside and quercetin 3-O-α-L-
arabinopyranoside were identified as potential candidates to be responsible for the 
biological activity of the active HWE plants in the glucose transport assay. 
In conclusion, we isolated several known compounds and identified a new 
active triterpene from fractionation of L. laricina. We also provide direct evidence 
evaluating and comparing of an insulin-like or insulin-sensitizing action of EE and 
HWE of Cree medicinal plants at the level of muscle, liver and adipose tissue. Part of 
their actions may be related to stimulation of insulin-dependent and insulin-
independent intracellular signaling pathways, as well as to PPARγ activation. The 
results indicate that plant species, target tissues or cells, as well as extraction 
methods, are all significant determinants of the biological activity of Cree medicinal 
plants on glucose and lipid metabolism.  
 
Keywords:  
type 2 diabetes, AMPK, Akt, PPAR γ, SREBP-1, C/EBP α, G6Pase, traditional 
medicine, lipid  and glucose homeostasis, 
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1.Introduction 
Type 2 diabetes (T2D) is a growing global health problem. A significant 
increase in prevalence is expected from 171 million people affected in 2000 to a 
possible 366 million in 2030 (Wild et al., 2004). According to WHO, 347 million 
people worldwide now have diabetes, and an estimated 3.4 million people died from 
consequences of hyperglycemia in 2004 (WHO, 2011). 
 The prevalence of T2D is especially high among some Canadian First 
Nations (Ayach and Korda, 2010). The age-adjusted prevalence of disease in Cree of 
Eeyou Istchee (CEI) of northern Quebec reached 29% in 2009 or 3 to 5 times higher 
compared with the rest of the Canadian population (Kuzmina et al., 2010 ). And the 
their rate of diabetic complications is also disproportional to the rate of diabetes 
(Young et al., 2000).  
This serous problem is most likely caused by factors such as sedentary 
lifestyle and non-traditional diet (Hegele, 2001), and a genetic predisposition towards 
obesity (Neel, 1999; Skyler, 2004). The difficulty to comply with modern medical 
treatment also contributes (Young et al., 2000). Therefore, new strategies are needed 
to address this specialized issue and to provide culturally acceptable alternative 
medicines (Brassard et al., 1993). 
We have used a collaborative community-based ethnobotanical approach to 
identify several plant species, which are used by the Cree for treating a variety of 
symptoms of diabetes (Leduc et al., 2006). Several screening studies were performed 
on 17 species identified in a survey of the Cree Nation (Harbilas et al., 2009; Harris 
et al., 2011b; Nachar et al., 2013; Nistor Baldea et al., 2010; Spoor et al., 2006). 
Firstly, Larix laricina Du Roi (K.Koch) (L. laricina) was recently identified as one of 
the top plants, which stimulated glucose uptake in C2C12 muscle cells and strongly 
potentiated the differentiation of 3T3-L1 pre-adipocytes indicating potentially 
enhanced insulin sensitivity (Spoor et al., 2006). Secondly, the screening studies for 
these 17 plants were performed on ethanol extracts (EE) using an in vitro bioassay 
platform, however, traditional preparations are often based on hot water.  
So the purpose of this PhD thesis was to isolate the active principles from L. 
laricina through adipogenesis-guided fractionation; to evaluate and compare the 
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antidiabetic activity and mechanisms of action of ethanol and hot water extracts of 
the 17 Cree plants, as well as to analyze the metabolites in these plants based on their 
activity. 
 
1.1 Energy homeostasis 
The main goal of the metabolic processes is to provide the required and 
proper amounts of energy to the body. Overall, there are two groups of metabolic 
processes: energy consuming or anabolic (gluconeogenesis, glycogenesis, 
lipogenesis, protein synthesis) and energy producing or catabolic (glycolysis, 
glycogenolysis, lipolysis, proteolysis) metabolisms. When energy is needed, it can be 
derived from the oxidation or breakdown of fat, protein or carbohydrates. When there 
is extra energy, the body can store carbohydrate in the form of glycogen and fat in the 
form of triglycerides (TGs).  
 
1.2 Glucose homeostasis 
Glucose is a monosaccharide and is the primary energy source, enabling the 
generation of adenosine triphosphate (ATP) following glycolysis. Although most 
tissues can also use fats and protein as an energy source, the brain mainly only use 
glucose (ketone bodies (Owen et al., 1967) provides a major alternative source during 
fasting).  
The low blood concentrations of glucose (hypoglycemia) can causes seizures, 
loss of consciousness, and death; while long lasting high blood glucose levels 
(hyperglycemia), can result in blindness, renal failure, and vascular disease. 
Therefore, blood glucose needs to be maintained within a narrow range and this 
process for maintaining stable blood glucose is called glucose homeostasis.  
There are several metabolisms for glucose homeostasis, including glycolysis 
(oxidation of glucose into ATP and energy); gluconeogenesis (endogenous glucose 
production in the liver and kidney); glycogenesis (the conversion of excess glucose 
into glycogen as storage energy); and glycogenolysis (the breakdown of glycogen 
and another supply of glucose besides gluconeogenesis).  
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The body can adjust blood glucose levels by a variety of cellular mechanisms, 
such as insulin and glucagon. When glucose levels increasing, insulin is released 
from pancreatic β cells in the islets of Langerhans to the blood. Then insulin could 
stimulate the uptake of glucose, and also promote storage in the body, especially in 
the liver, as glycogen (glycogenesis). Glucose transporters facilitate the uptake of 
glucose across the cell membrane into cells.  
In contrast, low glucose levels could stimulate the secretion of glucagon from 
pancreatic α cells. To increase the blood glucose, glucagon promotes the conversion 
of glycogen (the storage form of glucose in the liver) to glucose (glycogenolysis). 
Epinephrine also causes the release of glucose into the blood (Sherwin and Sacca, 
1984) when the sympathetic nervous system is activated. Glucose can also be 
generated from non-carbohydrate precursors including pyruvate and glycerol, by 
gluconeogenesis.  
 
1.2.1 Glucose transporters 
Because the lipid bilayer of the plasma membrane is impermeable to polar 
molecules, glucose is transported across the plasma membrane by glucose 
transporters. There are two different types of transporter proteins, sodium dependent 
glucose co-transporter (SGLT) and the facilitative glucose transporters (GLUT) 
(Mueckler, 1992).  
Both types of transporters belong to families of the solute carrier (SLC) 
(Scheepers et al., 2004) gene series. The two most well known members of SGLT 
family are SGLT1 and SGLT2, which are members of the SLC5A gene family and 
are involved in intestinal glucose absorption and renal reabsorption (Gerardi-Laffin et 
al., 1993; Scheepers et al., 2004). 
The human genome contains 14 members of the GLUT family (gene name 
SLC2A), which can be grouped into 3 classes. They differ in the functional 
characteristics, including substrate profiles, kinetic constants, and binding affinities 
as well as different tissue distribution and expression (Gould and Holman, 1993), for 
a complex and specific regulation of glucose uptake. 
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The widely distributed GLUT1, is targeted predominantly to the plasma 
membrane, indicating to mediate basal glucose transport in various cell types 
(Kozlovsky et al., 1997). On the other hand, GLUT4 is a glucose transporter 
expressed in several insulin-sensitive tissues (heart, skeletal muscle and adipose 
tissue). GLUT4 is the primary transporter expressed in the skeletal muscle (Zorzano 
et al., 2005), whereas GLUT1 account for only 5% of total expression of transporters. 
The newly synthesized GLUT4, present in the Golgi apparatus and the endoplasmic 
reticulum and undergo maturation and glycosylation. Normally, the GLUT4 is 
sequestered to the intracellular membrane compartments. In contrast, insulin, muscle 
contraction, and/or hypoxia increases GLUT4 expression at the cell surface by 
promoting the translocation of the transport protein from intracellular storage 
vesicles, resulting in an immediate 10- to 20-fold increase in glucose transport 
(Bryant et al., 2002). 
Skeletal muscle cells exhibit insulin-stimulated glucose uptake that is 
dependent on the phosphatidylinositol-3-kinase (PI3K) pathway. However, enhanced 
glucose transport could also be induced by an insulin-independent mechanism, which 
could be activated by muscle contractions and hypoxia (Azevedo et al., 1995; Nesher 
et al., 1985; Wallberg-Henriksson and Holloszy, 1985). Evidence suggests that the 
AMP-activated protein kinase (AMPK) plays an important role in glucose transport 
stimulated by contraction (Hayashi et al., 1998). There are also other possible signal 
intermediates, including calcium, nitric oxide and others (Balon, 1998; Jessen and 
Goodyear, 2005; Wright et al., 2005). 
 
1.2.2 Hepatic glucose production  
The liver is capable of maintaining blood glucose homeostasis by glucose 
production and release (through gluconeogenesis and glycogenolysis), as well as 
glucose uptake/storage (through glycogenesis). 
 
1.2.2.1 Gluconeogenesis and glycolysis 
Glycolysis is the pathway, which converts the glucose molecule (six-carbon) 
into two molecules of the pyruvate (three carbon) and occurs virtually in all tissues. It 
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consists of two phases: a preparatory phase, where ATP is consumed and a pay-off 
phase where ATP is produced. During fasting, low-carbohydrate diets, or 
intense exercise, gluconeogenesis occurs, mainly in the liver and kidney. It is a 
process by which glucose is synthesized from non-carbohydrate carbon substrates 
such as pyruvate, glycerol, alanine and lactate. These substrates mainly come from 
the breakdown from amino acids and lactate, transported to the liver by the 
bloodstream. This pathway consists of a series of enzyme-catalyzed reactions and 
begins in the mitochondria or cytoplasm, dependent on the substrate being used 
(Nordlie et al., 1999). The process of gluconeogenesis uses most of the reactions of 
glycolysis reversely to this pathway to re-synthesize glucose.  
In the first step in glycolysis, glucose is phosphorylated into glucose-6-
phosphate (G6P) by hexokinases. For glycolysis, G6P is then rearranged into fructose 
6-phosphate (F6P) by glucose phosphate isomerase and phosphofructokinase 
converts F6P into fructose-1,6-biphosphate, which eventually leads to the formation 
of phosphoenolpyruvate (PEP). Pyruvate kinase then converts PEP into pyruvate.  
 Glycolysis process continues as the one of the two methods: aerobic 
metabolism of glucose or anaerobic glycolysis. If there is oxygen, the process 
continues into aerobic respiration, where pyruvate is further metabolized to acetyl-
CoA and CO2 in the mitochondria in a process called oxidative decarboxylation (Voet 
and Voet, 2003). Then acetyl-CoA could enter the tricarboxylic acid cycle (TCA 
cycle), or the Krebs cycle and get completely oxidized into CO2, water. The 
anaerobic glycolysis usually occurs when there is no oxygen. In this case, pyruvate is 
converted to lactate, by lactate dehydrogenase.  
One common substrate for gluconeogenesis is lactate, which is produced in 
the muscle in the absence of oxygen. The lactate is released to the blood, and then 
transported into the liver and is converted to pyruvate, then into glucose, which goes 
back into the bloodstream and returns to the muscle. This is termed the “Cori cycle” 
(Garrett and Grisham, 2010). Gluconeogenesis begins with the formation of 
oxaloacetate by the carboxylation of pyruvate in the mitochondria. Oxaloacetate is 
decarboxylated and then phosphorylated to form PEP using the 
enzyme phosphoenolpyruvate carboxykinase (PEPCK) in cytosol. This is the first 
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rate-limiting step in gluconeogenesis. The next steps are the same as reversed 
glycolysis, however fructose-1,6-bisphosphatase (another rate-limiting enzyme) 
converts fructose-1,6-bisphosphate to F6P. Finally, glucose is produced when G6P is 
hydrolyzed by glucose-6-phosphatase (G6Pase), which is the last rate-limiting 
enzyme (Barthel et al., 2001) (Figure 1). 
 
 
 
Figure 1: Glucose metabolism in liver (Moller, 2001). 
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1.2.2.2 Glycogenolysis and glycogenesis 
Glycogen is a highly branched polymeric, formed by basic monomer 
glucose. Glycogenesis is the process of glycogen synthesis glucose storage.  Glucose 
is metabolized to G6P by hexokinase or glucokinase (Vinuela et al., 1963), and then 
converted to glucose-1-phosphate by phosphoglucomutase. Through UDP-glucose 
pyrophosphorylase, glucose-1-phosphate then is converted into UDP-glucose. 
Glycogen synthase (GS) then catalyzes the reaction between UDP-glucose and a pre-
existing glycogen primer, forming a chain (Voet and Voet, 2003). Then glycogen 
branching enzyme transfers the glucan chains into branches and glycogen (Voet and 
Voet, 2003). 
The first step is the conversion from glycogen to glucose-1-phosphate by 
glycogen phosphorylase and glucose-1-phosphate is then converted to G6P by 
phosphoglucomutase (Voet and Voet, 2003). In hepatocytes, the phosphate group of 
G6P is finally removed by G6Pse (Nordlie et al., 1999), which is not presenting in 
muscle. The free glucose exits through glucose transporters of the cell into the 
bloodstream for uptake by other cells.  
These hepatic functions are under tight metabolic control by hormones such 
as insulin, glucagon and epinephrine. In the fasting state, glucagon (released when 
blood glucose levels are low) binding to a G protein coupled-receptor triggers 
phosphorylation of enzymes and regulatory proteins by cAMP-dependent protein 
kinase (Protein Kinase A, PKA) (Wang et al., 2012). This results in an inhibition of 
glycolysis and concurrent stimulation of gluconeogenesis in the liver, providing the 
glucose needed for the brain and other tissues. Conversely, in the fed state, secreted 
insulin can suppress glucose production in liver cells by the inhibition of 
gluconeogenesis and glycogenolysis and induce glycogenesis. 
The transcriptional coactivator peroxisome proliferator activated receptor γ 
coactivator-1α (PGC-1α) functions as a central regulator of gluconeogenesis by 
binding to several factors, including hepatic nuclear factor 4α (HNF4α) (Rhee et al., 
2003) and a transcription factor called forkhead box o protein (Foxo-1) (Puigserver et 
al., 2003), lying upstream of several genes encoding gluconeogenic enzymes. Foxo1 
plays an important role in the control of several key gluconeogenic enzymes, 
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including G6Pase and PEPCK. One mechanism by which insulin signaling 
suppresses gluconeogenesis is through phosphorylation of Foxo-1 by Akt and its 
subsequent exclusion from the nucleus, thus inactivating the transcription of these 
rate-controlling enzymes of gluconeogenesis (Hall et al., 2000). 
For the induction of glycogenesis, insulin activates Akt resulting in the 
dephosphorylation and activation of GS through the phosphorylation and inhibition 
of glycogen synthase kinase-3 (GSK-3) (Ciaraldi et al., 2010; Ciaraldi et al., 2007; 
Nikoulina et al., 2002).  
 
1.3 Lipid metabolism  
Lipids are hydrophobic compounds, insoluble in aqueous solutions and 
soluble in organic solvents. Triglycerides (TGs) mainly stored in adipose tissue, for 
energy storage in humans. In non-adipose tissues, such as skeletal muscle, excessive 
TGs are associated with insulin resistance and can lead to T2D.  
Foods travel to the stomach and are digested into compounds, including TGs, 
protein and glucose. TGs are emulsified by bile salt to facilitate the hydrolyzation to 
monoglycerides, FFAs and glycerol by pancreatic lipase (Mattson and Beck, 1955) in 
the small intestinal. Then the formations of micelles with bile salt facilitate the 
transport and delivery of monoglycerides, FFAs to the intestinal epithelial cells, 
where they are absorbed through the simple diffuse.  
After entering the epithelial cell, the FFAs and monoglycerides are taken up 
by the endoplasmic reticulum, and here they are mainly re-esterified into new TGs. 
TGs are then packaged with apoprotein into blood soluble chylomicrons (CMs). CMs 
are excreted and travel through the bloodstream into adipocyte for storage or to 
muscle cells to oxidation as fuel for energy.   
Adipose tissue stays in a dynamic state with continuous synthesis and 
breakdown of TGs. When energy is required, free fatty acids (FFAs) are released into 
the blood by cleaving off the glycerol from TGs, a process called lipolysis. The 
oxidation of fatty acids provides 9 kcal/g while the breakdown of glucose and 
proteins provide 4 kcal/g. In contrast, lipogenesis is a process that stores extra 
energy.  
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1.3.1 Lipogenesis 
Lipogenesis is a metabolic process that converts carbohydrates to fatty 
acids and synthesizes TGs through the reaction of FFAs with glycerol, in adipose 
tissue and non-adipose tissue, such as liver.  
Fatty acids synthesis builds up by the addition of two carbon units in the 
cytoplasm staring with acetyl-CoA, through fatty acid synthase (FAS) (Chirala and 
Wakil, 2004). After lipogenesis, the TGs are packaged as lipoprotein and secreted by 
the liver or could store energy in adipose tissue for long term. 
FFAs and glycerol can be released from TGs of CMs and very-low-density 
lipoproteins (VLDLs) by lipoprotein lipase (LPL) (Eckel, 1989; Wood et al., 2011) 
secreted by adipocytes on the wall of blood vessel. After entering into the adipocytes, 
FFAs can be stored as TGs again in the adipose tissue (lipogenesis). 
FFAs are then transported across the membrane into the cytoplasm of the cell. 
Through two main pathways (glycerol-3-phosphate pathway and monoacylglycerol 
pathway (MAG)) (Shi and Burn, 2004), as shown in Figure 2.  
Glycerol-3-phosphate is esterified by glycerol 3-phosphate acyltransferases 
(GPAT) (Monroy et al., 1973; Wendel et al., 2009) producing 1-acylglycerol 3-
phosphate (lysophosphatidate, LPA). 1-Acylglycerol-3-phosphate acyltransferase 
(AGPAT) (Cattaneo et al., 2012) catalyzes the esterification of LPA forming 
phosphatidate (PA). The phosphatidate phosphatases (PAP) then dephosphorylate PA 
producing 1,2-diacylglycerol (DAG), which can then be used to synthesize TGs. 
DAG can also be generated via the monoacylglycerol acyltransferase (MGAT) 
pathway through the acylation of MAG. The last step of the lipogenesis is catalyzed 
by the enzyme diacylglycerol acyltransferase (DGAT) (Harris et al., 2011a) at the 
endoplasmic reticulum to form an ester bond.  
 
1.3.2 Lipolysis  
Lipolysis occurs during various conditions, including stress, exercise, and 
fasting, and uncontrolled diabetes mellitus. Several hormones (e.g., glucagon and 
epinephrine) increase cyclic adenosine monophosphate (cAMP) levels, which induce 
PKA to phosphorylate hormone sensitive lipase (HSL), thus activating it (Shi and 
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Burn, 2004). Released TGs are then catabolized by HSL, adipose triglyceride lipase 
(ATGL), and monoglyceride lipase (MGL) to generate FFAs and glycerol, as shown 
in Figure 2. Lipolysis products serve for energy production, cellular signaling, or 
lipid synthesis. 
 
 
 
Figure 2: Lipogenesis and lipolysis (Shi and Burn, 2004). 
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1.3.3 Adipogenesis 
Two distinct phases of adipogenesis are identified: determination of 
adipocytes from multipotent stem cells, (such as mesenchymal stem cells (MESCs)) 
and, terminal differentiation of pre-adipocytes into mature adipocytes.  
For in vitro bioassays, preadipocytes, such as 3T3-L1 cells, growth arrest 
(near confluence) are firstly required to start cell differentiation. After growth arrest 
at confluence, preadipocytes receive an appropriate mitogenic and adipogenic signals 
to continue differentiation, such as a mix of inducers, including insulin, 
dexamethasone (DEX), as well as 3-isobutyl-1-methylxanthine (IBMX). These 
inducers activate the insulin, glucocorticoid and cAMP-signaling pathways, 
respectively (Feve, 2005).  
After induction, grow-arrested cells undergo several rounds of DNA 
replication and cell division known as mitotic clonal expansion, which is 
accompanied by induction of CCAAT-enhancer-binding protein (C/EBP) β and 
C/EBP δ (Tang and Lane, 2012).  
Growth arrest and clonal expansion are then followed by early and late 
differentiation. C/EBP and peroxisome proliferator-activated receptor γ (PPAR γ) are 
induced during early adipocyte differentiation. 
Preadipocyte factor-1 (Pref-1), a recently described preadipocyte protein, was 
reported to be involved in maintaining the preadipocyte phenotype with high 
expression in preadipocyte and not detectable in mature adipocyte (Smas et al., 1997; 
Smas and Sul, 1993). 
Then during the late differentiation, adipocytes markedly increase lipogenesis 
and acquire sensitivity to insulin, with increased expression of C/EBP α, sterol 
regulatory element-binding proteins-1 (SREBP-1) and PPAR γ (Loftus and Lane, 
1997). These central transcriptional regulators of adipogenesis drive several 
adipocyte-specific gene expressions.  
PPAR γ can be thought of as a “master” gene regulator of adipocyte 
differentiation, being both necessary and sufficient to drive conversion of fibroblastic 
precursors into fat cells (Tontonoz et al., 1994). Thus preadipocytes lose their 
fibroblastic morphology, increase lipogenesis and accumulate triglycerides, finally 
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become mature adipocytes and start to express characteristic adipocyte markers, such 
as fatty acid-binding protein 4 or adipocyte protein 2 (FABP4 or aP2), fatty acid 
transport protein (FATP) (Chui et al., 2005; Frohnert et al., 1999; Motojima et al., 
1998) to promote FA and glycerol transport (Kishida et al., 2001), acetyl-CoA 
carboxylase (ACC), FAS (for FFA synthesis and lipogenesis) (Castelein et al., 1994; 
Jitrapakdee et al., 2005), and mitochondrial biogenesis and PGC-1α and carnitine 
palmitoyltransferase-1 (CPT-1, mediates the transport of fatty acids across the 
membrane for oxidation) for FFA oxidation (Bogacka et al., 2005a; Bogacka et al., 
2005b). 
 
1.4 Insulin receptor and insulin pathway 
The insulin receptor is a heterotetrameric transmembrane protein receptor 
composed of two α subunits and two β subunits, linked by disulphide bonds. It 
belongs to the tyrosine kinase receptor family. Insulin or insulin-like growth factor 
(IGF) binds to the extracellular α subunits and brings them closer to trigger the 
conformational changes (Saltiel and Kahn, 2001). This enables ATP binding to the β-
subunits and facilitates autophosphorylation (intrinsic tyrosine kinase activity) of 
various tyrosine residues and activation of the extrinsic tyrosine kinase activity of the 
receptor.  
This autophosphorylation creates several binding sites in the receptor and 
promotes the recruitment of phosphotyrosine binding (PTB) domain containing 
substrate proteins, such as Src, Grb2, Shc, Gab-1, Cbl, APS, and the insulin receptor 
substrate (IRS) proteins (Kimura et al., 2002). The subsequent tyrosine 
phosphorylation and activation of these substrates enables them to working as 
docking sites for downstream effectors with Src homology 2 domain (SH2) (Kimura 
et al., 2002). This triggers three signaling pathways: the mitogen-activated protein 
kinase (MAPK) pathway, the PI3K pathway, and the CAP/Cbl/ TC10 pathways, 
which involving in mediating the variety of responses to insulin (Saltiel and Kahn, 
2001). 
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Figure 3: Insulin signaling pathways (Saltiel and Kahn, 2001). 
 
1.4.1 PI3K pathway  
The PI3K pathway plays a central role in the metabolic actions of insulin and 
controls gluconeogenesis, glycogen and protein synthesis as well as glucose transport 
through GLUT4 translocation (Kido et al., 2001). It consists of a p110 catalytic 
subunit and a SH2 domains containing p85 regulatory subunit. Binding through the 
SH2 domain to IRS-1 leads to the phosphorylation and activation of PI3K. After 
activation, PI3K can convert the membrane lipid phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3). The increase 
in intracellular PIP3 leads to activation of the PI-dependent kinase-1 and -2 (PDK1 
and PDK2), which phosphorylate the protein kinase B (PKB or /Akt) on amino acid 
residues threonine 308 and serine 473 (Hill et al., 2002; Stokoe et al., 1997), leading 
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to its activation. Akt has been shown to mediate actions of insulin on GSK-3, the 
mammalian target of rapamycin (mTOR) and others such as PEPCK, GLUT4.  
PI3K/PDK1 also phosphorylate and activate atypical isoforms of PKC zeta and PKC 
delta (Chou et al., 1998; Le Good et al., 1998). 
 
1.4.2 MAPK pathway 
The MAPK pathway is involved in mitogenic cellular responses, cell growth 
and survival. Insulin triggers the MAPK pathway upon translocation and binding of 
cytosolic adaptor protein growth factor receptor binding protein 2 (Grb2) to 
phosphorylated Shc or IRS proteins via its SH2 domain. Grb2, through its SH3 
domain, is then able to bind to mammalian son of sevenless (SOS), a guanyl 
nucleotide exchange factor (GEF) that catalyzes the exchange of guanosine 
diphosphate (GDP) for GTP on Ras (a small GTP binding protein), thus resulting in 
activation of Ras (Vanderkuur et al., 1997). Upon activation, Ras binds the protein 
kinase Raf, recruiting Raf to the plasma membrane, which results in Raf activation 
(Avruch et al., 2001). Ras-Raf then activates MAP kinase-kinase (MEK) and MAP 
kinases ERK1 and ERK 2 (Vanderkuur et al., 1997). The activated MAPKs enter the 
nucleus and phosphorylate various nuclear transcription factors to elicit their actions. 
 
1.4.3 CAP/Cbl/ TC10 pathways  
This signalling cascade is initiated when the activated insulin receptor recruits 
and activates the adaptor proteins (APS) binding Cbl, Cbl and Cbl-associated protein 
(CAP) (Onnockx et al., 2009). CAP belongs to a family of adapter proteins with 
common SH3 domains and sorbin homology (SoHo) domain. Upon phosphorylation, 
the Cbl–CAP complex translocates to lipid raft domains (in the plasma membrane), 
by the interaction of the SoHo domain in CAP with the flotillin protein (Baumann et 
al., 2000) (Chang et al., 2004). Translocation of Cbl then recruits the adapter protein 
Crk and the GEF C3G to the membrane, where C3G catalyses the exchange of GTP 
in place of GDP on G protein TC10 (Chang et al., 2004). Once activated, GTP-bound 
TC10 provides another signal to the GLUT4 protein and promotes its translocations 
to the membrane, in parallel with the activation of the PI3K pathway.   
  
16 
1.5 Other mechanisms involved in energy metabolism:  
 
1.5.1 AMPK pathway  
AMPK is a “metabolic master switch”, which regulates whole-body and 
cellular energy metabolism, activated in condition of intracellular ATP depletion, 
including fasting, heat shock, hypoxia and exercise. The activation of AMPK 
regulates many downstream pathways to inhibit energy-consuming anabolic 
pathways (such as fatty acid and cholesterol synthesis, gluconeogenesis, protein 
synthesis and insulin secretion from β-cell) and accelerate ATP-producing catabolic 
ones (such as glucose uptake, fatty acid uptake and oxidation and mitochondrial 
biogenesis), as shown in Figure 4 (Hardie, 2011; Towler and Hardie, 2007).  
 
Figure 4: AMPK functions involved in energy metabolism (Hardie, 2004). 
 
AMPK is a heterotrimeric protein, composed of a catalytic (α) and two non-
catalytic (β and γ) subunits (Xiao et al., 2011). When the AMP to ATP ratio 
increases, AMP binds to both Bateman domains and leads to a conformational 
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change in the γ subunit, which exposes the catalytic domain of the α subunit. 
Moreover, as an allosteric activator, AMP also could make AMPK a poorer substrate 
for dephosphorylation.  
AMPK becomes activated when phosphorylated at threonine 172 by an 
upstream AMPK kinase (AMPKK) and inactivated by dephosphorylation (Oakhill et 
al., 2011; Xiao et al., 2011). One kinase activator of AMPK is Ca2+-calmodulin-
dependent kinase kinase β (CaMKKβ) (Oakhill et al., 2011), which responses to 
increased calcium and is primarily expressed in the brain. The serine/threonine liver 
kinase B 1 (LKB1) is required for the activation of AMPK (Oakhill et al., 2011). The 
active LKB1 is actually a complex of three proteins, including LKB1, Ste20-related 
adaptor (STRAD) and mouse protein 25 (MO25). Phosphorylation of AMPK by 
LKB1 also occurs on T172. LKB1 is widely expressed, and it is the primary AMPK-
regulating kinase. AMPK could also be activated by receptors that are coupled to 
phospholipase C-γ (PLC γ) and by adipokines such as adiponectin and leptin (Carling 
et al., 2008). 
 
 
Figure 5: PPAR γ activation and mechanisms involved in glucose and lipid 
metabolism. Adapted form http://inflammablog4.blogspot.ca/2011/05/ppar-gamma-
pathway-i-included-this.html 
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1.5.2 PPAR γ and regulation of lipid homeostasis  
 
When PPAR γ is bound with a ligand or other agonist, it becomes active and 
complexes with another transcription factor; namely, retinoid X-receptor (RXR) 
(Chandra et al., 2008). The complex PPAR-γ-RXR, with several co-activators is then 
bound to a speciﬁc DNA motif, known as peroxisome proliferate response element 
(PPREs) in the promoters of target gene (Lenhard, 2001), as shown in Figure 5. 
Activation of PPAR γ regulates a variety of adipocyte genes involved in 
virtually all pathways of lipid metabolism to increase FFAs influx to adipocyte and 
storage as TGs: LPL to promote FFAs release from circulating lipoproteins 
(Schoonjans et al., 1996), low density lipoprotein (LDL) receptor, fatty acid-binding 
protein 4 or adipocyte protein 2 (FABP4 or aP2), CD36, fatty acid transport protein 
(FATP) (Chui et al., 2005; Frohnert et al., 1999; Motojima et al., 1998) to promote 
FA and glycerol transport (Kishida et al., 2001),  PEPCK to enhance 
glyceroneogenesis (Tontonoz et al., 1995), acetyl-CoA carboxylase (ACC), FAS (for 
FFA synthesis and lipogenesis) (Castelein et al., 1994; Jitrapakdee et al., 2005), and 
mitochondrial biogenesis and PGC-1α and carnitine palmitoyltransferase-1 (CPT-1, 
mediates the transport of fatty acids across the membrane for oxidation) for FFA 
oxidation (Bogacka et al., 2005a; Bogacka et al., 2005b). 
PPAR γ activation functions as an “adipose remodeling factor” that could 
redistribute lipids from non adipose tissue and insulin-resistant adipocytes into 
differentiated and insulin-sensitive adipocytes by enhancing adipogenesis, regulating 
adipokines, increasing adiponectin, decreasing leptin, tumor necrosis factor-α (TNF-
α) and FFAs and exerting insulin-sensitizing effects (Bermudez et al., 2010; Lenhard, 
2001) as shown in Figure 6. The typical adipocyte remodeling induced by PPAR-γ 
agonist involves an increased number of small insulin-sensitive adipocytes and fewer 
large insulin-resistant adipocytes (Bergman et al., 2006; Laplante et al., 2003). 
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Figure 6: PPAR γ activation and improved insulin sensitivity. 
 
 
1.6 Metabolic syndrome and obesity 
 
1.6.1 Metabolic syndrome 
Metabolic syndrome (MetS) in an individual reflects the clustering of multiple 
metabolic abnormalities, including central obesity, T2D, dyslipidemia, hypertension, 
and non-alcoholic fatty liver disease (NAFLD). The definition of the MetS 
determined by the International Diabetes Federation (IDF) includes central obesity 
(increased waist circumference (WC) or waist-to-hip ratio of over 102 cm and 0.90 
for males, and of over 88 cm and 0.85 for females respectively) and at least 2 of the 
following: increased fasting serum glucose (over 5.6 mmol/L), TGs (over 
150 mg/dL), blood pressure (over 130/ 85 mm Hg), or a low HDL cholesterol 
concentration (under 40 mg/dL in males, under 50 mg/dL in females) (Alberti et al., 
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2005). Other MetS definitions have been put forth by the National Cholesterol 
Education Program-Adult Treatment Panel III (ATPIII) (Grundy et al., 2005) and the 
WHO (Alberti and Zimmet, 1998), who both imparted similar risks to MetS for 
developing cardiovascular disease and diabetes. 
 
1.6.2 Obesity 
Obesity is defined as excessive fat accumulation, which may impair health. 
Body mass index (BMI) is commonly used to determine obesity in adults, which is 
defined as a person's weight divided by the square of the height (kg/m2) (WHO, 
2012). The individual with BMI greater than 30 is considered to be obese (WHO, 
2012). Obesity, particularly central or visceral obesity, is associated with several 
diseases, including cardiovascular disease, diabetes and NAFLD. 
Indeed, many investigations demonstrated that excess in visceral adipose 
tissue (VAT) or abdominal adipose tissue (known as central obesity), but not that in 
subcutaneous adipose tissue, was characterized with adipocyte dysfunction and 
significantly correlated with insulin resistance, T2D, and cardiovascular disease 
(Banerji et al., 1999; Banerji et al., 1997; Fujimoto et al., 1999; Pouliot et al., 1992). 
 
1.6.3 Adipocyte dysfunction, inflammation and insulin resistance 
The importance of adipose tissue is confirmed by observations made in 
lipoatrophic diabetes in mice and human (Gavrilova et al., 2000) (Sovik et al., 1996). 
Such “individuals” have no white fat tissue (Reitman and Gavrilova, 2000). They 
also suffer from severe metabolic disorders (Sasaki et al., 1992), including insulin 
resistance, hyperglycemia, hyperlipidemia, and fatty livers. Therefore, having a 
proper quantity of functional adipose tissues is crucial (Gavrilova et al., 2000); too 
many (obesity) or too less (lipoatrophy) adipose tissue impairing energy homeostasis 
and insulin sensitivity. 
As we discussed in lipid metabolism in chapter 1.3, adipocytes store energy as 
triglyceride (lipogenesis and adipogenesis) and release fatty acids (lipolysis) to the 
blood or to be used for energy through oxidation. Human adipocytes can grow up to 
20 fold in diameter and several thousand-fold in volume (Jernas et al., 2006). 
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However when there is too much excess energy, adipocytes become too large 
(hypertrophy), and hypoxia occurs (Kabon et al., 2004; Ye et al., 2007) due to 
inadequate blood flow (West et al., 1987) in the expanded adipose tissue  
Stressed and hypertrophied adipocytes secrete monocyte chemo-attractant 
protein-1 (MCP-1) and other chemo-attractants to increase macrophage infiltration 
(Harman-Boehm et al., 2007) into adipose tissue. Adipose tissue of lean subjects 
usually consists of less than 10% macrophages, whereas in obese patients, 
macrophage content can rise as high as 50% (Weisberg et al., 2003).  
Infiltrating macrophage recruitment in turn results in adipocytes producing 
more pro-inflammatory adipokines and cytokines, such as TNFα (Hotamisligil et al., 
1993). This low-grade chronic inflammation decreases energy storage and increases 
lipolysis (Xu et al., 2003). The excess FFAs (Horowitz and Klein, 2000) and altered 
adipokines result in the accumulation of lipids in non-adipose tissue, including the 
liver and muscle, causing lipotoxicity and impairing the normal metabolism and 
insulin sensitivity. 
 
1.6.4 Adipose tissue and adipokines  
Adipose tissue is not only the main site for energy storage and a master 
regulator of whole-body lipid flux (by lipogenesis and fatty acid releasing and 
oxidation), but also functions as an endocrine organ. It modulates both glucose and 
lipid metabolism in other tissues by secreting a number of adipokines, including 
adiponectin, leptin, resistin, TNF-α, interleukin (IL)-1, and IL-6. 
Leptin plays a key role in inhibiting energy intake and promoting energy 
expenditure by acting on the receptors in the central nervous system. Humans and 
mice lacking leptin demonstrate obesity. Obesity and T2D are often associated with 
leptin deficiency or resistance, deregulating satiety signals (Considine et al., 1996), 
and are characterized by an elevated leptin-to-adiponectin ratio.  
Adiponectin (also called Acrp30 or adipoQ) is a fat cell-derived peptide and 
modulates glucose and fatty acid handling (Diez and Iglesias, 2003). Adiponectin is 
an insulin-sensitizing hormone with antidiabetic, anti-inflammatory and anti-
atherosclerotic properties (Diez and Iglesias, 2003; Ukkola O, 2002). Acute treatment 
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of mice with adiponectin decreases insulin resistance, plasma FFAs and the TGs 
content of muscle and liver, while increasing expression of genes involved in fatty-
acid oxidation and energy expenditure (Yamauchi et al., 2001). 
Inflammatory cytokines such as TNF-α are also adipocyte derived. The serum 
concentration of TNF-α is increased in obesity and is associated with chronic and 
low-grade inflammation of metabolic disease. TNF-α could induce insulin resistance 
by phosphorylation of IRS-1 at serine sites (Krogh-Madsen et al., 2006). 
 
1.7 Diabetes mellitus  
 
1.7.1 Diabetes definition and diagnosis  
As one of the chronic metabolic disease, diabetes mellitus is characterized by 
hyperglycemia. It might be caused by from impaired insulin secretion and/or insulin 
resistance (IR); the later being determined by impaired sensitivity of insulin in target 
organs (adipose tissue, liver, and muscle) (DeFronzo and Ferrannini, 1991).  
According to WHO, diabetes is diagnosed when fasting plasma glucose levels 
reach higher than 7.0 mmol/L (126 mg/dL) or when plasma glucose reaches higher 
than 11.1 mmol/L (200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT) 
(WHO, 1999). There are also two pre-diabetic states. Impaired fasting glucose (IFG) 
is recognized when fasting glucose levels range from 6.1 to 6.9 mmol/L (110 to 
125 mg/dL), whereas impaired glucose tolerance (IGT) is characterized by plasma 
glucose levels between 7.8 mmol/ L to 11.1 mmol/L (140 mg/dL to 200 mg/dL) 2 
hours after OGTT (WHO, 1999). 
 
1.7.2 Diabetes classification  
Diabetes is classified into four categories:  type 1 diabetes; type 2 diabetes; 
type 3 or others specific types; and type 4, gestational diabetes (ADA, 2006, 2011). 
They differ in terms of their causes and in their distribution in different populations. 
However, each type of diabetes will result in insufficient production and/or action of 
insulin to reduce blood glucose and will lead to hyperglycemia. 
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1.7.2.1 Type 1 diabetes (T1D) 
This form of diabetes, previously called insulin-dependent diabetes or 
juvenile diabetes, accounts for only 5-10% of cases and the majority of which are 
found in children (ADA, 2011). T1D is caused by β cell destruction and absolute 
deficiency of insulin secretion, involving cellular mediated autoimmune or idiopathic 
origins (Skyler, 2011). 
Most patients are otherwise healthy and not obese when onset occurs. 
Irregular hyperglycemia and ketoacidosis sometimes accompany newly recognized or 
untreated T1D. This type of diabetes is treated with exogenous insulin therapy, along 
with lifestyle management.  
 
1.7.2.2 Type 2 diabetes (T2D) 
T2D, formerly referred to as insulin-independent diabetes, is the most 
common type and accounts for 90-95% of all the diabetes cases (ADA, 2011). It is 
characterized by insulin resistance associated with relative (rather than absolute) 
insulin deficiency. Most patients with T2D are obese, and others who are not obese 
may have metabolic disorders and increased abdominal fat. 
 This category goes undiagnosed for a long period of time because it develops 
gradually and the degree of hyperglycemia may be not sufficient to cause clinical 
symptoms in the early stage.  The risk of developing T2D increases with obesity, age 
and lack of physical activity (Ansari, 2009; Colberg et al., 2010). Most patients need 
lifestyle modification as well as oral hypoglycemic drugs to control blood glucose. 
Insulin therapy may be not required initially but regularly occurs when β cell mass 
becomes insufficient as described further below. 
 
1.7.2.3 Type 3 diabetes  
Others specific types of diabetes are less common and can result from a 
variety of conditions, including specific genetic defects, endocrinopathies, drugs, 
infections, and other illnesses. For example, maturity onset diabetes of the young 
(MODY) might be caused by monogenetic defects (ADA, 2011). MODY 3, MODY 
2 and MODY 1 are the most common forms of MODY, which are caused by 
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mutation of HNF 4A, glucokinase and HNF 1 A genes respectively (Bell and 
Polonsky, 2001; Fajans, 1990). 
 
1.7.2.4 Type 4 diabetes  
Gestational diabetes mellitus (GDM) is diabetes with hyperglycemia, which is 
first recognized during pregnancy. It increases the risk of complications for both 
mother and neonate. It occurs in about 2%–10% of all pregnancies and is associated 
with the placental hormones being implicated in the development of insulin 
resistance (Desoye and Hauguel-de Mouzon, 2007). While GDM may go away after 
pregnancy, women who have had GDM have great risks of developing diabetes 
(mainly T2D) later in life (Kim et al., 2007; Oubré et al., 1997).  
 
1.7.3 Pathogenesis of T2D 
A variety of pathogenic processes are believed to be involved in the 
development of T2D. They range from insulin resistance (IR) in the complex 
pathways of the hormone action, to β cell failure in the pancreas with consequent 
insulin deficiency. 
T2D is considered to be a chronic and progressive disease. In the early stages 
of T2D, the abnormal high blood glucose is compensated by increased insulin 
production and secretion by β cells, generating hyperinsulinemia and termed β cell 
compensation. As the disease progresses, β cells become unable to secret enough 
insulin for the body's needs and β cells failure occurs.  This failure includes loss of β 
cells mass due to apoptosis (Butler et al., 2003) and secretory defect. Several factors 
are involved, such as genetic determinants, chronic inflammation, glucotoxicity and 
lipotoxicity (Buchanan, 2003). 
Insulin resistance is characterized with an impaired biologic response to either 
exogenous or endogenous insulin. So in IR patients, insulin fails to promote 
peripheral glucose utilization through glucose uptake (Utriainen et al., 1998) in 
muscle and adipose tissue; unable to suppress hepatic glucose production (Vaag et 
al., 1995); and fails to stimulate TGs production and to decrease lipolysis thereby 
resulting more FFAs efflux from adipocytes (Kelsey et al., 2013).  
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The majority of T2D patients are overweight or obese; however not all obese 
persons have insulin resistance. About 50% of overweight and 30% of obese adults 
are metabolically healthy in the USA (Wildman et al., 2008); that is, they do not have 
diabetes or exhibit disturbances in glucose and lipid metabolism. In reverse, such 
metabolic abnormalities occur in 23.5 % of people with normal body weights. So it is 
now commonly accepted that chronic and low-grade inflammation associated with 
visceral obesity (bad fat or abdominal fat, more details discussed in 1.6.2 and 1.6.3) 
are involved in insulin resistance and T2D.  
The cellular and molecular mechanisms underlying IR are still not fully 
understood. Several molecular mechanisms may contribute to IR, specifically in 
insulin responsive tissues such as liver, muscle and adipose tissue. These include 
decreases in 1) insulin receptor expression and tyrosine kinase activity; 2) the 
expression and phosphorylation of IRS-1/2; and 3) PI3K activity. It is reported that 
decreased expression of IRS-1 protein and especially increased IRS-1 serine 
phosphorylation is associated with IR (Anai et al., 1998; Goodyear et al., 1995; 
Kerouz et al., 1997; Saad et al., 1992; Stephens et al., 1997). The serine 
phosphorylation of IRS proteins reduces the ability of IRS proteins to attract PI3K. 
This impairs downstream effectors (Aguirre et al., 2002) and can also accelerate the 
degradation of the IRS-1 protein (Shah et al., 2004). Several serine/threonine kinases 
have been shown to phosphorylate IRS-1 within various inflammatory signalling 
pathways, such as c-Jun N-terminal kinase (JNK1), IκB kinase-β (IKK-β), or PKC. 
Furthermore, suppressor-of-cytokine-signalling (SOCS) proteins, upregulated by the 
cytokine IL-6, interfere with insulin signaling by promoting the degradation of IRS-1 
and IRS-2 (Wellen and Hotamisligil, 2003).  
 
1.7.4 Diabetes symptoms and complications  
Symptoms of marked hyperglycemia include polyuria, polydipsia, and 
polyphagia accompanied by weight loss as well as blurred vision and others. Acute, 
consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis and the 
nonketotic hyperosmolar syndrome (Kitabchi et al., 2001; Peden et al., 1984), which 
are two acute complications of diabetes that can result in increased morbidity and 
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mortality. Diabetes ketoacidosis is characterized by hyperglycemia, metabolic 
acidosis, especially high level of total body ketone, while hyperglycemia 
hyperosmolar syndrome is characterized by hyperglycemia and high osmolality 
without ketoacidosis (Gerich et al., 1971). 
Long-term chronic complications of diabetes are divided into microvascular 
and macrovascular. Microvascular complications include retinopathy, nephropathy 
and neuropathy. These are recognized as the three major complications of diabetes 
and increase the risk of blindness, kidney failure or diabetic foot (ulcers and 
amputations) (ADA, 2011). Macrovascular complications include cardiovascular 
disease, cerebrovascular disease as well as peripheral vascular disease, leading to 
increased mortality and morbidity rates in T2D (ADA, 2011). 
In the Canadian Institutes of Health Research Team in Aboriginal 
Antidiabetic Medicines (CIHR-ATTM) project (described further below), the 
following 15 symptoms and complications were used to ask informants about 
traditional remedies that would have beneficial potential for T2D: 
arthritis/rheumatism; frequent headaches; back and/or kidney pain; diarrhea; swelling 
and/or inflammation; general weakness; increased appetite; heart and/or chest pain; 
increased thirst; abscesses and/or boils; blurred vision; increased urination; foot 
numbness and/or foot sores; slow healing infections; and sore and/or swollen limbs 
(Leduc et al., 2006). 
 
1.7.5 Diabetes treatment  
Optimal glycemic control is the fundament and the main goal for the 
management of diabetes (Cade, 2008). For poorly controlled diabetes, excess glucose 
molecules enter into the red blood cells and attach to the hemoglobin to form 
glycated hemoglobin (A1C) through nonenzymatic reactions. A buildup of A1C stays 
for the lifespan of a red blood cell, so reflects blood glucose control for the past 2 to 3 
months (Gonen et al., 1977). A1C test is considered to be a gold standard for long-
term glycemic control (Nathan et al., 1984). The A1C concentration of 7.0% or less 
is recommended as a target for all patients with diabetes to reduce the risk of 
complications; and a target A1C concentration of 6.5% or less in T2D to further 
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reduce the risk of nephropathy if it can be safely achieved (Diabetes Care, 2009; 
Genuth et al., 2003). 
According to Canadian Diabetes Association (CDA) (Canadian Diabetes 
Association Clinical Practice Guidelines Committee, 2008), individuals may require 
lifestyle modifications,  as well as up to five groups of drugs to treat T2D and to 
prevent MetS and T2D associated complication, especially to reduce cardiovascular 
risk. These include: 1) oral hypoglycemia agents (OHAs); 2) insulin replacement 
therapy in more advanced stages; 3) lipid-lowering drugs (primarily statins) to reduce 
LDL-cholesterol, which is more susceptible to oxidation even at a normal level; 4) 
low-dose aspirin to prevent thrombosis; and 5) antihypertensive drugs, such as 
angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor 
antagonists (ARBs) to control blood pressure. Many also resort to some alternative 
medicines (Crawford, 2009; John et al., 2003; Vuksan et al., 2008). 
 
1.7.5.1 Lifestyle interventions  
Nonpharmacologic therapy, including a healthy diet, physical exercise, weight 
loss, smoke cessation and alcohol reduction, remains a critical component in the 
treatment of diabetes and should be superior to other treatment. It was reported that a 
7% body weight loss in human subjects with T2D resulted in 59±21 % improvement 
in insulin sensitivity (Hays et al., 2008). 
The optimal rate of weight loss is 1 to 2 kg/month and the modest weight loss 
of 5 to 10% of initial body weight (Goldstein, 1992) could substantially improve 
glycemic control, hypertension and dyslipidemia. It is recommended by CDA 
(Canadian Diabetes Association Clinical Practice Guidelines Committee, 2008) that 
Patients with diabetes should take aerobic exercise for at least 150 min per week 
(with no more than 2 consecutive days without exercise) and also be encouraged to 
perform resistance exercise 3 times per week. 
 
1.7.5.2 Oral hypoglycemia agents 
T2D can be delayed or prevented with lifestyle interventions or medication. 
But because lifestyle modifications are hard to instate and adhere to (Kravitz et al., 
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1993; Kurtz, 1990), pharmacological treatment is often necessary to treat T2D and to 
achieve optimal glycemic control. OHAs can be used either alone, or combined with 
other OHAs or insulin. There are various classes of OHAs (such as α-glucosidase 
inhibitors, biguanides, insulin secretagogues, insulin sensitizers and others) now 
available to target different factors (Table 1) (Krentz and Bailey, 2005; Moller, 
2001). 
 
1.7.5.2.1  α -Glucosidase inhibitors 
These drugs (Acarbose and Miglitol) competitively inhibit enzymes such as α-
glucosidase in the intestinal brush border. The latter is responsible for the breakdown 
of oligosaccharides and disaccharides into monosaccharides suitable for absorption 
(Tundis et al., 2010). α-Glucosidase inhibitors thus delay the intestinal absorption of 
glucose and lower postprandial glucose levels. They are very useful when 
combination with other OHAs. The main side effects of these drugs are 
gastrointestinal upset, including diarrhea and flatulence. 
 
 
 
Table 1: Current key therapeutic agents for type 2 diabetes (Moller, 2001). 
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1.7.5.2.2 Biguanides  
There were several biguanides available in the market 30 years ago. However, 
all but metformin were discontinued due to the high risk of lactic acidosis (Bolzano, 
1978). The mechanisms by which metformin exerts its antihyperglycemic effects are 
still not fully understood.  
Its major action in patients with diabetes is to reduce body glucose production 
by suppressing hepatic gluconeogenesis (Kirpichnikov et al., 2002). Secondly, 
metformin enhances glucose uptake in skeletal muscle partly by stimulating the 
translocation of GLUT4 to the membrane (Lee et al., 2011). Moreover, metformin 
increases peripheral insulin sensitivity (Li et al., 2011; Tamura et al., 2008), increases 
fatty acid oxidation, reduces triglyceride levels (Collier et al., 2006), and decreases 
absorption of glucose from the gastrointestinal tract (Grzybowska et al., 2011; 
Wilcock and Bailey, 1991). The insulin pathway, AMPK activation, as well as other 
AMPK-independent mechanisms are involved in these therapeutic effects (Foretz et 
al., 2010).  
Metformin is recommended as the first-line drug of choice for the treatment 
of T2D, in particular, in obese patients. It is also the only OHAs to show 
cardiovascular benefit in diabetes (Tankova, 2003). The most common adverse effect 
of metformin is gastrointestinal upset. 
 
1.7.5.2.3 Insulin secretagogues 
To stimulate insulin secretion, sulfonylureas (Gliclazide, glimepiride, 
glyburide) bind to the sulfonylurea receptor (SUR) on the surface of pancreatic β 
cells, which are coupled to subunits of an ATP sensitive potassium channel (Kir6.2) 
(Proks et al., 2002). The binding of a sulfonylurea to the sulfonylurea receptor results 
in the closure of the potassium channels, the depolarization of the cell membrane, and 
the opening of voltage-dependent calcium channels (Proks et al., 2002). The influx of 
calcium causes microtubules to contract and the exocytosis of insulin from secretory 
granules (Winkler and Gero, 2011). Non-sulfonylureas secretagogues  (Meglitinides) 
have similar effects to sulfonylureas but bind to the receptor at a different site (Ojima 
et al., 2004). Hypoglycemia and weight gain are probably the main side effects for 
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these insulin secretagogues. The second generations of sulfonylureas are more 
effective and less associated with hypoglycemia than the first generations. They are 
useful only in T2D and cannot be used in T1D, since they work by stimulating 
endogenous release of insulin. But it also needs to concern the potential acceleration 
of β cell failure occurring as a result of β cell decompensation as described earlier.  
 
1.7.5.2.4 Insulin sensitizers 
Thiazolidinediones (TZDs, including troglitazone, rosiglitazone and 
pioglitazone) function as ligands for the PPAR γ, to improve insulin sensitivity. 
Through PPAR γ activation, TZDs improve insulin sensitivity partly by enhancing 
differentiation of pre-adipocyte to adipocyte to improve lipogenesis and avoid 
lipotoxicity in non-adipose tissue. They also reduce lipolysis and hence FFAs in 
circulation. Finally, they alter cytokine and adipokines secretion (Bermudez et al., 
2010) from adipose tissue (notably, by decreasing TNF-α and leptin, and increasing 
adiponectin).  
The major side effects of TZDs include water retention (Tang et al., 2003), 
edema, congestive heart failure (Hernandez et al., 2011; Toprani and Fonseca, 2011) 
and weight gain (Fonseca et al., 2013). Although the latter side effect appears counter 
productive (obesity being a prominent risk factor for T2D), beneficial fat distribution 
changes occur since there is less visceral or abdominal fat and more subcutaneous fat. 
Troglitazone was withdrawn due to high risk of hepatic damage and failure (Faich 
and Moseley, 2001; Graham et al., 2003); pioglitazone has been withdrawn in some 
countries due to high risk of bladder cancer (Lewis et al., 2011). Rosiglitazone was 
found to increase cardiovascular disease (Graham et al., 2010), therefore has been 
withdrawn in Europe and is used in significant restrictions in the US. 
 
1.7.5.2.5 Others 
 Incretins are gastrointestinal peptide hormones and the short-lived activities 
of native incretins such as glucagon-like peptide 1 (GLP-1) are due to the rapid 
degradation by the dipeptidyl peptidase 4 (DPP4) enzyme. Unlike other 
secretagogues acting on the potassium channel, GLP-1 stimulates pancreas insulin 
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secretion by promoting proinsulin gene expression (Drucker et al., 1987) and β cells 
proliferations through GLP-1 receptor (GLP-1R). In addition to this, GLP-1 has also 
multi actions to treat T2D including, inhibiting glucagon secretion and reducing 
gastric emptying and thus induce satiety after nutrient ingestion (Ahren, 1998; Ahren 
and Schmitz, 2004) (shown in Figure 7). This prompted the development of GLP-1 
analogues (exenatide and liraglutide) and DPP4-selective inhibitors (sitagliptin, 
vildagliptin, and linagliptin) (Behme et al., 2003; Doupis and Veves, 2008; Nauck et 
al., 2011) to address hyperglycemia. 
Beyond the GLP-1 analogues and DPP4 inhibitors, there are other potential 
targets: SGLT2 (Idris and Donnelly, 2009); G-protein-coupled receptors (GPCRs) 
and partial agonists of PPAR γ as well as selective PPAR α/γ modulators. Indeed, 
canagliflozin (or Invokana) is the first in class SGLT2 targeting drug approved by the 
FDA (Traynor, 2013) this March. 
 
        
 
Figure 7: Direct actions of GLP-1 on pancreas, heart, stomach, brain and 
indirect actions on liver and muscle. (Drucker, 2006) 
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1.7.5.3 Insulin therapy 
Since T2D progresses over time, many patients need to add insulin when their 
blood glucose is no longer well controlled by OHAs. There are various types of 
injectable insulin, which are classified into rapid acting, short acting, immediate 
acting and long acting insulin. Blood glucose levels need to be measured and 
monitored daily (often at mealtime) to adjust the doses of insulin therapy. 
 
1.7.5.4  Complementary and alternative medicines  
Dissatisfaction with the high costs and side effects of conventional 
pharmaceuticals has resulted in increasingly patients seeking for various 
complementary and alternative medicines (CAM) with antihyperglycemic effect. In 
both the developing countries, those are Asia, Africa, Latin America and the Middle 
East and some industrialized nations, Canada, France, Germany and Italy for 
instance, 70–90% of the populations rely on traditional medicines (TM) as primary 
health care to address their health-care concerns (Robinson and Zhang, 2011). 
There are many plant species that have been identified worldwide as having 
antidiabetic potential. Examples of some widely used herbal medicines with 
antidiabetic potentials are Trigonella foenum graecum (Fenugreek) (Gupta et al., 
2001); Momordica charantia (bitter melon)(John et al., 2003); Cinnamomum cassia 
(Chinese cinnamon) (Crawford, 2009; Khan et al., 2003); Aloe vera 
(Bunyapraphatsara et al., 1996) and Ginseng (Sotaniemi et al., 1995; Vuksan et al., 
2008). A number of drugs currently used to treat diabetes were derived from plant or 
fungal material. These include metformin (derived from Galega officinalis L. (Oubré 
et al., 1997)), acarbose (derived from Actinoplances spp.) (Lee and Egelkrout, 1998; 
Lee et al., 1997). 
As we discussed previously, Canadian Aboriginals, such as the CEI, exhibit a 
much higher prevalence of T2D than the general populations. Their age-adjusted 
prevalence of disease reached 29% in 2009 or 3 to 5 times higher (Kuzmina et al., 
2010 ) compared with the rest of the Canadian population. They also suffer from 
higher rate of diabetic complications (Young et al., 2000). This serious problem has 
been related to a sedentary lifestyle and non-traditional diet (Hegele, 2001), a genetic 
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predisposition towards obesity (Neel, 1999; Skyler, 2004), as well as cultural 
disconnect (Young et al., 2000) of the modern or western pharmaceutical therapies 
described above.  
For centuries, the aboriginal peoples relied on traditional healing for many 
diseases, knowledge that was verbally taught and handed down from generation to 
generation (Young et al., 2000). Medicinal plants played an important role in this 
holistic approach. Although some of this knowledge was lost, anthropologists 
documented the use and administration of many plant species belonging to aboriginal 
medicine.  
For responding to this primary health care needs of the CEI and to search for 
culturally adapted T2D therapies, in 2013, CIHR Team in Aboriginal Antidiabetic 
Medicines (CIHR-TAAM) was instated. It was a multipartite project researching the 
antidiabetic effects of plants used by aboriginals. This project especially required a 
highly coordinated effort between three parts, including the CEI, research scientists, 
and health care professionals. The multi-disciplinary research team assembled for this 
project possessed considerable expertise in pharmacology, phytochemistry, and in 
nutrition, human clinical as well as health systems research.  
An ethnobotanical approach (Fraser et al., 2007) was used to identify 
medicinal plants, based on several symptoms related to diabetes. Seventeen plant 
species were evaluated in several screening studies (Harbilas et al., 2009; Harris et 
al., 2011b; Nachar et al., 2013; Nistor Baldea et al., 2010; Spoor et al., 2006) using a 
variety of in vitro bioassays to assess their antidiabetic potentials. As explained 
earlier in terms of the clinical consequences of IR, bioassays were selected for 
primary (those likely to result in a reduction in blood glucose) and for secondary 
(diabetes complications) antidiabetic potential. Hence, among primary antidiabetic 
bioassays, the potential to increase glucose uptake in muscle cells, the inhibition of 
hepatic glucose production, the effects on adipogenesis, and those on insulin 
secretion in pancreatic β cells were evaluated (Haddad et al., 2012; Harbilas et al., 
2009; Nachar et al., 2013; Spoor et al., 2006), whereas secondary bioassays such as 
for antioxidant capacities were also carried out.  
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1.8 Secondary metabolites and bioactive compounds 
Secondary metabolites are a group of non-essential compounds that play a key 
role in the wellbeing of plants. They are involved in defense against ultraviolet 
radiation or aggression by parasites, as well as contributing to flavours and colors of 
plants. Several natural bioactive compounds have been discovered for their potential 
health benefit effects related to the prevention and treatment of chronic disorders 
such as cardiovascular disease, cancer, inflammatory and metabolic diseases 
including diabetes and obesity (Adisakwattana et al., 2009; Ishikawa et al., 2007; 
Wahle et al., 2010; Welsch et al., 1989). They are grouped into classes such as 
phenolics, terpenoids, alkaloids, and glycosides, based on similar structures or their 
plant origin.  
 
1.8.1 Natural Phenolics  
Phenolics are compounds with one or more aromatic rings containing at least 
one hydroxyl group covalently bonded to the aromatic ring. They are widely 
distributed and are one of the most abundant secondary metabolites of plants. There 
are more than 8,000 known phenolics, ranging from simple molecules to highly 
polymerized substances such as tannins. Natural phenolics include several subclasses 
such as flavonoids, phenolics acids, tannins and the less common stilbenes and 
lignans (Crozier et al., 2009).  
 
1.8.1.1 Flavonoids  
Flavonoids are one of the most important polyphenols in plants and our diets. 
All flavonoids share the basic C6-C3-C6 structural skeleton, consisting of two 
aromatic C6 rings and a heterocyclic ring that contains one oxygen atom (Crozier et 
al., 2009) (Figure 8). Studies show that flavonoids have strong antioxidant, anti-
inflammatory, anti-allergic, anti-microbial and anti-cancer activities, as well as 
antidiabetic potentials (Crozier et al., 2009). They have been classified into six 
subgroups: flavones, flavonols, flavanols, flavanones, isoflavones, and anthocyanins, 
according to the oxidation state of the central carbon ring.  
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Figure 8: Structures of flavonoids. 
 
1.8.1.2 Phenolic acids 
Phenolic acids can be divided into two classes: derivatives of benzoic acid 
such as gallic acid, and derivatives of hydroxycinnamic acid such as caffeic, 
coumaric and ferulic acids. Caffeic acid is one of the most abundant phenolic acids in 
many fruits and vegetables. Besides their well-known antioxidant properties, several 
studies showed that phenolic acids also have antidiabetic potentials. Chlorogenic acid 
was reported to enhance glucose uptake in time- and dose-dependent manner in 
myotubes (Prabhakar and Doble, 2009). A series of phenolic acids, including caffeic 
acid, chlorogenic acid (ester of caffeic acid) and p-coumaric acid exhibited α-
glucosidase inhibitory activity, thus indicating a potential to reduce intestinal glucose 
absorption (Adisakwattana et al., 2009; Ishikawa et al., 2007; Welsch et al., 1989). 
Caffeic acid phenethyl ester (CAPE) and other derivatives were confirmed to 
stimulate glucose uptake and uncouple isolated mitochondria. Additionally, their 
activity required that there is no strongly ionized group in the compound (Eid et al., 
2010).  
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1.8.1.3 Tannins 
Tannins are polyphenols ubiquitously present in plants and diets. They have 
attracted attention recently for their beneficial properties to human health, which 
include antioxidant (Barreiros et al., 2000), immunomodulatory (Lin et al., 2002), 
antidiabetic (Klein et al., 2007; Li et al., 2005) and cardioprotective activities (Bagchi 
et al., 2003). 
Tannins are divided into two groups: hydrolysable tannins and condensed 
tannins. The former are polyphenolic acids esterified to a carbohydrate core, made up 
mostly of glucose, with phenolic groups such as gallic acid for gallotannins or ellagic 
acid for ellagitannins. Condensed tannins, like proanthocyanidinson, are polymers of 
covalently bonded flavonols with high molecular weights of up to 23 900 Da.   
One particular type of condensed tannin, are procyanidins, which are 
oligomers or polymers (2 to 50, or more) of flavan-3-ols (mostly catechins or 
epicatechins) units linked by carbon-carbon bonding (Santos-Buelga, 2000). 
 
1.8.1.4 Stilbenes  
Stilbenes are a small group of phenolics characterized by a 1,2-
diphenylethylene backbone. Resveratrol has been extensively studied and has been 
shown to possess potent life extension (Howitz et al., 2003), cancer prevention (Jang 
et al., 1997; Sheth et al., 2012). Rhapontigenin (an analog of resveratrol), rhaponticin 
(the glycosylated form of rhapontigenin) and piceatannol were shown to have anti-
allergic and anti-oxidant activities (Matsuda et al., 2001; Park et al., 2002). 
Rhapontigenin has also been shown to have antidiabetic activity by inhibiting 
mammalian intestinal α-glucosidase activity (Suresh Babu et al., 2004). These 
stilbenoids, but not resveratrol were identified in L. laricina (Figure 9) (Shang et al., 
2012). See Chapter 2 for further details about its isolation and biological activity. 
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Figure 9: Structure of rhapontigenin (7), piceatannol (8), rhaponticin (9) 
identified in Larix laricina (Shang et al., 2012). 
 
1.8.1.5 Lignans 
Lignans are another major polymer polyphenols compounds that are 
distributed in a large number of plants and foods, such as flax and sesame seeds. 
They represent a major class of phytoestrogens; other classes including isoflavones, 
coumestans and stilbenes (Gencel et al., 2012). Only a few of lignans (such as seco-
isolariciresinol, matairesinol, pinoresinol and lariciresinol) can be converted into the 
absorbable enterolignans by the intestinal microflora.  
Lignans possess several biological activities, associated with decreasing the 
risk of breast cancers (Dai et al., 2002; Pietinen et al., 2001) as well as cardiovascular 
diseases (Vanharanta et al., 2003). Two derivates of lariciresinol were isolated in 
L.laricina and are further presented in Chapter 2 (Shang et al., 2012). 
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Figure 10: Structures of (+)-lariciresinol-3-acetate (5) and (+)-lariciresinol-9’-
p-coumarate (6) found in Larix laricina. (Shang et al., 2012) 
 
1.8.2 Terpenes 
 Terpenes and terpenoids (the modified triterpenes) are biosynthetically 
derived from a branched isoprene (C5H8). According to the numbers of the units, 
they have been further subdivided into: hemiterpene (C5); monoterpene (C10); 
sesquiterpene (C15); diterpenes (C20); sesterterpene (C25); triterpenes (C30) and 
higher terpenoids with more units (Turner et al., 1999).  
A new terpenoid, determined to be 23-oxo-3-hydroxycycloart-24-en-26-oic 
acid, as well as several diterpenes were identified in L. laricina (Figure 11), as 
detailed in Chapter 2 (Shang et al., 2012). Ginsenosides are steroid-like triterpenoids 
found exclusively in Ginseng. Ginsenosides have multiple targets in cells and a 
multitude of therapeutic effects, e.g. being used in inflammatory diseases, cancer and 
neurodegenerative disorders and diabetes. 
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Figure 11: Structure of the new terpenoid as 23-oxo-3α-hydroxycycloart-24-
en-26-oic acid (compound 1) and three diterpenes 13-epitorulosol (compound 2) and 
13-epicupressic acid (compound 3), 19-norlabda-8 (17), 14-dien-4,13-diol 
(compound 4) found in Larix laricina. (Shang et al., 2012) 
 
1.8.3 Metabolites analysis 
Individual plant species contain thousands of metabolites. Metabolomics is a 
comprehensive analysis for small molecules in a biological system, such as cell, 
tissue, organ and plants. It has been applied in various research areas. . Wide variety 
of extraction, separation, detection and the statistical analyses techniques are 
currently under use to study plant compounds.  
These include separation methods like gas chromatography (GC) and liquid 
chromatography (LC) and detection methods like mass spectrometry (MS) and 
nuclear magnetic resonance (Griffin, 2003; James et al., 2013; Negi et al., 2012; 
Trethewey et al., 1999). Coupling separation and detection methods, like LC-MS, is 
preferred to explore changes in metabolite profiles at qualitative and quantitative 
levels. 
High performance liquid chromatography (HPLC) is a powerful separation 
technique to separate compounds with a wide range of polarity with high resolution. 
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Majority of HPLC applications are covered under reversed phase chromatography, 
with non-polar stationary phase and an aqueous, polar mobile phase. Application of 
ultra performance liquid chromatography (UPLC) is a recent advancement which has 
considerably further improved chromatographic resolution of overlapping 
metabolites and the sensitivity of MS detection (Wu et al., 2006).  
A mass spectrometer is typically composed of three major parts: an ion source 
(like electrospray ionization (ESI) to convert metabolites into ions), a mass analyzer, 
and a detector. The main function of the mass analyzer is to separate these ionized 
molecules according to the mass-to-charge (m/z) ratios. There are a number of mass 
analyzers available now, include quadrupoles, time-of-flight (TOF) ， magnetic 
sector, ion-trap and fourier transformation ion cyclotron. Tandem (MS-MS) mass 
spectrometers have more than one analyzer, like quadrupole-time-of-flight (QTOF) 
(Thurman et al., 2013), can be used for structural identification and quantitative 
studies. UPLC coupled to MS, especially with a high mass resolution such as a 
QTOF MS (Abu-Reidah et al., 2013), is a powerful approach to separate, detect, and 
analyze metabolites present in plant extracts.  
Then the raw LC-MS data is converted into a peak list with m/z and retention 
time by different software before the statistic analysis, aiming to detect the peaks 
whose intensity levels are significantly altered between distinct groups. 
In multivariate analyses, categorized as unsupervised principal component 
analysis (PCA) as well as supervised orthogonal partial least squares discriminant 
analysis (OPLS-DA). As one projection method, PCA could be used to reduce and 
summarize the variability of the matrix of peaks data form LC-MS. PCA could show 
a good overview of all the variables in score plots, with two new variables. 
Observations those near to each other are probably similar; while those who are far 
away from each other are different.  
OPLS-DA is a maximum separation projection method used for classification 
study and biomarker identification (Boccard and Rutledge, 2013), especially from the 
S-plot. These usually lie in the top or bottom extremities of the S-plot, and are 
characterized by sufficiently important statistical differences to render them potential 
biomarkers. Biomarker identification is accomplished by performing a match of 
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elemental composition and / or monoisotopic mass with entries in online databases 
including METLIN, ChemSpider, PlantMetaboliteNetwork, ADC labs, NIST.  
 
1.9 Objectives of the study 
17 CEI medicinal plants have been identified through a comprehensive 
approach by our group as candidate antidiabetic plants used by the CEI First Nation 
to treat various symptoms of T2D. Among them, L. laricina was recently identified 
as one of the top plants. It stimulated glucose uptake in C2C12 muscle cells and 
strongly potentiated the differentiation of 3T3-L1 pre-adipocytes indicating 
potentially enhanced insulin sensitivity (Spoor et al., 2006). The thesis firstly aimed 
at isolating putative antidiabetic active principles responsible for the potentiation of 
adipogenesis of the extract of the inner bark of L. laricina by using a bioassay-guided 
fractionation approach. 
Secondly, all screening studies performed thus far by the CIHR-TAAM have 
focused on ethanol extracts (EE) using an in vitro bioassay platform. However, 
traditional preparations are often based on hot water. This thesis thus also aimed to 
evaluate and compare the antidiabetic potentials of ethanol and water extracts of 
these plants using the same three in vitro bioassays, namely adipogenesis in 3T3-L1 
cells, glucose uptake in C2C12 myocytes and glucose production in H4IIE 
hepatocytes.  The possible mechanisms involved in the regulation of glucose and 
lipid metabolism was also assessed for a selected subset of Boreal forest plant 
species.  
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Chapter 2: Article 1 
Published in the Journal of Ethnopharmacology, 2012 Jun 14, 141(3):1051-
1057; Epub, 2012 Apr 19 
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           Abstract 
 
Ethnopharmacological relevance: Diabetes is a growing epidemic 
worldwide, especially among indigenous populations. Larix laricina was identified 
through an ethnobotanical survey as a traditional medicine used by Healers and 
Elders of the Cree of Eeyou Istchee of northern Quebec to treat symptoms of diabetes 
and subsequent in vitro screening confirmed its potential. Materials and Methods: 
We used a bioassay-guided fractionation approach to isolate the active principles 
responsible for the adipogenic activity of the organic extract (80% EtOH) of the bark 
of L. laricina. Post-confluent 3T3-L1 cells were differentiated in the presence or 
absence of the crude, fractions or isolates of L. laricina for 7 days, then Triglycerides 
content was measured using AdipoRed reagent. Results: We identified a new 
cycloartane triterpene (compound 1), which strongly enhanced adipogenesis in 
3T3-L1 cells with an EC50 of 7.7 µM. It is responsible for two thirds of the activity of 
the active fraction of L. laricina. The structure of compound 1 was established on the 
basis of spectroscopic methods (IR, HREIMS, 1D and 2D NMR) as 23-oxo-
3α-hydroxycycloart-24-en-26-oic acid. We also identified several known compounds, 
including three labdane-type diterpenes (compounds 2-4), two tetrahydrofuran-type 
lignans (compounds 5-6), three stilbenes (compounds 7-9), and taxifolin (compound 
10). Compound 2 (13-epitorulosol) also potentiated adipogenesis (EC50 8.2 µM) and 
this is the first report of a biological activity for this compound. Conclusions:  This 
is the first report of putative antidiabetic principles isolated from L. laricina, 
therefore increasing the interest in medicinal plants from the Cree pharmacopeia.  
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1. Introduction 
 
Type 2 diabetes (T2D), a chronic metabolic disorder characterized by 
impaired insulin secretion and insulin sensitivity, has become a worldwide epidemic 
according to WHO (Roglic and Unwin, 2010; Shaw et al., 2010; Whiting et al., 2010; 
Wild et al., 2004). T2D is more pronounced among indigenous populations, as is the 
case in the Cree Nation of Eeyou Istchee (CEI) of northern Quebec, where the age-
adjusted prevalence of disease reached 29% in 2009 (Kuzmina et al., 2010 ). The 
burden of T2D and the ensuing deleterious complications (cardiovascular, 
retinopathy and nephropathy) prompted the search for culturally adapted treatment 
alternatives for these aboriginal populations. 
Larix laricina (Watnagan, Tamarack, mélèze) is a highly respected plant used 
by many First Nations throughout Canada as a culturally important medicine to treat 
several ailments, including cuts, burns, coughs, stomach pain, sores (mouth, skin and 
throat), heart problems and frostbite (Holmes, 1884; Leighton, 1985; Marles et al., 
2000; Marshall et al., 2006; Marshall et al., 1989; Siegfried, 1994). The bark was 
especially identified for the treatment of sores, frequent urination, poultice on 
infected wounds and to heal the insides by Aboriginals of Eastern Canada (Arnason 
et al., 1981; Black, 1980; Holmes, 1884). Through a quantitative ethnobotanical 
study of traditional medicines conducted by our team in collaboration with Healers 
and Elders of four CEI communities, the inner bark L. laricina was recently 
identified as one of the top eight plants for the treatment of symptoms of diabetes 
[namely frequent urination, blurry vision, slow healing wounds, etc.] (Leduc et al., 
2006). The extract of this plant was tested in a comprehensive platform of in vitro 
bioassays designed to detect potential antidiabetic biological activities (Haddad et al., 
2012). L. laricina stimulated glucose uptake in C2C12 muscle cells and strongly 
potentiated the differentiation of 3T3-L1 pre-adipocytes indicating enhanced insulin 
sensitivity (Spoor et al., 2006). The present study aims at isolating putative 
antidiabetic active principles responsible for the potentiation of adipogenesis of an 
organic extract of the inner bark of L. laricina by using a bioassay-guided 
fractionation approach.   
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 2. Materials and Methods 
 
2.1 Cell lines, chemicals, biochemical and equipment  
2.1.1Bioassay:  
The pre-adipocyte 3T3-L1 cell line was purchased from the American Type 
Culture Collection (ATCC; Manassas, VA). Dexamethasone (DXM), bovine 
pancreatic insulin, 3-isobutyl-1-methylxanthine (IBMX), dimethyl sulfoxide 
(DMSO) were purchased from Sigma-Aldrich. Rosiglitazone came from Alexis 
Biochemicals (Hornby, ON). Dubelcco’s Modified Eagle Medium (DMEM), fetal 
bovine serum (FBS) and bovine calf serum (BCS) were from Wisent Inc (St-Bruno, 
QC). Triglyceride content was measured using Adipored reagent purchased from 
Lonza Walkersville Inc (Walkersville, MD). 
2.1.2 Phytochemistry:  
The preparative scale isolation of the phytochemicals was undertaken on a 
reverse phase Gemini Axia column 250 × 21.2 mm I.D., particle size 10 microns 
(Phenomenex Inc., Torrance, CA, USA) using a 30 minute linear gradient of 20 to 
80% of CH3CN in water at the flow rate of 31.5 mL/min, at the monitoring 
wavelength of 210 nm, band width 4, reference off. The Agilent 1200 Series 
preparative HPLC system (Agilent Technologies, Montreal, QC, Canada) consisted 
of a binary pump (flow rate range 5-100 mL/min), an autosampler with a 2mL loop, a 
diode array detector with a flow cell (path length 3 mm and maximum pressure limit 
120 bars) and a fraction collector (40 mL collection tubes). IR spectra were recorded 
using a Shimadzu 8400-S FT/IR spectrometer. Optical rotations were assessed on a 
Perkin-Elmer 241 digital polarimeter. NMR spectra were obtained from a Bruker 
Avance 400 spectrometer (Bruker, Biospin Corporation, Billerica, MA, USA) in 
C5D5N, either at 400 MHz (1H) or 100 MHz (13C), using tetramethylsilane (TMS) as 
an internal standard. EIMS and HREIMS were obtained on a Kratos Concept IImass 
spectrometer (Kartos Analytical, Chestnut Ridge, NY, USA). Open column 
chromatography was carried out on silica gel 60 (70-230 mesh; Merck & Co., 
Whitehouse Station, NJ, USA). TLC analyses were performed on silica gel 60 F254 
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plates (Merck & Co, Whitehouse Station, NJ, USA), and visualization of the plates 
was carried out using a ceric sulfate (10%) solution in H2SO4. 
2.2 Plant material  
Stem bark (1.5 Kg) of L. laricina was collected in Mistissini, Quebec, in 
August 2008 and identified by Dr. Alain Cuerrier, a taxonomist at the Plant Biology 
Research Institute, Université de Montréal. A voucher specimen (MIS0312) was 
deposited at the Marie-Victorin Herbarium (MT) of the same Institute. 
2.3 Extraction and Isolation 
Dried and shredded bark (1.5 Kg) was extracted with 15.0 L of 80% EtOH: 
20% water during 24 h at room temperature. The supernatant was removed and the 
pellet was re-extracted with 8.0 L of 80% EtOH: 20% water. The pooled supernatants 
were evaporated in vacuo to yield 430 g of a dark red residue (crude extract, LLE). 
Part of the dried crude extract (100 g) was then chromatographed in a glass column 
(600 mm × 100 mm I.D.) packed with silica gel (2.0 Kg) eluting with hexanes-ethyl 
acetate (EtOAc) (1:0→0:1) and EtOAc-methanol (MeOH) (1:0→0:1) to yield a total 
of one hundred and forty fractions (250 ml each), which were combined on the basis 
of their TLC profiles. After solvent evaporation and combination of the fractions, 
sixteen primary fractions (LLE1 – LLE16) were obtained. From fraction LLE10 (1.0 
g) eluted with EtOAc (100%), 600 mg of rhaponticin (compound 9) spontaneously 
precipitated. The structure of each compound is illustrated in Figure 1. 
From fraction LLE1 (20.0 g) eluted with hexanes-EtOAc (9:1), 15 mg of 19-
norlabda-8(17),14-dien-4,13-diol (compound 4) were obtained by reversed phase 
preparative scale HPLC using the same analytical condition as described above. 
Fraction LLE-2 (9.0 g) eluted with hexanes-EtOAc (8:2), afforded 25 mg of 13-
epitorulosol (compound 2) and 15 mg of 13-epicupressic acid (compound 3), which 
were obtained by preparative scale. Fraction LLE4 (4.0 g) eluted with hexanes-
EtOAc (4:6) was subjected to the same purification HPLC procedure yielding 8 mg 
of (+)-lariciresinol-3-acetate (compound 5), 12 mg of (+)-lariciresinol-9’-p-
coumarate (compound 6), 10 mg of rhapontigenin (compound 7) and 15 mg of 
piceatannol (compound 8). From fraction LLE5 (1.0 g), eluted with hexanes-EtOAc 
(3:7), 20 mg of the new compound 23-oxo-3α--hydroxycycloart-24-en-26-oic acid 
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(compound 1) were obtained by the same preparative scale HPLC methodology. In 
addition to compound 1, compounds 4 to 7 were also obtained from fraction LLE5 as 
well as 15 mg of taxifolin (compound 10). 
 
2.4 Identification of 23-oxo-3α-hydroxycycloart-24-en-26-oic acid (1) 
Compound 1 was determined to be a novel chemical entity. The purified 
compound presented as a beige amorphous powder, with the following optical 
properties: [α]25D +34.5° (c 1.09, MeOH). UV spectrum (MeOH) yielded two peaks: 
λmax 205 and 215 nm. Infrared spectroscopy (KBr) yielded the following values: 
νmax3350, 2920, 1705 (br), 1675, 1375, 1220 and 1146 cm-1. For mass spectroscopy, 
the following results were obtained: EIMS m/z 470 [M]+(8), 452 [M-H2O]+(16), 431 
[M –CO2 + H]+(25); HREIMS m/z 471.3936 [M + H]+ (calcd. for C30H47O4: 
471.8368). For 13C NMR (100 MHz, Pyr-d5), the following signals were displayed δ 
15.0 (q, C-27), 18.2 (q, C-18), 19.5 (q, C-30), 19.6 (q, C-21), 19.8 (q, C-9), 21.4 (t, 
C-6), 21.7 (q, C-28), 26.1 (t, C-11), 26.5 (t, C-16), 26.9 (q, C-29), 27.1 (s, C-10), 28.1 
(t, C-7), 28.5 (t, C-19), 29.7 (t, C-2), 29.8 (t, C-1), 33.1 (t, C-12), 33.5 (d, C-20), 35.6 
(t, C-15), 40.1 (s, C-4), 41.1 (d, C-5), 45.6 (s, C-13), 48.1 (d, C-8), 49.3 (s, C-14), 
52.3 (t, C-22), 52.6 (d, C-17), 76.0 (d, C-3), 132.9 (d, C-24), 142.2 (s, C-25), 170.5 
(s, C-26), 202.7 (s, C-23); 1H NMR (400 MHz, Pyr-d5) δ1.90 (2H, m, H-1a, H-1b), 
1.28 (2H, m, H-2a, H-2b), 3.69 (H, t, J = 2.4 Hz, H-3β),2.23 (H, m, H-5),0.75 (H, m, 
H-6a), 1.04 (H, m, H-6b), 1.05 (H, m, H-7a),2.3 (H, m, H-7b), 1.65 (H, m, H-8), 1.14 
(2H, m, H-11a, H-11b), 1.58 (2H, m, H-12a, H-12b), 1.28 (2H, m, H-15a, H-
15b),1.90 (H, m, H-16a), 1.98 (H, m, H-16b),1.64 (H, m, H-17),1.04 (3H, s, H3-
18),0.32 (H, d, J = 3.4 Hz, H-19a),0.48 (H, d, J = 3.4 Hz, H-19b),1.53 (H, m, H-
20),1.02 (3H, d, J = 6.0 Hz, H3-21),2.36 (H, dd, J = 15.6, 9.8 Hz, H-22a),2.73 (H, dd, 
J = 15.6, 2.8 Hz, H-22b), 7.57 (H, d, J = 1.2 Hz, H-24), 2.57 (3H, d, J = 1.2 Hz, H3-
27), 0.96 (3H, s, H3-28), 1.2 (3H, s, H3-29), 0.89 (3H, s, H3-30). 
 
2.5 Cell culture  
Pre-adipocyte 3T3-L1 cells were grown to confluency in DMEM containing 
10% FBS (proliferation medium). 24 h post-confluence (day 0), cell were induced to 
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differentiate with high-glucose DMEM supplemented with 10 % FBS, 1 µM 
dexamethasone, 250 µM 3-isobutylmethylxanthine (IBMX) and 500 nM insulin. 
After 48 h, the media was replaced with DMEM containing 10 % FBS and 500 nM 
Insulin. Cells were differentiated for a total of 7 days with media change every 2 
days. Plant extracts and fractions (25 µg/ml), compounds (0.5 to 100 µM) as well as 
rosiglitazone (10 µM; inducer of differentiation) were dissolved in DMSO (0.1 % 
final concentration), and added to the cells at day 0 of differentiation and replenished 
at every medium change thereafter. 
 
2.6 Adipogenesis 
Adipogenesis was assessed in the well-characterized 3T3 L1 cell model by 
measuring the accumulation of triglycerides (TG) upon differentiation (at day 7), 
using the AdipoRed reagent according to the manufacturer’s instructions as described 
previously with minor modifications (Harbilas et al., 2009; Spoor et al., 2006). 
Briefly, after washing each well twice with Phosphate-Buffered Saline (PBS: 8.1 mM 
Na2HPO4, 1.47 mM KH2PO4, 137 mM NaCl, and 2.68 mM KCl; pH 7.4), 2 mL of 
PBS containing 60 µL of AdipoRed reagent were added to each well and incubated 
for 15 minutes at room temperature. AdipoRed becomes fluorescent when partitioned 
in a hydrophobic compartment. The fluorescence of each well was measured by 
fluorimeter (Wallac Victor2; Perkin-Elmer, St-Laurent, Qc) at 485 nm excitation and 
572 nm emission wavelengths. The results were reported as percentage of the vehicle 
control (0.1 % DMSO). 
 
2.7 Statistical analysis 
Intracellular TG content results are presented as mean ± SEM of 3 
independent experiments, each performed in triplicate. Statistical calculations and 
EC50 (calculated using sigmoidal dose-response (variable slope) analysis was 
performed with Prism GraphPad software. Differences between groups were 
analyzed by one-way analysis of variance (ANOVA). A p value below 0.05 was 
considered statistically significant. 
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3. Results 
 
3.1 Adipogenic activity of L. laricina fractions and compounds 
The crude 80% EtOH extract of L. laricina bark (LLE) at a concentration of 
25 µg/mL increased the accumulation of TG in 3T3-L1 cells by approximately 2.5 
fold, when compared to the DMSO vehicle control (Figure 2A). The sixteen primary 
fractions (LLE-1-LLE-16) obtained from silica gel column chromatography of LLE 
were also assessed alongside the parent extract. Also tested at 25 µg/ml, fractions 
LLE-1 as well as LLE-3 to LLE-7 significantly increased intracellular TG up to 5.4 
fold as compared to vehicle control (0.1% DMSO; Figure 2A). More specifically, 
fractions LLE-1 (317 ± 71 %), LLE-3 (367 ± 35 %), LLE-4 (401 ± 53 %), and LLE-5 
(538 ± 46 %) demonstrated significantly stronger adipogenic activity than the crude 
extract (238 ± 32 %; p ≤0.05; Figure 2A). 
Compounds 1 to 8 and 10 were isolated from fractions LLE-1 to LLE-5 after 
preparative scale isolation (Figure 1). These isolates were: a new cycloartane 
triterpenoid identified as 23-oxo-3α-hydroxycycloart-24-en-26-oic acid (compound 
1); three labdane diterpenes: 13-epitorulosol (compound 2) 13-epicupressic 
(compound 3) and one 4-hydroxy-nor-diterpene: 19-norlabda-8(17),14-dien-4,13-diol 
(compound 4); two lignans: (+)-lariciresinol-3-acetate (compound 5) and (+)-
lariciresinol-9’-p-coumarate (compound 6); two stilbenoids: rhapontigenin 
(compound 7), piceatannol (compound 8), and one flavonoid taxifolin (compound 
10). In addition, significant amounts of rhaponticin (compound 9) were obtained 
from the fraction LLE-10. The known compounds 2 to 10 were identified by 
comparison of their spectroscopic data with those already reported in the literature. 
(Caputo et al., 1973; Chen et al., 2009; Kashiwada et al., 1984; Markham, 1976; 
Mills, 1973; Nair and Von Rudloff, 1959; Pacheco et al., 2009; Pichette et al., 2006; 
Rajasekhar and Subbaraju, 2000; Xue et al., 2004; Xie et al., 2003; Yang et al., 
2005). The identification of the new compound (compound 1) was conducted by 1D 
NMR (1H, 13C, DEPT) and 2D NMR (NOESY, COSY, HMQC) analysis, as 
described further below. 
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The compounds were tested at varying concentrations ranging from 0.5 to 
25 µg/mL (0.5-100 µM) on 3T3-L1 cells to determine their adipogenic effect. As 
illustrated in Figure 2B, most isolates did not show significant potentiation of 
adipogenesis as compared to vehicle when tested at concentrations up to 10 µg/ml. 
Only the new compound 1 (23-oxo-3α-hydroxycycloart-24-en-26-oic acid) and 
compound 2 (13-epitorulosol) caused significant increases in adipogenesis with 
physiological dose-response relationships yielding EC50 values of 7.7 µM (3.6 
µg/mL) and 8.2 µM (2.5 µg/mL) respectively (Table 1). Indeed, the maximal 
potentiating effect of compound 1 (453± 30 %; 10 µg/ml) was significantly higher 
than that of the crude extract (305 ± 23 %; 25 µg/mL; p ≤0.01), while not 
significantly different from that of the active fraction LLE-5 (555 ± 36 %; 25 µg/ml; 
not significant (ns); Figure 2B). 3T3-L1 cells treated with 10 µg/mL of compound 2 
potentiated adipogenesis by 275 ± 40 % (p ≤0.001 as compared to DMSO; Figure 
2B), which almost reached the crude extract level (305 ± 23 %; 25 µg/mL; ns), 
however it caused cell death and detachment at high concentrations, as determined 
morphologically (25 µg/mL; data not shown). The remaining 8 compounds did not 
display any toxicity to 3T3-L1 adipocytes at any of the concentrations tested. 
Noteworthy, compound 7 (rhapontigenin) significantly potentiated adipogenesis of 
3T3-L1 cells at high concentration only (337 ± 36 %; 25 µg/ml; p ≤0.001; data not 
shown), with an EC50 of 145 µM (37.5 µg/mL).  
 
3.2 Chemical identification of compound 1 
Compound 1 was obtained as a white amorphous powder. A molecular 
formula of C30H46O4 was assigned for this compound by HREIMS, which was 
corroborated by 13C NMR data recorded in pyridine d-5. Its IR spectrum showed a 
broad carbonyl (1705 cm-1) band, an alpha beta unsaturated double bond (1675 cm-1) 
and hydroxyl group associated band (3350 cm-1). The 1H NMR spectrum of 1 
indicated the presence of a pair of upfield doublets at δ0.32 (H, d, J = 3.4 Hz, H-19a) 
and 0.48 (H, d, J = 3.4 Hz, H-19b), characteristic of cycloartane triterpenoids (Li et 
al., 2012). The 1H NMR spectrum of 1 also displayed four angular methyls at δH 18.2 
(s, H3-18), 19.5 (s, H3-30), 21.7 (s, H3-28) and 26.9 (s, H3-29), a methyl doublet at δH 
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19.6 (d, J = 6.0 Hz, H3-21), and an olefinic methyl doublet at δH 19.6 (d, J = 1.2 Hz, 
H3-27). The 13C NMR spectrum of 1 showed two signals belonging to its carbonyls: 
an enone at δC 202.3 (C-23), and a carboxyl at δC 171.5 (C-26). Comparisons of the 
13C NMR spectra data with those of cycloartanes, particularly the 3-oxo-23-
hydroxycycloart-24-en-26-oic acid isolated from Mangifera indica (Anjaneyulu et 
al., 1989; Anjaneyulu et al., 1999) and the 23-dioxo-cycloart-24-en-26-oic acid 
isolated from Pseudolarix amabilis (Jayasuriya et al., 2005) indicated that 1 is 23-
oxo-3-hydroxycycloart-24-en-26-oic acid, a new cycloartane triterpene derivative. 
The analysis of the coupling constant values for H-3 (δH 3.69, t, J = 2.4 Hz) indicated 
the alpha configuration for the hydroxyl group in C-3. The structural assignment of 
compound 1 (see Experimental part) was confirmed by the exhaustive analysis of 
their 1D (1H, 13C, DEPT) and 2D (NOESY, COSY, HMQC) NMR spectrums and the 
key HMBC correlations of H3-27 to C-24, C-25, and C-26; H-24 to C-23, C-26, and 
C-27; H3-21 to C-17, C-20, and C-21; H2-22 to C-20 and C-23; H3-29 to C-3, C-4, 
and C-5; H3-18 to C-12, C-13, C-14, and C-17; H3-30 to C-8, C-13, C-14, and C-15; 
and H3-28 to C-3, C-4, and C-5 in 1 (Figure3). 
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4. Discussion 
 
Larix laricina du Roi (K. Koch; Pinaceae) is a medicinal plant identified by 
our group as a candidate antidiabetic plant used by the CEI First Nation to treat 
various symptoms of Type 2 diabetes (Leduc et al., 2006). It was notably found to 
significantly enhance adipogenesis in differentiating 3T3-L1 adipocytes in a 
screening study using in vitro cell based bioassays (Spoor et al., 2006). In the present 
study, we used the same cell line to carry out bioassay-guided fractionation in order 
to identify potential active principles of the plant. 
The results of a silica gel column chromatography showed that fractions LLE-
1, LLE-3, LLE-4 and LLE-5 exhibited the largest increases of 3T3-L1 cell 
adipogenesis, the most active one (LLE-5) reaching more than double the activity of 
the crude LLE and some two-thirds of the activity of the reference drug rosiglitazone. 
Nine compounds were then isolated from these active fractions and two (compounds 
1 and 2) were found to be most active; displaying physiological dose-response 
curves. 
We also calculated the expected activity of each compound according to their 
mass yield and their absolute concentration in LLE-5 (Table 1). Compounds 3 
through 7 displayed weak adipogenic activity, which was not statistically or 
physiologically significant (data not shown). However, taking into account these 
weak activities, we could hypothesize that a synergistic relationship might exist 
between these compounds that could contribute to the activity of the crude extract 
LLE and to the potentiating effect found in fraction LLE-5. This warrants further 
investigation. Interestingly, the expected activity of the new triterpenoid (compound 
1) at the concentration found in LLE-5 (12.78 µM) was estimated at 351%; this 
accounts for almost 63% of LLE-5 adipogenic activity. 
Although compounds 2 and 7 were previously identified (Chen et al., 2009; 
Pichette et al., 2006), this is the first report of such antidiabetic activity. Indeed, there 
is currently no reported biological activity for 13-epitorulosol (compound 2). On the 
other hand, rhapontigenin, a natural analogue of resveratrol with known antioxidant 
and anti-cancer activities (Roberti et al., 2003; Roupe et al., 2005), has been shown to 
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inhibit mammalian intestinal α-glucosidase activity (responsible for first step in 
glucose degradation and therefore absorption (Suresh Babu et al., 2004). Here, we 
report a glitazone-like insulin sensitizing activity for rhapontigenin, albeit at high 
concentrations. 
Finally, no antidiabetic activity was reported for compound 3 (13-epicupressic 
acid), compound 4 (19-norlabda-8(17),14-dien-4,13-diol), compound 5 (lariciresinol-
3-acetate), compound 6 (lariciresinol-coumarate), or compound 10 (taxifolin). 
In conclusion, we have identified one major active principle responsible for 
the effect of L. laricina on adipogenesis. The compound is a previously unidentified 
cycloartane triterpenoid, 23-oxo-3α-hydroxycycloart-24-en-26-oic acid, which 
strongly potentiates adipogenesis with an EC50 of 7.7 µM. In addition, we report a 
new biological activity for 13-epitorulosol (EC50 8.2 µM) and rhapontigenin (at high 
concentrations). Further investigation is needed to determine the possible synergistic 
activity between compound 3 (13-epicupressic acid), compound 5 (lariciresinol-3-
acetate) and compound 6 (lariciresinol-coumarate) at the concentration present in the 
most active fraction (LLE-5). 
Finally, L. laricina was the object of previous pharmacological studies. One 
study identified anti-tumor active principles [labdane-type diterpenes (Pichette et al., 
2006)], while others studied the effect of the environment on phytochemicals 
components of L. laricina [volatiles (Nair and Von Rudloff, 1959; Powell and Raffa, 
1999; Von Rudloff, 1987), phenolics (Niemann, 1969; Niemann and Bekooy, 1971) 
and diterpenes (Mills, 1973)]. Hence, ours is the first study that focuses on the 
identification of the active principles responsible for the adipogenic effect as putative 
antidiabetic mechanism of L. laricina, as used by traditional Healers in Canadian 
Aboriginal populations. In support of this, we have recently shown that L. laricina 
decreases hyperglycemia and insulin resistance in vivo, using the diet-induced obese 
mouse model (Harbilas et al., 2012). In addition to the expected terperenes, our study 
has identified compounds from other chemical classes including lignans, phenolics 
and stilbenes. This is interesting and of significance due the fact that L. laricina 
belongs to Pinaceae family, which has been mainly used for timber, pulp and paper. 
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Indeed, very little work was done on its biological effects and only a few reports 
focus on their essential oils as predominant class of compounds. 
The identification of such active compounds of L. laricina paves the way to 
developing methods for the quality control/quality assurance of traditional 
preparations that could be used alongside modern pharmaceuticals to provide 
culturally adapted treatment options for Cree diabetics. Likewise, methods are being 
developed to measure L. laricina bioactives in biological fluids in order to enable 
pharmacokinetic studies of Cree Traditional Medicine, alone and in combination with 
diabetes drugs. Our study thus provides an important piece to the puzzle of an 
evidence-based approach to favor the inclusion of Cree Healing Ways into diabetes 
care. 
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7. Figure legends 
 
Figure 1: Chemical structure of compounds 1-8 isolated from L. laricina. 
A new cycloartane triterpenoid identified as 23-oxo-3α-hydroxycycloart-24-
en-26-oic acid (compound 1); three labdane diterpenes: 13-epitorulosol (compound 
2) and epicupressic acid (compound 3), 19-norlabda-8 (17), 14-dien-4,13-diol 
(compound 4); two lignans: (+)-lariciresinol-3-acetate (compound 5) and (+)-
lariciresinol-9’-p-coumarate (compound 6); three stilbenoids: rhapontigenin 
(compound 7), piceatannol (compound 8), rhaponticin (compound 9) and taxifolin 
(compound 10). 
 
Figure 2: The adipogenic activity of L. laricina crude extract, fractions and 
compounds. 
A) Preadipocytes (3T3-L1 cells) were induced to differentiate in the presence 
of L. laricina crude extract (LLE; 25 µg/mL), fractions (LLE-1-LLE-16; 25 µg/mL) 
or rosiglitazone (inducer of differentiation; 10 µM). DMSO 0.1% was used as vehicle 
control. Following 7 days of differentiation, cells were washed and the intracellular 
content of triglycerides (TG) was determined as detailed in Materials and Methods 
Section. * denotes statistically significant from vehicle control (p ≤0.05). $ denotes 
statistically significant from crude extract LLE (p ≤0.05). B). Preadipocytes were 
treated with rosiglitazone (10 µM), LLE (25 µg/mL), LLE-5 (25 µg/mL) and 8 of the 
isolated compounds (10 µg/mL) for 7 days then TG content was determined. 
** denotes statistically significant from vehicle control (p ≤0.01). *** denotes 
statistically significant from vehicle control (p ≤0.001). 
 
Figure 3: Key HMBC (H→C) correlations of compound. 
 
 
 
  
  
63 
               Table 1: EC
50 , activity and yields of L. laricina com
pounds  
     
  
64 
 
Figure 1 
 
  
  
65 
Figure 2 
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Figure 3 
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Chapter 3: Article 2 
To be submitted to the journal of Evidence-Based Complementary and 
Alternative Medicine.  
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Abstract 
 
Aim: We aimed to evaluate and compare the antidiabetic and antiobesity 
potential of 17 Cree plants’ ethanol extracts (EE) and hot water extracts (HWE) on 
lipid homeostasis in vitro as well as to assess underlying molecular mechanisms. 
Materials and methods: Post-confluent 3T3-L1 cells were differentiated in 
the presence of each of the extracts for 7 days and intracellular triglyceride content 
was measured. Peroxisome proliferator-activated receptor (PPAR) γ, sterol-
regulatory element-binding protein-1 (SREBP-1) and CCAAT-enhancer binding 
proteins (C/EBP) α, key transcription factors involved in adipocyte differentiation, 
were also assessed by Western blot analysis. Both EE and HWE were characterized 
by UPLC-QTOF/MS and the data subjected to multivariate analysis using MassLynx 
and MarkerLynx software. 
Results: Our results confirmed that 10 of the 17 EE potentiated adipocyte 
differentiation and adipogenesis, whereas 2 inhibited the same. Corresponding HWE 
exhibited partial or complete loss of such adipogenic or anti-adipogenic activity. R. 
groenlandicum and K. angustifolia EEs increased the expressions of PPARγ, 
SREBP-1 and C/EBPα whereas P. balsamifera and A. incana decreased them. P. 
balsamifera’s inhibitory effect was also found to involve AMP-activated protein 
kinase (AMPK) activation. R. groenlandicum HWE and EE stimulated the expression 
of these transcription factors but HWE of other selected plants lost such effects 
compared to their respective EE. Multivariate analysis uncovered clustering of active 
versus inactive species, notably when species were segregated by plant family. 
Conclusion: These studies indicate that the method of extraction is a 
significant determinant of the biological activity of Cree medicinal plants on 3T3-L1 
adipogenesis.  
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1. Introduction 
 
Metabolic syndrome (MetS) in an individual reflects the clustering of multiple 
metabolic abnormalities and is related to the continuum between obesity (especially 
visceral in origin) and Type 2 diabetes (T2D). The latter conditions are currently 
considered to be worldwide epidemics. For instance, about 1 in 5 Canadian adults 
have MetS [1], 1 in 10 adults of the world's population is now obese [2], and 346 
million people worldwide have diabetes [3]. In particular, T2D and obesity are more 
pronounced among indigenous peoples than in the rest of the population. This is the 
case in the Cree Nation of Eeyou Istchee (CEI) of northern Quebec, where the age-
adjusted prevalence of T2D reached 29% in 2009 and where the prevalence of 
obesity and overweight is also 2-3 times higher than in the general Canadian 
population [4]. 
In order to respond to the primary health care needs of the CEI and to search 
for culturally adapted T2D therapies, our team (CIHR-TAAM) conducted a number 
of quantitative ethnobotanical studies to identify culturally relevant anti-diabetic 
treatments [4, 5]. Seventeen plant species were evaluated in two screening studies 
using a variety of in vitro bioassays to assess their anti-diabetic potentials. We found 
that several CEI plant extracts strongly enhanced the differentiation and adipogenesis 
of 3T3-L1 pre-adipocytes (thus potentially enhancing insulin sensitivity). 
Unexpectedly, two extracts displayed a potent anti-obesity potential in vitro by 
effectively preventing the differentiation [6, 7]. Adipogenesis is highly complex and 
numerous key factors are involved in the regulation of transcription, such as 
peroxisome proliferator-activated receptor γ (PPAR γ), CCAAT-enhancer binding 
proteins α (C/EBP α) and sterol-regulatory element-binding protein-1 (SREBP-1) [8-
11].  
In these studies, plant materials were extracted with 80% ethanol at room 
temperature, which is a well-established phytochemical approach to enhance the 
extraction of bioactive phenolic secondary metabolites. However, such an approach 
does not correspond to traditional methods used by Aboriginals, which often rely on 
hot water as an extraction solvent.  It is expected that ethanol (EE) and hot water 
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extracts (HWE) may contain different levels and/or combinations of molecules and 
thus exert different antidiabetic biological activities. Therefore, the present study 
aimed to evaluate and compare the adipogenic or anti-adipogenic activities of Cree 
plant EE and HWE in 3T3-L1 cells, as well as to begin elucidating the possible 
underlying mechanisms responsible for the activities in vitro. 
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2. Materials and Methods 
 
2.1 Plant material and extraction 
The 17 Cree medicinal plant species identified as being relevant to the 
treatment of symptoms of diabetes [4] are listed in Table 1. The specific organ part 
tested and the concentrations used are also presented in accordance with previous 
studies [4]. These samples were collected in a culturally respectful manner in two 
areas of the CEI territory in northern Quebec, Canada. Dr. Alain Cuerrier, taxonomist 
at the Montreal Botanical Garden, ascertained the botanical identity of the plant 
species. Voucher specimens were deposited in the Marie-Victorin herbarium of the 
Montreal Botanical Garden in Montreal, Quebec, Canada. The collected plant 
samples were air dried and then sent to University of Ottawa, where they were 
cleaned and separated into plant organ parts. Plant material was ground using a Wiley 
Mill (Arthur H. Thomas, Swedesboro, USA) and a filter with a 2-millimetre mesh-
size. EE were prepared by extracting ground material in 80% ethanol twice for 24 h 
on a mechanical shaker. Following vacuum filtration with Whatman paper, EE were 
dried using a rotary evaporator at 40°C followed by lyophilization. HWE were 
prepared by boiling ground material for 75 minutes. Following vacuum filtration with 
Whatman paper, HWE were dried using a spray dryer. All dried extracts were 
conserved at 4 °C in a desiccator and protected from light. 
 
2.2 Phytochemical characterization of extracts and metabolites analysis 
Chromatography was carried out on Acquity BEH C18 column (1.7µm 2.1 × 
100 mm) connected with a VanGuard Pre-column 2.1 × 5 mm using an Acquity 
UPLCTM system with the column temperature at 50 °C and sample temperature at 10 
°C. The mobile phase consisted of (A) water containing 0.1% formic acid and (B) 
acetonitrile containing 0.1% formic acid  (Fisher Optima LC-MS). The gradient 
conditions of the mobile phase were: 0-1 min 5% A isocratic, 1-6 min linear gradient 
5-50% B, 6-8 min 50-95%B, 8.01-10 min 5% A isocratic (total run time 10 min). The 
flow rate was 0.5 mL/min, and 1 µL of sample was injection followed by a strong 
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wash 200 µL (90% acetonitrile+10% water) and weak wash 600 µL (10% 
acetonitrile+90% water).  
Mass spectrometric analysis was performed using a Waters Synergy 
Quantitatvie Time of Flight mass spectrometer (QTOF/MS) equipped with an 
electrospray ionization (ESI) interface (Xevo G2, Waters Inc.). The ESI source was 
operated in positive ionization mode with source temperature of 120 °C, desolvation 
temperature of 400 °C, Cone gas (N2) flow of 50 L/hr, and desolvation gas (N2) flow 
of 1195 L/hr. Leucine-enkephalin was used as the lock mass generating an [M+ H]+ 
ion (m/z 556. 2615). The optimal conditions used for MSe analysis were as follows: 
mass range 100-1500 Da, function 1 CE, 6V, function 2 CER 10-30V, cone voltage 
20 V, scan time 0.1 sec. System was calibrated with, sodium formate and the data 
were acquired and processed with MassLynx (version 4.1) and MarkerLynx (version 
8.03) software with principal component analysis (PCA). The retention times and the 
protonated masses were generated at a noise threshold of 500 counts and no 
smoothing was applied. Pareto scaling was applied to generate the score plots. To 
maximize class discrimination and biomarkers, the data were further analyzed using 
the orthogonal partial least square discriminant analysis (OPLS-DA) method. S-plots 
were calculated to visualize the relationship between covariance and correlation 
within the OPLS-DA results. Variables that had significant contributions to 
discrimination between groups were considered as potential biomarkers. 
 
2.3 Cell culture 
Pre-adipocyte 3T3-L1 cell line was purchased from the American Type 
Culture Collection (ATCC; Manassas, VA). Dexamethasone (DXM), bovine 
pancreatic insulin, 3-isobutyl-1-methylxanthine (IBMX), dimethyl sulfoxide 
(DMSO) were purchased from Sigma-Aldrich. Rosiglitazone came from Alexis 
Biochemicals (Hornby, ON). Dubelcco’s Modified Eagle Medium (DMEM), fetal 
bovine serum (FBS) and bovine calf serum (BCS) were from Wisent Inc (St-Bruno, 
QC). Pre-adipocyte 3T3-L1 cells were cultured in high-glucose DMEM 
supplemented with 10% BCS and penicillin-streptomycin antibiotics in a 5% CO2 
atmosphere at 37°C. Cells were passaged at about 80% confluence or grown to full 
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confluence for differentiation experiments. On day 0 (24 h post-confluence), cells 
were induced to differentiate with high-glucose DMEM supplemented with 10 % 
FBS, 1 µM dexamethasone (DXM), 250 µM 3-isobutylmethylxanthine (IBMX), and 
500 nM insulin. After 48 h, the media was replaced with DMEM containing 10 % 
FBS and 500 nM Insulin. Cells were differentiated for a total of 7 days with media 
change every 2 days. Plant extracts (mg/ml) at previously determined optimal 
concentrations [4], as well as positive control rosiglitazone (10 µM), were dissolved 
in DMSO (0.1 % final concentration) and added to the cells at day 0 of differentiation 
and replenished at every medium change thereafter. Cells treated with vehicle (0.1% 
DMSO) in proliferation medium for the entire process served as a negative 
(undifferentiated) control and cells treated with 0.1% DMSO in differentiation 
medium for this same duration served as the vehicle control. 
 
2.4 Adipogenesis assay and assessments of intracellular triglycerides 
Adipogenesis was assessed in the well-characterized 3T3-L1 cell model by 
measuring the accumulation of triglycerides (TGs) upon differentiation (at day 7), 
using the AdipoRed reagent (Lonza Walkersville Inc, Walkersville, MD) according 
to the manufacturer’s instructions, as described previously with minor modifications 
[7]. Briefly, after washing each well twice with Phosphate-Buffered Saline (PBS: 
8.1 mM Na2HPO4, 1.47 mM KH2PO4, 137 mM NaCl, and 2.68 mM KCl; pH 7.4), 1 
ml of PBS containing 30 µl of AdipoRed reagent were added to each well of a 24-
well plate and incubated for 15 min at room temperature. AdipoRed becomes 
fluorescent when partitioned in a hydrophobic compartment. The fluorescence of 
each well was measured using a fluorimeter (Wallac Victor2; Perkin-Elmer, St-
Laurent, Qc) at 485 nm excitation wavelength and 572 nm emission wavelength. For 
each experiment, the mean fluorescence value from the negative undifferentiated 
control condition was considered as background and was subtracted from all other 
fluorescence readings.  The results were reported as a percentage of the vehicle 
control. 
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2.5 Western blot 
 3T3-L1 cells were placed on ice and washed 3 times with ice-cold PBS and 
lysed in RIPA lysis buffer (50mM Hepes, 150mM NaCl, 5mM EGTA, 2mM 
MgCl2.6H2O, 5% glycerol, 1% Trition X-100, 0.1% SDS, 1% Na-deoxycholate, 
2mM phenylmethanesulfonyl fluoride (PMSF), 10mM NaF, 100uM Na-
orthovanadate, 1mM Na-pyrophosphate and one tablet of commercial cocktail of 
protease inhibitors (Complete Mini; Roche, Mannheim, Germany)) at pH 7.4. Protein 
content was determined by the bicinchoninic acid (BCA) method (Thermo Scientific 
Pierce, Rockford, IL, USA) standardized to bovine serum albumin (BSA).  The 
proteins of each sample were boiled for 5 minutes, separated in 10% SDS-PAGE and 
transferred to a nitrocellulose membrane. Membranes were blocked with 5% non-fat 
milk in TBST (200 mM Tris base, 1.37m NaCl and 0.1% Tween-20) pH 7.6 for 1 
hour and then incubated with primary antibody (PPAR γ (E-8), Santa Cruz, 1:500; 
C/EBP α (14AA), Santa Cruz, 1:500; SREBP-1 (H160), Santa Cruz, 1:500; Phospho-
AMPKα (Thr172), Cell Signaling, 1:500; AMPKα, Cell Signaling, 1:1000 or β-actin, 
Cell Signaling, 1: 1000) overnight at 4 ° C. Membranes were washed with TBST 
followed by a 1h incubation at room temperature with horseradish-peroxidase-
conjugated secondary antibodies (anti-rabbit, Jackson, 1:20000 or anti-mouse IgG, 
Cell Signaling, 1:2000). The bands were detected by enhanced chemiluminescence 
(ECL) method with ECL Plus (Perkin Elmer, Woodbridge, Canada). All experiments 
were conducted on three different cell preparations. All samples from a given passage 
were separated and transferred simultaneously to a single membrane. Quantification 
of the integrated density of bands was performed using NIH Image J 1.45s software 
(National Institutes of Health, Bethesda, MD, USA). 
 
2.6 Statistical analysis 
 Intracellular TG content results are presented as mean ± SEM of 3 
independent experiments, each performed in triplicate. Statistical calculations were 
performed with Prism GraphPad software. We used one-way analysis of variance 
(ANOVA) and post hoc Dunnett's test to assess differences between vehicle controls 
and stimulating, inactive plant extracts (EE or HWE) as well as between vehicle 
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controls and inhibiting plant extracts (EE or HWE), respectively. Differences 
between ethanol and water extracts of all plants were analyzed by two-way analysis 
of variance (ANOVA).  
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3. Results 
 
3.1 Effects of ethanol and hot water extracts on adipogenesis and 
adipocyte differentiation  
Extracts were tested and compared for adipogenic activity in 3T3-L1 
preadipocytes treated continuously with optimal concentrations throughout a 7-day 
differentiation period. At the end of the differentiation, intracellular content of TG 
was assessed fluorescently in cells. TG content was significantly increased by 5.7-
fold by treatment with 10 µM rosiglitazone (positive drug control) when compared 
with vehicle control. 
TG content was significantly stimulated by 2- to 5-fold by treatment with the 
EE of 10 out of the 17 plants (namely, A. balsamea, P. glauca, R. groenlandicum, R. 
tomentosum, L. laricina, K. angustifolia, V. vitis-idaea, P. banksiana, L. clavatum, 
and P. mariana; Figure 1). Out of this subset of plants, the HWE of 3 species (A. 
balsamea, P. glauca and R. groenlandicum) had lower activity but still significantly 
stimulated adipogenesis. However, for the other stimulating species, the effects of 
their EE in 3T3-L1 cells were completely lost when HWE were used. In contrast to 
these species, EE of P. balsamifera and A. incana could inhibit adipogenesis in 3T3-
L1 cells to 0.3% and 15% compared with vehicle control, respectively. As seen with 
several species having positive adipogenic activity, P. balsamifera and A. incana 
completely lost their action (inhibitory, in this case) on adipogenesis when the water 
extracts were used instead. 
 
3.2 Effect of selected extracts on the expression of PPAR γ, C/EBP α and 
SREBP-1 
Five plants were selected for further in-depth pharmacological mechanism 
analysis; namely, R. groenlandicum, K. angustifolia, S. purpurea, A. incana and P. 
balsamifera. The selection process sought to compare species with adipogenic or 
anti-adipogenic potentials as well as species with varying or stable activities between 
EE and HWE. 
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PPAR γ, C/EBP α and SREBP-1 are three key transcription factors involved 
in the regulation of adipocyte differentiation. As shown in Figure 2A, EE of R. 
groenlandicum and K. angustifolia, which stimulated 3T3-L1 differentiation and 
adipogenesis, also increased PPAR γ, C/EBP α and SREBP-1 levels. The HWE of R. 
groenlandicum, which had a lesser albeit significant effect on adipogenesis than its 
EE, also maintained its activation of the same transcription factors. K. angustifolia 
HWE, which completely lost its potentiating effect on adipogenesis as compared to 
its EE, was also ineffective in modulating PPAR γ, C/EBP α and SREBP-1.  
The inhibition of adipocyte differentiation and adipogenesis is a potential 
therapeutic target for obesity. EE of P. balsamifera and A. incana, which inhibited 
adipogenesis, were found to successfully decrease PPAR γ and SREBP-1 levels 
(Figure 2). However, only the EE of P. balsamifera, but not that of A. incana, could 
also successfully decrease C/EBP α levels. On the other hand, the HWE of P. 
balsamifera and A. incana lost all of these effects. Neither the EE nor the HWE of S. 
purpurea could activate the three transcription factors, consistent with the plant’s 
lack of effect on adipogenesis.  
As suspected from the above results, there were strong and significant 
positive correlations between the selected plants’ abilities to modulate PPAR γ, 
C/EBP α and SREBP-1 levels and their adipogenic activity (R2>0.8, p < 0.05, Figure 
2E, F and G.) 
 
3.3 The ethanol extract of P. balsamifera inhibits adipogenesis partly via 
activating AMPK 
We also investigated the AMPK pathway, which has been shown to inactivate 
PPAR γ transcriptional activity and to inhibit adipocyte differentiation [12]. 
Metformin, a known activator of AMPK signaling, served as a positive control and 
greatly enhanced the activation and phosphorylation of AMPK (Figure 3A). Of the 
selected five plant species, only treatment with the EE of P. balsamifera significantly 
increased the phosphorylation of the AMPK (Fig. 3B). 
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3.4 Metabolites analysis   
Using the optimal UPLC–QTOF/MS conditions described above, 
representative fingerprints for all HWE and EE of 17 plants were processed.  Overall, 
more than 4000 metabolites were detected from these extracts within the 
chromatographic retention time range of 0.4-6.5 min. In order to better visualize the 
subtle similarities and differences among these complex data, multivariate analysis, 
PCA and OPLS-DA were used to classify the phenotypes of phytochemical 
metabolites. 
Using an unbiased PCA approach, all HWE and EE of the 17 plants clustered 
together (data not shown). Moreover, such analysis did not allow any clear 
distinction between the active species (stimulating or inhibiting adipogenesis) and 
inactive ones (having no effect on adipogenesis).  
We then carried out more specific PCA approaches guided by bioactivity, 
notably examining results for HWE and EE samples separately. For HWE, the PCA 
process did not show any discriminating characteristics when adipogenic 
(stimulating) and antiadipogenic (inhibiting) plants were grouped with inactive 
species (data not illustrated). This held true even if an additional segregation of plants 
was made on the basis of plant families.  
Similarly, when all EE samples were analyzed together (stimulating, 
inhibiting and inactive species), the PCA process did not show any clustering (data 
not illustrated). However, clear clustering of active species could be observed as 
shown in Figure 4. In the case of species stimulating adipogenesis, clear clustering of 
active and inactive species was obtained and more obviously when plants were 
segregated according to their affiliation with the Ericaceae (R. gromenlandicum, R. 
tomentosum, and K. augusfolia; Figure 4A and 4B) or Pinaceae (A. balsamea, L. 
laricina, P. mariana, P. banksiana; Figure 4A and 4C) plant families.  
A S-plot was then generated to determine plant metabolites that could 
significantly contribute to discriminating species. These usually lie in the top or 
bottom extremities of the S-plot, and are characterized by sufficiently important 
statistical differences to render them potential biomarkers for the biological activity 
studied. As shown in Figure 5C and 5E, there were several potential markers. 
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4. Discussion 
 
Using ethnobotanical surveys, our group identified 17 CEI medicinal plants as 
candidate antidiabetic species used by the CEI First Nations to treat various 
symptoms of Type 2 diabetes [13-18]. We found that several CEI plants (ethanol 
extracts) strongly potentiated the differentiation and adipogenesis of 3T3-L1 pre-
adipocytes (associated with enhanced insulin sensitivity, a hallmark of the 
thiazolidinedione (TZDs) class of antidiabetic medications) and two extracts 
displayed a potent anti-obesity potential in vitro by effectively inhibiting the 
differentiation [6, 7]. In the present study, we used the same bioassay to evaluate and 
compare the antidiabetic potentials of ethanol and water extracts of these plants as 
well as potential underlying mechanisms in vitro. 
Generally in line with previous observations [4, 5], our results showed that 10 
of the 17 plants EE stimulated adipogenesis, hence indicating their antidiabetic 
potential. Out of these plants, only 3 HWE (R. groenlandicum A. balsamea, and P. 
glauca) still significantly stimulated adipogenesis, albeit at a lower level than their 
EE counterparts. However, this does not imply that the traditional method of 
preparation and usage is not efficient. Firstly, for the purpose of this study, it was 
important, in a pharmacological perspective, to compare equal concentrations of raw 
ethanol and water extracts. Hence, our results agree with the generally accepted 
contention that the phytochemical approach by ethanol extraction is more efficient at 
concentrating bioactive plant components (notably, phenolic compounds) than the 
traditional hot water extraction. This suggests that phenolic compounds may underlie 
the biological activity of the active EE samples and this is consistent with our 
findings on a number of the concerned species [19-21].  
Secondly numerous parameters might affect the quality of extractions carried 
out using hot water, such as extraction time, temperature, and water quality. 
Traditional medicinal plant preparations of Aboriginal healers might thus differ from 
the HWE conditions used in this study and could yield more concentrated solutions. 
Further studies should therefore compare crude plant extracts prepared by Cree 
healers with those prepared in the laboratory over a wider range of concentrations. 
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Thirdly, the analysis of phytochemical metabolite profiles for the 17 plants 
extracted by either ethanol or hot water support our interpretations. Overall, more 
than 4000 metabolites were detected from these extracts by UPLC-QTOF. The PCA 
scores take into consideration both the quality and quantity of plant 
metabolites/biomarkers. At first view, the clustering together of the EE and HWE of 
all species in the initial unbiased PCA process may be seen to indicate that the 
selected antidiabetic Boreal plant species have no discriminating characteristics that 
can relate to their effects on the adipogenesis of 3T3-L1 cells. However, the fact that 
we have two extracts of 17 plants with varying composition and biological activities 
that include stimulating, inactive (neutral) and inhibiting actions limits the 
discriminating capacity of the otherwise powerful PCA process. We thus used two 
approaches to “guide” the PCA. Firstly, we segregated HWE or EE extracts and 
found no discriminating characteristics when all plants species were included. We 
then selected active stimulating species and combined them specifically with inactive 
ones, thereby excluding inhibitory species. In doing so, we successfully uncovered 
two strongly discriminating relationships among the EE. Both discriminating 
conditions were obtained when active plant species were grouped according to their 
belonging to either the Ericaceae or Pinaceae plant families (after removal of outlier 
species, V. vitis-idaea and P. glauca respectively) in PCA and OPLS-DA. Such 
results strongly support the contention that these plant families can be characterized 
by common phytochemical profiles that can explain, at least in part, the capacity of 
member species to stimulate the differentiation of pre-adipocytes in culture. Although 
clearly beyond the scope of the present work, further in-depth discriminant analyses 
will be correlated with additional phytochemical assessments to elucidate and 
identify plant metabolites that could then gain the status of adipogenic stimulating 
biomarkers at the plant species or family levels. 
Finally, the present studies sought to gain further insight into the mechanisms 
of action underlying the activity of CEI plants on adipogenesis. We selected five 
plant species that represented the full spectrum of conditions that we sought to study. 
R. groenlandicum was a plant that strongly stimulated adipogenesis (as previously 
observed [22]) and whose HWE maintained a significant level of activity. Likewise, 
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the UPLC total ion chromatographic (TIC) profiles of its EE and HWE showed 
strong similarities. In contrast, K. angustifolia lost its adipogenic potential when 
HWE was used instead of EE, despite relatively similar phytochemical profiles. S. 
sarracenia was selected as a “neutral” plant that showed no adipogenic or anti-
adipogenic activity and whose EE and HWE UPLC profiles showed good similarity. 
Finally, we selected both inhibiting species. Indeed, although the HWE of both plants 
lost inhibitory potential, the UPLC TIC profile was quite similar to its corresponding 
EE profile for A. incana but not for P. balsamifera. We thus examined several 
transcription factors that regulate a variety of genes and represent key elements 
involved in the process of adipocyte differentiation and lipogenesis, namely PPAR γ, 
C/EBP α and SREBP -1[8, 9]. PPAR γ agonists function as ‘adipose remodeling 
factors’ that could redistribute lipids from non adipose tissue and insulin-resistant 
adipocytes into insulin-sensitive adipocytes by enhancing adipogenesis, regulating 
adipokines, decreasing free fatty acids and exerting insulin-sensitizing effects. In this 
study, we confirmed that several selected stimulators of adipogenesis activated PPAR 
γ, as well as other transcription factors. In fact, strong correlations were obtained 
between the expression of each transcription factor and the adipogenic potential of 
each plant extract. Our results thus further support the use of R. groenlandicum and 
K. angustifolium as potential insulin sensitising plants that could complement modern 
pharmaceuticals and represent culturally adapted additions to help Cree diabetics 
manage their disease. As mentioned above, traditional preparations of these plants 
need to be compared with EE, which exerted the strongest effects in this regard, as 
compared with laboratory HWE. 
Conversely, the inhibition of adipogenesis is also a potential therapeutic target 
of antiobesity and ensuing antidiabetic therapies [23, 24]. Numerous plant extracts 
and naturally occurring compounds are known to inhibit adipogenesis, and a variety 
of mechanisms by which this is mediated have been identified [25-27]. The EE of 
two species (P. balsamifera and A. incana) inhibited adipogenesis in vitro and the EE 
of P. balsamifera also showed antidiabetic and antiobesity potential and improved 
insulin sensitivity in a mouse model of diet-induced obesity in vivo without fat 
redistribution to ectopic sites [28]. In the present study, we found that both species 
  
84 
inhibited adipogenesis partly through decreasing the expression of the same key 
transcription factors, namely PPAR γ and SREBP-1 or C/EBP α. Since our previous 
reports highlighted the fact that the two plants acted at different steps in the 
adipogenesis program [20, 29], our results suggest that these sites of action appear to 
lie upstream of the three transcription factors studied. We further tested another 
important pathway regulating adipogenesis and confirmed that P. balsamifera, but 
not A. incana, stimulated the phosphorylation of AMPK, a key energy sensor. In fact, 
a number of natural compounds, such as genistein and curcumin, demonstrated an 
anti-adipogenic effect by activating AMPK [12, 30, 31]. The fact that the HWE of 
both P. balsamifera and A. incana lost anti-adipogenic activity, despite the variable 
changes in their respective metabolite profiles, will require further in-depth study 
through PCA and additional chemical analysis.  
In summary, we evaluated and compared the adipogenic/anti-adipogenic 
potentials of EE and HWE of 17 plants as well as the possible molecular mechanisms 
responsible for such activities in 3T3-L1 cells. We confirmed that the method of 
extraction is a significant determinant of the biological activity of several medicinal 
plants. UPLC-QTOF TIC profiles and corresponding principal component analysis 
enabled us to segregate the metabolomes of active plant species from the inactive 
ones, in particular when stimulating species were further grouped based on plant 
family. This powerful approach enabled us to uncover similarities and differences of 
the chemical profiles of these plants. Mining such PCA results offers an interesting 
avenue to identify potential bioactive plant metabolites. Our work and its future 
applications can help to develop novel as well as culturally relevant plant-based 
therapeutic approaches against insulin resistance and obesity that target pre-
adipocytes and adipocytes directly. Studies comparing different plant extracts in 
other insulin sensitive tissues, such as liver and muscle, can complement this. Finally, 
our studies can serve as quality control tools to foster reliable and effective plant-
based treatments, using the information relative to the content of active ingredients 
and/or the biological activity. 
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7. Figure legends  
 
Figure 1: Effects of extracts on rate of adipogenesis. The effects of extracts 
on rate of adipogenesis were assessed by TG content at the end of a 7-day 
differentiation period with continuous treatment with vehicle (0.1% DMSO), EE or 
HWE extract (concentrations indicated in Table 1), or positive control (10 µM 
rosiglitazone). Results are means ± SE for 3 separate experiments, normalized to the 
vehicle-treated condition. # Denotes stimulator EE samples statistically significant 
from vehicle control (p<0.05), one-way ANOVA and post hoc Dunnett's test. $ 
Denotes HWE samples statistically significant from vehicle control (p < 0.05), one-
way ANOVA and post hoc Dunnett's test. & Denotes inhibitory EE samples 
statistically significant from vehicle control (p<0.05), one-way ANOVA and post hoc 
Dunnett's test. * (p<0.05), **(p<0.01) and *** (p<0.001) denote statistically 
significant between EE and HWE counterpart, Two-way ANOVA.  
 
Figure 2: Effect of the selected extracts on expression of PPAR γ, C/EBP α 
and SREBP-1. 3T3-L1 cells were differentiated and treated for 7 days with either 
0.1% DMSO (vehicle control), Rosiglitazone (10 µM, positive control), EE or HWE 
of the 5 selected plants. Expression of PPAR γ, C/EBP α and SREBP-1 were 
measured by western blot and representative samples are illustrated in Panel A. 
Western blot results for 3 separate experiments are also presented as means ± SE, 
normalized to the vehicle-treated condition (Panels B, C and D). # Denotes EE 
samples statistically significant from vehicle control (p<0.05), one-way ANOVA and 
post hoc Dunnett's test. $ Denotes HWE samples statistically significant from vehicle 
control (p < 0.05), one-way ANOVA and post hoc Dunnett's test. * (p<0.05),    ** 
(p<0.01) and *** (p<0.001) denote statistically significant between EE and HWE 
counterpart, Two-way ANOVA. Correlations between the expression of PPAR γ, 
C/EBP α and SREBP-1 levels and the adipogenic activity are shown in panels E, F 
and G. Correlation results were analyzed by linear regression and the equations were 
y = 163.6x - 47.39, y = 207.7x - 70.12, y = 245.6x - 98.96 respectively. 
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Figure 3: EE of P. balsamifera stimulates the AMPK signaling pathway to 
inhibit adipogenesis. 3T3-L1 cells were differentiated and treated for 7 days with 
either 0.1% DMSO (vehicle control), Metformin (400 mM. positive control), EE or 
HWE of the 5 selected plants. Phosphorylation of AMPK was measured by western 
blot and representative samples are illustrated in Panel A. Western blot results for 3 
separate experiments are also presented as means ± SE, normalized to the vehicle-
treated condition (Panel B). # Denotes EE samples statistically significant from 
vehicle control (p<0.05), one-way ANOVA and post hoc Dunnett's test. *** 
(p<0.001) Significantly different between EE and HWE counterpart, Two-way 
ANOVA. 
 
Figure 4: Metabolite analysis of selected ethanol extracts. 
PCA scores plot of stimulators of ethanol extract for adipogenesis in 
Ericaceae family, Pinaceae family and the five inactive plants are shown in Panel A 
OPLS-DA scores plot and S-plot of stimulators of ethanol extract for adipogenesis in 
Ericaceae family (R. gromenlandicum, R. tomentosum, and K. augusfolia) and the 
five inactive plants are shown in Panel B and C. Likewise stimulators of ethanol 
extracts of species belonging to the Pinaceae family (A. balsamea, L. laricina, P. 
mariana, P. banksiana) are compared with inactive species in Panel D and E..  
In PCA and OPLS-DA scores plots, t [1], t [2] and t [1] P and t [2] O are the 
new most important indices in summarizing the peak lists of the plants. In S-plot, it 
displays easily the observations that have a large absolute value of p (corr) [1] and a 
large absolute value of the coefficients. These are the observations that differentiate 
the most between the 2 groups 
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Table 1: List of investigated plant species and the concentrations of the 
extracts tested in 3T3-L1 cells 
 
 
 
  
Species Abbreviation Plant part Family 
3T3-L1 cells   
 µg/mL 
Rhododendron groenlandicum 
(Oeder) Kron and Judd  R.groenlandicum  Leaves Ericaceae 75 
Abies balsamea (L.) Mill. A.balsamea Inner bark Pinaceae 50 
Larix laricina Du Roi (K.Koch) L.laricina Inner bark Pinaceae 25 
Picea mariana (P. Mill.) BSP P.mariana Cones Pinaceae 10 
Sorbus decora (Sarg.) C.K.Schneid. S.decora Inner bark Rosaceau 15 
Alnus incana subsp. rugosa (Du Roi) 
R.T. Clausen A.incana   Inner bark Betulaceau 50 
Sarracenia purpurea L. S.purpurea Whole plant Sarraceniaceau 100 
Pinus banksiana Lamb. P.banksiana Cones Pinaceae 15 
Rhododendron tomentosum 
(Stokes) Harmaja 
subsp.subarcticum (Harmaja) 
G.Wallace 
R.tomentosum Leaves Ericaceae 50 
Kalmia angustifolia L.  K.augustifolia Leaves Ericaceae 50 
Picea glauca (Moench) Voss P.glauca Leaves Pinaceae 125 
Juniperus communis L. J.communis Berries Cupressaceau 5 
Salix planifolia Pursh S.planifolia Inner bark Saliaceau 25 
Lycopodium clavatum L. L.clavatum Whole plant Lycopodiaceau 100 
Populus balsamifera L. P.balsamifera Inner bark Saliaceau 100 
Gaultheria hispidula (L.) Muhl. G.hispidula Leaves Ericaceae 25 
Vaccinium vitis-idaea L. V.vitis-idaea Berries Ericaceae 200   
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Chapter 4: Article 3 
To be submitted to the journal of Plos one. 
 
Role of each co-author belonging to this manuscript 
 
I performed the experimental work, data analysis and wrote the paper.  
Dr Lina Musallam, contributed to conceptual input. 
Brendan Walshe-Roussel contributed to the preparation of the plant species in 
the lab of Dr. John T. Arnason. 
Dr. Ammar Saleem helped with the phytochemical analysis of the plant 
species. 
Dr. Alain Cuerrier contributed in the characterization of the plant species. 
Dr. Alaa Badawi contributed to provide funding to this project. 
Dr. Pierre S. Haddad, my supervisor, contributed conceptual and intellectual 
input as well as correcting the article. 
  
  
97 
Comparative cellular and molecular effects of ethanol and hot water 
extracts of several Canadian medicinal plants of Cree Eeyou Istchee on glucose 
homeostasis 
 
Nan Shang (1,2,3,4,5), Lina Musallam(1,4,5), Ammar Saleem(4,6), Brendan Walshe-
Roussel(4,6), Alaa Badawi (7), Alain Cuerrier(4,8), John T. Arnason(4,6), Pierre S. 
Haddad(1,4,5) 
 
1Natural Health Products and Metabolic Disease Laboratory, Department of 
pharmacology, Faculty of Medicine, Université de Montréal, Montreal, Quebec, 
Canada;  
2Department of Hepatology and Gastroenterology, Qilu Hospital, Shandong 
University, Jinan, PR China; 
3Department of Geriatrics, Qilu Hospital, Shandong University, Jinan, PR 
China 
4Canadian Institutes of Health Research Team in Aboriginal Antidiabetic 
Medicines and Montreal Diabetes Research Center, Montreal, Quebec, Canada; 
5Institute of Nutraceuticals and Functional Foods, Université Laval, Quebec, 
Quebec, G1V 0A6, Canada; 
6Center for Advanced Research in Environmental Genomics, University of 
Ottawa, Ottawa, Ontario, K1N 6N5, Canada; 
7Office for Biotechnology, Genomics and Population Health, Public Health 
Agency of Canada, Toronto, Ontario, M5V 3L7, Canada; 
8Jardin botanique de Montréal. Institut de recherche en biologie végétale, 
Université de Montréal, Montréal, Quebec, H1X 2B2, Canada. 
 
 
 
 
 
 
  
98 
Addresses for correspondence 
Pierre S. Haddad, PhD  
Department of Pharmacology  
Université de Montréal  
P.O. Box 6128, Station Centre-Ville  
Montréal, Québec, Canada   
H3C 3J7  
  
 
Key words:  
C2C12 cell; H4IIE cell; diabetes; glucose uptake; glucose production; 
Glucose-6-phosphatase; glucose transporter 4; AMP-activated protein kinase; 
Aboriginal traditional medicine. 
 
Abbreviations:  
ACC, acetyl-coA carboxylase;  
AICAR, aminoimidazole carboxamide ribonucleotide;  
AMPK, AMP-activated protein kinase;  
GLUT4, glucose transporter 4; 
GU, glucose uptake; 
G6Pase, Glucose-6-phosphatase. 
  
  
99 
Abstract 
Aim: Our Team previously identified 17 Cree medicinal plants having 
antidiabetic potential. We aimed to evaluate and compare the biological activity and 
molecular mechanisms of the 17 Cree plants’ ethanol extracts (EE) and hot water 
extracts (HWE) on glucose homeostasis in vitro as well as to assess the relationships 
between phytochemical metabolites and biological phenotype. 
Materials and methods: Two main bioassays routinely applied in our 
laboratory were used: 1) stimulation of muscle glucose transport by measuring 3H-2-
deoxyglucose uptake in C2C12 myoblasts, and 2) inhibition of hepatic glucose 
production by measuring inhibition of glucose-6-phosphatase activity (G6Pase) in 
H4IIE cells. We also investigated the phosphorylation of Akt and AMP-activated 
protein kinase (AMPK) for the selected plants by Western blot analysis. Both EE and 
HWE were characterized by UPLC-QTOF/MS and the data subjected to metabolites 
analysis using principal component analysis and discriminant analysis. 
Results: Our results confirmed that several EE stimulated muscle glucose 
uptake and inhibited hepatic G6Pase activity. Some of the HWE partially or 
completely lost these antidiabetic activities in comparison to EE. Only one plant (R. 
groenlandicum) retained similar potential between EE and HWE in both assays. In 
C2C12 muscle cells, EE of R. groenlandicum, A. incana and S. purpurea stimulated 
glucose uptake by activating AMPK pathway and increasing GLUT4 expression 
level. In comparison to EE, HWE of R. groenlandicum exhibited similar activities; 
HWE of A. incana completely lost its effect on all parameters; interestingly, HWE of 
S. purpurea activated insulin pathway instead of AMPK pathway to increase glucose 
uptake. In the liver, for a subset of 5 plants, HWE and EE activated AMPK pathway 
whereas the EE and HWE of S. purpurea and K. angustifolia also activated insulin 
pathways. Quercetin-3-O-galactoside and quercetin 3-O-α-L-arabinopyranoside, 
were identified as strong potential to be responsible for the biological activity of the 
active HWE plants with stimulation of glucose uptake. 
Conclusion: These studies indicate that plant species, target tissues or cells, 
as well as extraction methods are all significant determinants of the biological 
activity of Cree medicinal plants on glucose metabolism.  
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1. Introduction 
 
Type 2 diabetes (T2D) is characterized by impaired insulin secretion and/or 
insulin sensitivity. There are 346 million people worldwide having diabetes [1]. In 
particular, T2D is more pronounced among indigenous populations, such as the Cree 
of Eeyou Istchee (CEI) of northern Quebec, where the age-adjusted prevalence of 
T2D reached 29% in 2009 [2, 3]. The burden of T2D and the ensuing deleterious 
complications (cardiovascular, retinopathy and nephropathy) prompted the search for 
culturally adapted treatment alternatives for these aboriginal populations. 
In order to identify such culturally adapted T2D alternative therapies and to 
respond to CEI primary health care needs, our team (CIHR-TAAM) conducted 
quantitative ethnobotanical studies [2]. Seventeen plant extracts were tested for their 
anti-diabetic potential in several screening studies through a variety of in 
vitro bioassays. Results showed that several extracts strongly potentiated glucose 
uptake (GU) in muscle cells and inhibited Glucose-6-Phosphatase (G6Pase) activity 
in H4IIE cells [4-7]. Indeed, the muscle is the principal tissue involved in 
postprandrial glucose disposal, accounting for about 80% of GU, occurring 
principally through glucose transporter 4 (GLUT4) [8]. On the other hand, G6Pase is 
the rate-limiting enzyme for the final step of gluconeogenesis and glycogenolysis, 
two pathways controlling hepatic glucose production (HGP) [9]. In T2D, 
unsuppressed HGP has been linked to the increased G6Pase activity [10].  
In these previous studies, a well-established and standard phytochemical 
extraction method was used, based on 80% ethanol to prepare crude plant extracts. 
However, traditional preparations of medicinal plants rely on other methods, such as 
hot water extraction. The first aim of the present study was therefore to evaluate and 
compare the biological activity of ethanol and hot water extracts (EE and HWE, 
respectively) of the 17 identified putative antidiabetic plant species from CEI 
traditional pharmacopeia. Secondly, we also began examining the molecular 
mechanisms underlying the modulating action of a subset of plants on glucose 
metabolism using the same in vitro bioassays. 
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2. Materials and methods 
 
2.1 Plant material and extraction 
The 17 Cree medicinal plant species identified as being relevant to the 
treatment of symptoms of diabetes [2] are listed in Table 1. Table 1 also lists the 
specific organ part tested, in accordance with the ethnobotanical data [2] and the 
concentrations used in different cell lines. Plant samples were collected for each 
species in a culturally respectful manner in two areas of the CEI territory in northern 
Quebec, Canada. Dr. Alain Cuerrier, taxonomist at the Montreal Botanical Garden, 
ascertained the botanical identity of the plant species. Voucher specimens were 
deposited in the Marie-Victorin herbarium of the Montreal Botanical Garden in 
Montreal, Quebec, Canada. The collected plant samples were air dried and then sent 
to the University of Ottawa, where they were cleaned and separated into relevant 
plant organ parts. Plant material was ground using a Wiley Mill (Arthur H. Thomas, 
Swedesboro, USA) with a 2-millimetre filter. The generated plant powder was 
extracted in two ways: the first (standard phytochemical) method used 80% ethanol 
(10 mL/g dry material) and extraction carried out twice for 24 h on a mechanical 
shaker (herafter designated as EE); the second method (mimicking CEI traditional 
preparation) used boiling water for 75min (hereafter designated as HWE). In both 
cases, extracts were filtered with Whatman paper. Extracts were subsequently dried 
using a rotary evaporator followed by lyophilization. All lyophilized extracts were 
preserved at 4 °C in a desiccator and protected from light. 
 
2.2 Phytochemical characterization of extracts and UPLC-QTOF/MS 
analysis  
Chromatography was carried out on Acquity BEH C18 column (1.7µm 2.1 × 
100 mm) connected with a VanGuard Pre-column 2.1 × 5 mm using an Acquity 
UPLCTM system with the column temperature at 50 °C and sample temperature at 10 
°C. The mobile phase consisted of (A) water containing 0.1% formic acid and (B) 
acetonitrile containing 0.1% formic acid  (Fisher Optima LC-MS). The gradient 
conditions of the mobile phase were: 0-1 min 5% A isocratic, 1-6 min linear gradient 
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5-50% B, 6-8 min 50-95%B, 8.01-10 min 5% A isocratic (total run time 10 min). The 
flow rate was 0.5 mL/min, and 1 µL of sample was injection followed by a strong 
wash 200 µL (90% acetonitrile+10% water) and weak wash 600 µL (10% 
acetonitrile+90% water).  
Mass spectrometric analysis was performed using a Q-TOF mass 
spectrometer equipped with an electrospray ionization (ESI) interface (Xevo G2, 
Waters Inc.). The ESI source was operated in positive ionization mode with source 
temperature of 120 °C, desolvation temperature of 400 °C, Cone gas (N2) flow of 50 
L/hr, and desolvation gas (N2) flow of 1195 L/hr. Leucine-enkephalin was used as 
the lock mass generating an [M+ H]+ ion (m/z 556. 2615). The optimal conditions 
used for MSe analysis were as follows: mass range 100-1500 Da, function 1 CE, 6V, 
function 2 CER 10-30V, cone voltage 20 V, scan time 0.1 sec. The system was 
calibrated with sodium formate and the data were acquired and processed with 
MassLynx (version 4.1) and MarkerLynx (version 8.03) software with principal 
component analysis (PCA). The retention times and the protonated masses were 
generated at a noise threshold of 500 counts and no smoothing was applied. Pareto 
scaling was applied to generate the score plots. To maximize class discrimination and 
biomarkers, the data were further analyzed using the orthogonal partial least square 
discriminant analysis (OPLS-DA) method. S-plots were calculated to visualize the 
relationship between covariance and correlation within the OPLS-DA results. 
Variables that had significant contributions to discrimination between groups were 
considered as potential biomarkers and subjected to further identification of the 
molecular formula. 
 
2.3 Cell culture 
The C2C12 murine skeletal myoblasts and H4IIE rat hepatoma cell lines were 
acquired from the American Type Culture Collection (ATCC), Manassas, USA. Cell 
culture media was purchased from Invitrogen Life Technologies (Burlington, 
Canada) and Wisent (St. Bruno, Canada). Other reagents were purchased from 
Sigma-Aldrich (Oakville, Canada), unless otherwise specified below. All cell lines 
were cultured in a humidified incubator in a 5% CO2: 95% air atmosphere at 37°C. 
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The C2C12 myoblasts were proliferated in high-glucose Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10% horse 
serum (HS), and penicillin–streptomycin antibiotics. The C2C12 cells were 
proliferated until 80% confluence and then were passaged or differentiated for a 
period of 7 days into myotubes in DMEM containing 2% HS and antibiotics. The 
H4IIE cells were grown in DMEM supplemented with 10% FBS and antibiotics. 
Hepatic glucose production assay was performed when H4IIE cells reached 
approximately 90% confluence.  
 
2.4 Glucose uptake bioassay 
The effects of plant extracts on the rate of uptake of glucose by differentiated 
C2C12 skeletal myotubes were assessed with a 3H-deoxyglucose uptake assay as 
described previously [5, 6]. Briefly, cells were grown in 12-well plates to 80% 
confluence and then differentiated as described above. On day 6 of differentiation, 
cells were treated for 18 h with either vehicle control (0.1% DMSO) alone, with a 
positive control Metformin (400 µM) or with extracts (EE and HWE respectively) in 
vehicle at optimal concentrations, as shown in Table 1. After the treatment, cells 
were rinsed twice with warm Krebs phosphate buffer, (KPB, 20 mM Hepes, 4.05 mM 
Na2HPO4, 0.95 mM NaH2PO4, 136 mM NaCl, 4.7 mM KCl, 1 mM CaCl2, and 1 mM 
MgSO4, 5 mM glucose, pH 7.4). A subset of vehicle wells were treated with 100 nM 
insulin in KPB for 30 min, as a second positive control. Cells were then rinsed twice 
in warm glucose-free KPB and incubated in this buffer containing 0.5 µCi/mL 2-
deoxy- D-[1-3H]-glucose (TRK-383, Amersham Biosciences, Baie d’Urfe ́, Canada) 
for exactly 10 min at 37°C. Cells were then placed on ice and rapidly rinsed 3 times 
in ice-cold glucose-free KPB. Cells were lysed in 0.5 mL of 0.1 M NaOH for 30 min, 
scraped and rinsed twice by 0.5 mL water. The lysates, along with 1 mL of water, 
were each added to 4 mL of liquid scintillation cocktail (Ready-Gel 586601, 
Beckman Coulter Inc., Fullerton, USA), and the incorporated radioactivity was 
measured in a scintillation beta counter (LKB Wallac 1219; Perkin-Elmer, 
Woodbridge, Ontario, Canada). Protein content was determined by the bicinchoninic 
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acid (BCA) method (Thermo Scientific Pierce, Rockford, IL, USA) standardized to 
bovine serum albumin (BSA).   
 
2.5 Hepatic Glucose Production and Glucose-6-phosphatase assay 
The effects of plant extracts on HGP were assessed in H4IIE rat hepatoma 
cells with a Glucose-6-phosphatase (G6Pase) enzyme activity assay as described 
previously [7, 11]. Briefly, 90% confluence cells were treated for 18h with vehicle 
control, or insulin (100 nM), EE or HWE plants extracts (at optimal concentrations 
described in Table 1). After the treatment, cells were washed and lysed in 15 mM 
phosphate buffer containing 0.05% Triton and 1.3 mM phenol (pH = 6.5). Cells 
lysates were incubated in the presence or absence of 200 mM glucose-6-phosphate 
(G6P) buffer for 40 min at 37°C, where G6P serves as a substrate for endogenous 
G6Pase to yield glucose. Lysates of plant treated cells in the absence of G6P were 
used as negative controls. Quantification of the glucose generated in this reaction was 
measured using a Wako AutoKit Glucose (Wako Chemicals USA Inc., Richmond, 
VA, USA), according to the manufacturer's recommendations. This is a colorimetric 
assay based on the glucose oxidase method where samples are incubated for 5 min at 
37°C with Wako kit color reagent (composed of Mutarotase, Glucose oxidase, 
Peroxidase, 4-Aminoantipyrine and Ascorbate oxidase), then absorbance is recorded 
at 505 nm. Protein content was determined using the BSA method. Results were 
presented as percent activity of vehicle control. 
 
2.6 Western blot 
The effects of plants on the insulin and AMP-activated protein kinase 
(AMPK) signalling pathways in C2C12 muscle cells or H4IIE hepatocytes were 
assessed by Western blot. EE and HWE of plants, Metformin (400 µM) or vehicle 
alone were applied for 18 h to 6-day differentiated C2C12 cells or to 90% confluent 
H4IIE cells. Insulin (100 nM, 30 minutes) or aminoimidazole carboxamide 
ribonucleotide (AICAR; 2mM, 2h) was added prior to the end of the treatment to 
some vehicle-treated wells to serve as positive controls for the insulin or AMPK 
pathways, respectively. At the end of experiments, cells were placed on ice, washed 3 
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times with ice-cold PBS and lysed in RIPA lysis buffer (50mM Hepes, 150mM NaCl, 
5mM EGTA, 2mM MgCl2.6H2O, 5% glycerol, 1% Trition X-100, 0.1% SDS, 1% 
Na-deoxycholate, 2mM phenylmethanesulfonyl fluoride (PMSF), 10mM NaF, 
100uM Na-orthovanadate, 1mM Na-pyrophosphate and 1 tablet of commercial 
cocktail of protease inhibitors (Complete Mini; Roche, Mannheim, Germany)) at pH 
7.4. A sucrose buffer (20mM Tris, 250mM sucrose, 1mM EDTA, 2mM PMSF, 2 
tablets of protease inhibitor cocktail, pH 7.4) was used instead of RIPA lysis buffer in 
order to measure the amount of GLUT4 in total cellular membrane protein [12, 13]. 
Protein content was determined by the bicinchoninic acid (BCA) method (Thermo 
Scientific Pierce, Rockford, IL, USA) standardized to bovine serum albumin (BSA).  
The proteins of each sample were boiled for 5 min, separated in 10% SDS-PAGE and 
transferred to a nitrocellulose membrane. Membranes were blocked with 5% non-fat 
milk in TBST (200 mM Tris base, 1.37 mM NaCl and 0.1% Tween-20) pH 7.6 for 1 
h and then incubated with primary antibody (GLUT4 (1F8), Cell Signalling, 1:1000; 
Phospho-Akt (Ser473), Cell Signalling, 1:500; Phospho-AMPKα (Thr172), Cell 
Signalling, 1:500; Akt, Cell Signalling, 1:1000; AMPKα, Cell Signalling, 1:1000 or 
β-actin, Cell Signalling, 1: 1000) overnight at 4°C. Membranes were washed with 
TBST followed by a 1h incubation at room temperature with horseradish-peroxidase-
conjugated secondary antibodies (anti-rabbit, Jackson, 1:20000 or anti-mouse IgG, 
Cell Signalling, 1:2000). The bands were detected by enhanced chemiluminescence 
(ECL) method with ECL Plus (Perkin Elmer, Woodbridge, Canada). All experiments 
were conducted on 3 different cell preparations. All samples from a given passage 
were separated and transferred simultaneously to a single membrane. Quantification 
of the integrated density of bands was performed using NIH Image J 1.45s software 
(National Institutes of Health, Bethesda, MD, USA). 
 
2.7 Statistical analysis: 
Results are presented as mean ± SEM of 3 independent experiments. 
Statistical calculations were performed with Prism GraphPad software. Differences 
between EE (or HWE) and vehicle controls were analyzed by one-way analysis of 
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variance (ANOVA) and post hoc Dunnett's test. And differences between EE and 
HWE were analyzed by two-way analysis of variance (ANOVA).  
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3. Results 
 
3.1 Stimulation of glucose uptake in myotubes by different plant extracts 
Plant extracts were tested for enhancing glucose transport properties in an 
insulin-responsive and GLUT4-containing cell line, namely, C2C12 myoblasts [14, 
15]. Metformin (400 µM, 18h) and insulin (100nM, 30 min), applied as positive 
controls, significantly stimulated glucose transport to 130% and 119% of DMSO 
vehicle values, respectively. Eight out of the 17 EE of plants (namely, S. purpurea, S. 
decora, R. groenlandicum, R. tomentosum, A. incana, V. vitis-idaea, L. laricina and 
A. balsamea) enhanced glucose uptake in C2C12 cells after 18 h incubation. Among 
these, S. purpurea showed the strongest potential (144% compared with vehicle 
control) (Figure 1). In the case of HWE, only 3 species (namely, R. groenlandicum, 
S. purpurea, R. tomentosum) also elicited significant increases in glucose uptake. 
Only the HWE of R. groenlandicum exhibited an effect as strong as its EE. The HWE 
of S. purpurea and R. tomentosum exhibited a decreased effectiveness compared to 
the stimulation of their EE. For other species (such as A. incana), their HWE 
completely lost their effect in C2C12 cells as compared to their EE counterparts.  
 
 
3.2 Inhibition of hepatic glucose production and G6Pase activity of 
extracts 
Insulin 100 nM, applied as a positive control to H4IIE liver cells, inhibited 
G6Pase activity by 62% compared with vehicle control (Figure 2). When the Cree 
plant extracts were tested, a statistically significant reduction in G6Pase activity 
(varying from -54% to -17% compared with vehicle control) was observed for both 
the EE and HWE of 9 species (P. glauca, A. balsamea, P. balsamifera, R. 
groenlandicum, K. angustifolia, S. purpurea, A. incana, L. laricina, V. vitis-idaea), as 
well as by the EE of one species (S. decora). Hence, the inhibitory potential of most 
active species was maintained at a near equivalent level when HWE was used instead 
of EE. In three cases (P. glauca, P. balsamifera and A. incana), HWE biological 
activity on G6Pase was significantly lower (-34%, -22%, -17% respectively) when 
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compared with the respective EE counterpart (-54%, -44%, -37% respectively), 
whereas for S. decora the inhibitory effect of its EE (-22%) was completely lost with 
its HWE. 
 
 
3.3 Effects of selected CEI plant extracts on expression of GLUT4 and 
phosphorylation of AMPK and Akt in C2C12 myotubes 
Five plants, namely R. groenlandicum, K. angustifolia, S. purpurea, A. incana 
and P. balsamifera were selected for further in-depth pharmacological analysis. The 
selection process sought to capture representative situations encountered, namely, 
species with or without biological activity in our bioassays, as well as species with 
varying or stable biological activities between their EE and HWE. 
To begin understanding the mechanisms underlying the observed effect of 
extracts on skeletal muscle cell glucose uptake, we evaluated the total membrane 
protein expression of GLUT4, the insulin-dependent kinase, Akt, and the insulin-
independent AMPK pathway (the latter two representing main signaling pathways 
regulating glucose uptake in this cell line). Insulin served as a positive control for the 
first pathway, whereas metformin and AICAR were applied as activators of AMPK 
signaling. At the end of treatments in C2C12 cells, there was a clear increase in the 
expression of GLUT4 with all three positive controls as compared with vehicle (2.8-
fold, 2.7-fold and 2.3-fold increases for insulin, metformin and AICAR respectively, 
Figure 3A). R. groenlandicum represents a species whose HWE and EE had 
comparable effects on glucose uptake. Both its extracts also stimulated the expression 
of GLUT4 (2.0-fold for both HWE and EE, Figure 3A and B), as well as AMPK 
phosphorylation (3.6-fold and 3.5-fold respectively, Figure 3D and E) in a similar 
manner, whereas Akt was not affected by either extract. In contrast, A. incana 
represents a species whose HWE completely lost its potentiating effect on GU as 
compared with its EE.  Consistent with this, A. incana HWE was without effect on 
C2C12 GLUT4 content and AMPK phosphorylation whereas its EE increased both 
parameters by 1.9-fold (Figure 3A and B) and 3.4-fold (Figure 3D and E), 
respectively. In fact, linear regression analysis clearly demonstrated that effects of 
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selected species on glucose uptake were tightly correlated with their corresponding 
impact on C2C12 GLUT4 content (R2=0.80, p < 0.05; Figure 3C). A similar, albeit 
less tight, correlation was also observed between a given plant extract’s ability to 
increase glucose uptake and to enhance AMPK phosphorylation (R2=0.46, p < 0.05, 
Figure 3F). 
On the other hand, S. purpurea was the specie that yielded interesting 
observations. As shown in Figure 1, its HWE significantly stimulated GU, although 
at lower levels than its EE. When underlying mechanisms were probed, GLUT4 
expression results were consistent with GU results (EE greater than HWE). However, 
S. purpurea HWE was the only extract found to significantly enhance Akt 
phosphorylation (3.9-fold increase, p < 0.05; Figure 3G and H), yet was without 
effect on AMPK phosphorylation (Figure 3D and E). Conversely, the plant’s EE 
stimulated AMPK phosphorylation (3.1-fold, p < 0.05; Figure 3D and E) without 
impacting Akt phosphorylation.  
 
 
3.4 Effects of the selected extracts on phosphorylation of AMPK and Akt 
in H4IIE cells  
We used the same positive controls and probed the same molecular 
parameters to determine the latters’ implication in the selected plant extracts’ actions 
on hepatic glucose production.  
In H4IIE hepatocytes, the EE and HWE of all selected plant species increased 
AMPK phosphorylation with similar intensity (around 4-fold compared with vehicle, 
p < 0.05; Figure 4A and B). Despite this, linear regression analysis uncovered a 
statistically significant correlation between the capacity of a given plant extract to 
stimulate AMPK and its ability to inhibit G6Pase (R2=0.48, p < 0.05, Figure 4C). In 
contrast, only S. purpurea and K. angustifolia were found capable of stimulating Akt 
phosphorylation (2-3-fold, p < 0.05; Figure 4D and E); this effect being comparable 
for their EE and HWE crude preparations. There was no clear correlation found 
between Akt phosphorylation and inhibition of hepatic G6Pase activity (data not 
illustrated).  
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3.5 Metabolites analysis  
Using the optimal UPLC–QTOF/MS conditions described above, 
representative fingerprints for all HWE and EE of the 17 plants were obtained.  
Overall, more than 4000 metabolites were detected from these extracts by UPLC-
QTOF. This generated a matrix of data comprising qualitative (relating to 
phytochemical compounds, notably retention time and accurate mass) and relative 
quantitative (signal intensities) components. Information on the biological activity of 
each plant species was also incorporated into the data matrix. The PCA process was 
then used to assess the relationships between phytochemical metabolites (profiles) 
and biological phenotype. Using an unbiased PCA approach including HWE and EE, 
as well as all species regardless of their biological phenotype (e.g. active versus 
inactive for a given bioassay), all 17 plants clustered together (data not shown). We 
then carried out more specific PCA approaches guided by the biological activity 
found in our bioassays (presence or absence of effects on muscle glucose uptake or 
hepatic G6Pase activity) for HWE and EE samples separately.  
We first examined EE preparations and compared species with a stimulating 
action on GU with inactive ones using the PCA process, but no discriminating 
characteristics were observed (data not illustrated). Similarly, when inhibiting 
G6Pase EE or HWE samples were analyzed against corresponding inactive species, 
the PCA process did not show any clustering (data not shown).  
In contrast, when the HWE preparations of the 17 plants were specifically 
analyzed taking into consideration their capacity or not to stimulate glucose uptake in 
C2C12 cells, a clear discrimination of species was obtained (Figure 5A and 5B). 
Indeed, plants stimulating glucose uptake, namely R. groenlandicum, S. purpurea and 
R. tomentosum, clustered together. Similarly, inactive species (A. balsamea, L. 
laricina, S.decora, P. glauca, P. banksiana V. vitis,) were found to group together 
(outliers K. augusfolia being excluded from the analysis).  
A so-called S-plot was then generated to determine plant metabolites that 
could significantly contribute to discriminating species. These usually lie in the top or 
bottom extremities of the S-plot, and are characterized by sufficiently important 
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statistical differences to render them potential biomarkers for the biological activity 
studied. As shown in Figure 5C, two such markers were extracted and identified as 
the potential biomarkers from S-plots constructed following the OPLS-DA Figure 
5B.  
The UPLC–QTOF/MS analysis that was performed in positive ion mode 
indicated the retention time and accurate mass within 5 ppm accuracy, and provided 
the high voltage fragmentation data that was necessary for the structural 
identification of the biomarkers. We searched for the presumed molecular formula in 
the ChemSpider (http://www.chemspider.com/), Metlin (http://metlin.scripps.edu/) 
and other databases to confirm possible chemical compositions, and the high 
fragmentation signals were used to determine the potential structures of the ions. The 
two biomarkers were identified as Quercetin 3-O-α-L-arabinopyranoside (with 
retention time 3.09 min, accurate mass of [M+H]+ 435.0931) and Quercetin-3-O-
galactoside (with retention time 2.83min, accurate mass of [M+H]+ 465.1034), 
respectively. 
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4. Discussion 
 
Through ethnobotanical surveys, our group identified 17 CEI medicinal plants 
as candidate antidiabetic species used by the CEI First Nations to treat various 
symptoms of Type 2 diabetes [2, 9]. We found that several CEI plants’ ethanol 
extracts strongly potentiated glucose transport in C2C12 cells, whereas another group 
of species significantly inhibited G6Pase in H4IIE liver cells, indicating a potential to 
increase peripheral glucose disposition and to suppress hepatic glucose production, 
respectively [5-7]. In the present study, we used the same bioassays to evaluate the 
biological activity of a more traditional-like HWE preparation and compare it with 
the standard phytochemical ethanol extraction procedure. We also sought to begin 
assessing the potential underlying molecular mechanisms in this in vitro system. 
Generally in line with previous observations by our group [2, 4], our results 
showed that several EE of CEI plants enhanced glucose transport in C2C12 
differentiated myoblasts. The present studies demonstrated that three species (both 
Rhododendrons and S. purpurea) completely or partially maintained their capacity to 
stimulate such glucose transport when more traditional HWE preparations were used. 
Five other species completely lost this biological activity in similar conditions. All 
inactive species remained inactive when HWE was used instead of EE. These results 
could be interpreted to mean that more traditional preparations are not as “good” as 
the classical ethanol extraction procedure used in phytochemistry. However, a 
number of considerations can argue differently. Firstly, EE and HWE extracts were 
tested at identical mg/mL concentrations of the crude extracts for purposes of proper 
pharmacological comparison. Since ethanol is known to be a better solvent than 
water to extract several bioactive plant molecules (notably of the large class of 
phenolic compounds), our observations could simply reflect the fact that certain 
bioactives were more concentrated in EE and hence were able to enhance biological 
activity. Future studies should use wide ranges of extract concentrations to better 
compare the pharmacological potential of EE and HWE plant preparations. Secondly, 
the laboratory method used to prepare the HWE mimicked procedures used by 
traditional CEI healers and was indeed adjusted after discussions with them. 
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However, traditional healers may use lake water instead of distilled water and 
different heating conditions than was used in the laboratory. Hence, future studies 
should compare laboratory HWE with true traditional preparations of CEI healers.  
Nonetheless, the present results confirmed the soundness of our current and 
previous studies to assess the biological activity of putative antidiabetic CEI plant 
species. Indeed, we found that the capacity of both EE and HWE preparations of five 
representative species to increase glucose transport strongly correlated with their 
extracts’ ability to increase GLUT4 protein content in C2C12 cells. Hence, the 
potential of the various extracts to enhance peripheral glucose disposition is related to 
their action on the major glucose transport protein of skeletal muscle. As importantly, 
a significant, albeit somewhat weaker, correlation was observed between increased 
glucose transport and AMPK phosphorylation for both EE and HWE preparations 
tested. This is in full agreement with what was described in our previous study on a 
subset of 8 CEI plants [16]. Indeed, we had shown that glucose uptake was increased 
by several species though the AMPK pathway rather than the insulin-dependent 
pathway involving Akt [16]. The insulin-independent AMPK signaling pathway is 
also the one through which the common oral hypoglycemic drug, metformin, 
increases glucose uptake in skeletal muscle and inhibits glucose production in liver 
while also restoring insulin sensitivity in these tissues [17, 18].  
On the other hand, we made a very interesting observation concerning the 
species Sarracenia purpurea L., commonly known as the purple pitcher plant, which 
was among the top ranked species in the C2C12 glucose uptake bioassay. We found 
that the EE of S. purpurea triggered significant AMPK phosphorylation (activation), 
whereas its HWE counterpart was the only one of all species tested to activate Akt 
phosphorylation, which is related to the insulin pathway. In parallel, the capacity of 
S. purpurea HWE to stimulate glucose transport was lower than the corresponding 
EE. In previous studies, we had tested the effect of the same plant’s EE in the same 
bioassay and in the presence or absence of physiological and pharmacological 
concentrations of insulin [5]. We found that EE of S. purpurea had a tendency to 
increase the glucose uptake induced by insulin, consistent with an action on the 
“insulin-sensitizing” AMPK pathway. In contrast, preliminary studies with S. 
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purpurea HWE showed similar results on C2C12 glucose uptake with or without 
insulin (N. Shang and P.S. Haddad, unpublished information). We also isolated 
several bioactive compounds from S. purpurea EE using C2C12 cells to guide a 
fractionation process and some of these compounds were also shown to activate 
AMPK [11, 16]. The present studies thus suggest that the HWE of S. purpurea may 
contain other compounds that activate instead the insulin-dependent pathway 
involving Akt. Future studies using a similar bioassay-guided fractionation approach 
with HWE may clarify this interpretation.  
The second assay related to glucose homeostasis that we have used is based 
on the inhibition of G6Pase in H4IIE liver cells as an indicator of an antidiabetic 
potential to reduce hepatic glucose production. Our results clearly showed that 
several species had a significant inhibitory effect of G6Pase. Unlike the C2C12 
bioassay, however, the inhibitory action of most HWE was similar to that of their EE 
counterparts, only three species showing lower activities and only one losing it 
completely with HWE. Likewise, all five of the selected subset of representative 
species enhanced AMPK phosphorylation and this was equivalent between the plants’ 
respective EE and HWE. This is consistent with the reported effects of metformin 
and many natural products that inhibit hepatic glucose production in liver [19-21]. In 
addition, two plants extracts (S. purpurea and K. angustifolia) also activated insulin 
pathways by inducing Akt phosphorylation; this being true for both their respective 
EE and HWE. The differences in results comparing EE and HWE in C2C12 
differentiated myoblasts and H4IIE hepatocytes demonstrate that in some cases, 
bioactive components (and combinations thereof) of CEI plants can be extracted with 
similar efficiency by the two extraction methods used. 
Rhododendron groenlandicum, (known as Ledum groenlandicum or Labrador 
tea), is a good case for this point. It is a flowering plant in the subsection Ledum of 
the large genus Rhododendron in the Ericaceae family. Leaves and other parts have 
showed antioxidant and anti-inflammatory [22] activity, as well as benefits against 
cancer [23], asthma [24], rheumatism [25] and diseases of the kidney [24]. In the 
present studies, R. groenlandicum was the only specie whose EE and HWE 
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preparations were found to be active in both assays and to exert their anti-diabetic 
effect through similar molecular pathways. 
R. groenlandicum was also one of three species stimulating glucose transport 
(alongside S. purpurea and R. tomentosum) whose HWE clustered in a way that was 
clearly separated from inactive species, when photochemical profiling and PCA 
process were applied to our data. Most importantly, the discriminant analysis 
uncovered significant differences in the chemical profiles of these plants. Notably, 
two biomarkers were identified as strong potential to be responsible for the biological 
activity of the active plants, due to their highest contribution to this separation of 
clustering. One of these, quercetin-3-O-galactoside, was previously identified by our 
team and reported to be one of the active principles capable of enhancing glucose 
transport in C2C12 through the activation of AMPK [11, 16]. On the other hand, the 
second putative antidiabetic compound, identified in the present report as quercetin 
3-O-α-L-arabinopyranoside, has not been isolated in prior bioassay-guided 
fractionation studies by our group or associated with this biological activity by 
others. However, because of the labor-intensive and tedious characteristics of the 
bioassay-guided fractionation approach, only the most active subfractions were 
selected for the identification of active principles. Hence, other active metabolites 
may exist in the active species and quercetin 3-O-α-L-arabinopyranoside may thus 
contribute to the antidiabetic potential of some CEI plant species. Future studies will 
need to carefully assess the biological activity of this compound in the context of 
glucose metabolism and diabetes. 
In summary, we evaluated and compared the potentials of the EE and HWE of 
17 plants to modulate glucose homeostasis in muscle and liver cells, two major 
targets of insulin action. We also assessed the possible molecular mechanisms 
responsible for such activities in vitro. We confirmed that the different species, target 
tissues or cells (muscle or liver), as well as extraction methods (EE or HWE), are all 
significant determinants of the biological activity of Cree medicinal plants on glucose 
metabolism. By applying principal component analyses to mass spectrometric data 
obtained by UPLC-QTOF enabled us to partly segregate the metabolomes of active 
plant species from the inactive ones.  This powerful approach offers an interesting 
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avenue to identify potential bioactive plant metabolites. Our work and its future 
applications can help to develop novel as well as culturally relevant plant-based 
therapeutic approaches against insulin resistance that target muscle and liver cells 
directly. Finally, our studies can serve as quality control tools to foster reliable and 
effective plant-based treatments, using the information relative to the content of 
active principles as well as that pertaining to biological activity. 
  
117 
 5. Acknowledgements 
 
This work was supported by a Team Grant from the Canadian Institutes of 
Health Research (CIHR Team in Aboriginal Antidiabetic Medicines) to PSH, JTA 
and AC, and by funding from the Office of Biotechnology, Genomics and Population 
Health of Health Canada. It was conducted with the consent and support of the Cree 
Nation of Mistissini, of the Whapmagoostui First Nation and of the Cree Board of 
Health and Social Services of James Bay (Quebec, Canada). Very special thanks are 
due to Elizabeth Coon Come, Mable Gunner, Charlotte Husky Swallow, Johnny 
Husky Swallow, Ronny Loon and Girty Loon from the Cree Nation of Mistissini, to 
Eliza Kawapit, Abraham Mamianskum, Andrew Natachequan, Maggie Natachequan 
and John Petagumskum from Whapmagoostui First Nation, as well as 54 other Elders 
and healers who kindly agreed to be interviewed. They made this article possible by 
allowing us to use, for the purposes of this research, their knowledge relating to 
medicinal plants, transmitted to them by their Elders. Their trust has also enabled a 
useful exchange between Indigenous knowledge and Western science. 
  
118
6. Reference 
 
1.WHO, Diabetes Fact sheet N°312. 2011. 
2.Leduc, C., et al., Plants used by the Cree Nation of Eeyou Istchee (Quebec, 
Canada) for the treatment of diabetes: A novel approach in quantitative ethnobotany. 
J Ethnopharmacol, 2006. 105(1-2): p. 55-63. 
3.Kuzmina, E., D. Dannenbaum, and J. Torrie, Cree Diabetes Information 
System (CDIS) 2009 Annual Report, in Public Health Report Series 3 on Diabetes, 
P.H. Department, Editor. 2010 Cree Board of Health and Social Services of James 
Bay  Chisasibi. 
4.Haddad, P.S., et al., Comprehensive evidence-based assessment and 
prioritization of potential antidiabetic medicinal plants: a case study from canadian 
eastern james bay cree traditional medicine. Evid Based Complement Alternat Med, 
2012. 2012: p. 893426-. 
5.Spoor, D.C., et al., Selected plant species from the Cree pharmacopoeia of 
northern Quebec possess anti-diabetic potential. Can J Physiol Pharmacol, 2006. 
84(8-9): p. 847-858. 
6.Harbilas, D., et al., Evaluation of the antidiabetic potential of selected 
medicinal plant extracts from the Canadian boreal forest used to treat symptoms of 
diabetes: part II. Can J Physiol Pharmacol, 2009. 87(6): p. 479-92. 
7.Nachar, A., Vallerand, D., Musallam, L., Lavoie, L., Badawi, A., Arnason, 
J.T., Haddad, P.S., 2013. The action of antidiabetic plants of the Canadian James Bay 
Cree traditional pharmacopeia on key enzymes of hepatic glucose homeostasis. Evid 
Based Complement Alternat Med. (In press). 
8.Ferrannini, E., et al., The disposal of an oral glucose load in patients with 
non-insulin-dependent diabetes. Metabolism, 1988. 37(1): p. 79-85. 
9.Boustead, J.N., et al., Identification and characterization of a cDNA and the 
gene encoding the mouse ubiquitously expressed glucose-6-phosphatase catalytic 
subunit-related protein. J Mol Endocrinol, 2004. 32(1): p. 33-53. 
10.Consoli, A., Role of liver in pathophysiology of NIDDM. Diabetes Care, 
1992. 15(3): p. 430-41. 
  
119 
11.Muhammad, A., et al., Antidiabetic Compounds from Sarracenia purpurea 
Used Traditionally by the Eeyou Istchee Cree First Nation. J Nat Prod, 2012. 75(7): 
p. 1284-8. 
12.Peyron-Caso, E., et al., Regulation of glucose transport and transporter 4 
(GLUT-4) in muscle and adipocytes of sucrose-fed rats: effects of N-3 poly- and 
monounsaturated fatty acids. Horm Metab Res, 2002. 34(7): p. 360-6. 
13.Garvey, W.T., et al., Pretranslational suppression of a glucose transporter 
protein causes insulin resistance in adipocytes from patients with non-insulin-
dependent diabetes mellitus and obesity. J Clin Invest, 1991. 87(3): p. 1072-81. 
14.Niu, W., et al., Contraction-related stimuli regulate GLUT4 traffic in 
C2C12-GLUT4myc skeletal muscle cells. Am J Physiol Endocrinol Metab, 2010. 
298(5): p. E1058-71. 
15.Takazawa, K., et al., Insulin-induced GLUT4 movements in C2C12 
myoblasts: evidence against a role of conventional kinesin motor proteins. Kobe J 
Med Sci, 2008. 54(1): p. E14-22. 
16.Eid, H.M., et al., Stimulation of AMP-activated protein kinase and 
enhancement of basal glucose uptake in muscle cells by quercetin and quercetin 
glycosides, active principles of the antidiabetic medicinal plant Vaccinium vitis-
idaea. Mol Nutr Food Res. 54(7): p. 991-1003. 
17.Musi, N., et al., Metformin increases AMP-activated protein kinase 
activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 2002. 51(7): p. 
2074-81. 
18.Klip, A. and L.A. Leiter, Cellular mechanism of action of metformin. 
Diabetes Care, 1990. 13(6): p. 696-704. 
19.Kim, Y.D., et al., Metformin inhibits hepatic gluconeogenesis through 
AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor 
SHP. Diabetes, 2008. 57(2): p. 306-14. 
20.Zhang, M., et al., Sodium caprate augments the hypoglycemic effect of 
berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol, 
2012. 
  
120
21.Yuan, H.D., et al., Ginsenoside Rg2 induces orphan nuclear receptor SHP 
gene expression and inactivates GSK3beta via AMP-activated protein kinase to 
inhibit hepatic glucose production in HepG2 cells. Chem Biol Interact, 2012. 195(1): 
p. 35-42. 
22.Moerman, D.E., Native American Ethnobotany 2000, Portland, USA 
Timber Press. 
23.Dufour, D., et al., Antioxidant, anti-inflammatory and anticancer activities 
of methanolic extracts from Ledum groenlandicum Retzius. J Ethnopharmacol, 2007. 
111(1): p. 22-8. 
24.Chandler, R.F., L. Freeman, and S.N. Hooper, Herbal remedies of the 
Maritime Indians. J Ethnopharmacol, 1979. 1(1): p. 49-68. 
25.Gunther, E., Ethnobotany of Western Washington. 1973, Seattle, USA.: 
University of Washington Press. 
 
  
  
121 
 7. Figure legends 
 
Figure 1: Effects of extracts on muscle glucose transport. C2C12 skeletal 
muscle cells were treated with either 0.1% DMSO (vehicle), Metformin (400 µM), 
EE and HWE (at concentrations described in Table 1) for 18 h, or with insulin 
(100nM) for 30 min. Results represent means ± SE for 3 separate experiments, 
normalized to the vehicle-treated condition. # Denotes EE samples significantly 
different from vehicle control (p<0.05), one-way ANOVA and post hoc Dunnett's 
test. $ Denotes HWE samples significantly different from vehicle control (p< 0.05), 
one-way ANOVA and post hoc Dunnett's test. * (p<0.05), **(p<0.01) and *** 
(p<0.001) denote significant differences between respective EE and HWE 
counterparts, two-way ANOVA. 
 
Figure 2: Effects of extracts on hepatic Glucose-6-phosphatase activity. 
H4IIE rat hepatoma cells were treated for 18h with vehicle control, or insulin (100 
nM), EE or HWE plants extracts (at concentrations as described in Table 1). Results 
represent means ± SE for 3 separate experiments, normalized to the vehicle-treated 
condition. # Denotes EE samples significantly different from vehicle control 
(p<0.05), one-way ANOVA and post hoc Dunnett's test. $ Denotes HWE samples 
significantly different from vehicle control (p< 0.05), one-way ANOVA and post hoc 
Dunnett's test. * (p<0.05), **(p<0.01) and *** (p<0.001) denote significant 
differences between EE and HWE counterpart, Two-way ANOVA. 
 
Figure 3: Effect of selected extracts on expression of GLUT4, Insulin and 
AMPK pathway in C2C12 cells. Cells were differentiated and treated for 18 h with 
either 0.1% DMSO (vehicle) or with EE and HWE of the 5 selected plants. 
Metformin (400 µM, 18h), AICAR (2mM, 2h) or insulin (100 nM, 30min) was 
applied as positive controls for the AMPK or insulin pathways, respectively. GLUT4 
(A), phosphorylation of AMPK (D), phosphorylation of Akt (G) were measured by 
western blot and results (B, E, H) were expressed as means ± SE for 3 separate 
experiments, normalized to the vehicle-treated condition. # Denotes EE samples 
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significantly different from vehicle control (p<0.05), one-way ANOVA and post hoc 
Dunnett's test. $ Denotes HWE samples significantly different from vehicle control 
(p < 0.05), one-way ANOVA and post hoc Dunnett's test. * (p<0.05),  **(p<0.01) 
and *** (p<0.001) denote significant differences between EE and HWE counterpart, 
two-way ANOVA. Correlation results (C, F) were analyzed by linear regression and 
the equations were y = 32.06x + 52.95 (R=0.80, p < 0.05), y = 11.602x + 84.825 
(R=0.46, p < 0.05), respectively. 
 
Figure 4: Effect of selected extracts on the modulation of insulin and AMPK 
pathway components in H4IIE hepatoma cells. The cells were treated for 18h with 
vehicle control, insulin (100 nM), EE or HWE plants extracts. Metformin (400 µM, 
18h), AICAR (2mM, 2h) or insulin (100 nM, 18h) was used as positive controls for 
AMPK or insulin pathways, respectively. Phosphorylation of AMPK (A) and of Akt 
(D) were measured by western blot and results (B, E) expressed as means ± SE for 3 
separate experiments, normalized to the vehicle-treated condition. # Denotes EE 
samples significantly different from vehicle control (p<0.05), one-way ANOVA and 
post hoc Dunnett's test. $ Denotes HWE samples significantly different from vehicle 
control (p< 0.05), one-way ANOVA and post hoc Dunnett's test. Correlation results 
(C) were analyzed by linear regression and the equation was y = -45.418x + 285.3 
(R=0.48, p< 0.05). 
 
Figure 5: Metabolites analysis of selected hot water extracts based on 
stimulating glucose uptake activity.  
PCA scores (A), OPLS-DA scores (B) S-plot (C) of HWE stimulating glucose 
transport (R. gromenlandicum, R. tomentosum, and S. purpurea) compared with 
inactive ones (K. augusfolia was found to be outliers and were excluded from the 
process). The scores t [1], t [2] and t [1] P and t [2] O are the new most important 
indices in PCA and OPLS-DA in summarizing the peak lists of the plants. In S-plot, 
it displays easily the observations that have a large absolute value of p (corr) [1] and 
a large absolute value of the coefficients. These are the observations that differentiate 
the most between the 2 groups. 
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Table 1: List of investigated plant species and the concentrations of the extracts 
tested in C2C12 and H4IIE cells 
 
 
  
Species Abbreviation Plant part 
C2C12 cells H4II E cells 
 µg/mL  µg/mL 
Rhododendron groenlandicum 
(Oeder) Kron and Judd  R.groenlandicum  Leaves 75 50 
Abies balsamea (L.) Mill. A.balsamea Inner bark 50 50 
Larix laricina Du Roi (K.Koch) L.laricina Inner bark 25 25 
Picea mariana (P. Mill.) BSP P.mariana Cones 10 10 
Sorbus decora (Sarg.) 
C.K.Schneid. S.decora Inner bark 15 15 
Alnus incana subsp. rugosa (Du 
Roi) R.T. Clausen A.incana   Inner bark 50 50 
Sarracenia purpurea L. S.purpurea Whole plant 100 25 
Pinus banksiana Lamb. P.banksiana Cones 15 10 
Rhododendron tomentosum 
(Stokes) Harmaja 
subsp.subarcticum (Harmaja) 
G.Wallace 
R.tomentosum Leaves 50 50 
Kalmia angustifolia L.  K.augustifolia Leaves 50 50 
Picea glauca (Moench) Voss P.glauca Leaves 125 125 
Juniperus communis L. J.communis Berries 5 3.75 
Salix planifolia Pursh S.planifolia Inner bark 25 15 
Lycopodium clavatum L. L.clavatum Whole plant 100 100 
Populus balsamifera L. P.balsamifera Inner bark 100 100 
Gaultheria hispidula (L.) Muhl. G.hispidula Leaves 25 25 
Vaccinium vitis-idaea L. V.vitis-idaea Berries 200  200  
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Figure 1 
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Figure 2 
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Figure 3 
 
       
 
 
 
  
R.
gr
oe
nla
nd
icu
m 
A.
inc
an
a
S.p
ur
pu
rea
K.
au
gu
sti
fol
ia
P.b
als
am
ife
ra
0
1
2
3
4
EE
HWE
# $
#
# $

R
el
at
iv
e 
pr
ot
ei
n 
ex
pr
es
si
on
 o
f G
LU
T4
/ β
-a
ct
in
R.
gr
oe
nla
nd
icu
m 
A.
inc
an
a
S.p
ur
pu
rea
K.
au
gu
sti
fol
ia
P.b
als
am
ife
ra
0
1
2
3
4
5
EE
HWE
$# #
#
 
R
el
at
iv
e 
pr
ot
ei
n 
ex
pr
es
si
on
 o
f p
-A
M
PK
/to
ta
l A
M
PK
0 1 2 3 4
60
80
100
120
140
160
y = 32.06x + 52.95
R2= 0.80
Relative protein expression
 of GLUT4/ β-actin
3 H
- D
eo
xy
-g
lu
co
se
 u
pt
ak
e
(%
 o
f v
eh
ic
le
 c
on
tro
l)
0 1 2 3 4
60
80
100
120
140
160
y = 11.602x + 84.825
R2= 0.46
Relative protein expression
 of p-AMPK/total AMPK
3 H
- D
eo
xy
-g
lu
co
se
 u
pt
ak
e
(%
 o
f v
eh
ic
le
 c
on
tro
l)
!"#$%&
'"#$%&
(&&&&&&& )& *& +& ,& -& .& /& 0& (1& ((& ()&
23
4&
23
4&
23
4&
23
4&
23
4&
567
89:
;<=
;>
?@A
B&
&
44
&&
44
&&
44
&&
44
&&
44
&&
@9
;'8
9<&
C;D
A<?
;&
#6?
;@
=;
=&
E6!
A8!
A8:
=&
$6=
A7
AD
FG9
<?=
&
H6I
=<D
=B
?G:
8=&
Ins
uli
n
S.p
ur
pu
rea
R.
gr
oe
nla
nd
icu
m 
A.
inc
an
a
K.
au
gu
sti
fol
ia
P.b
als
am
ife
ra
0
1
2
3
4
5
6
EE
HWE
#
#

R
el
at
iv
e 
pr
ot
ei
n 
ex
pr
es
si
on
 o
f p
-A
K
T/
to
ta
l A
kt
D
E F
G H
!"#$%&'
()*+",'
-''''''' .' /' ,' 0' 1' 2' 3' 4' -5' --' -.' -/' -,'
67
8'
67
8'
67
8'
67
8'
67
8'
9:;
<=>
&?#
&@
A$B
C'
'
88
''
88
''
88
''
88
''
88
''
$=
&D<
=?'
E>
F=
<C
A&'
G:A
&$
#&
#'
H:I
B<I
B<>
#'
J:#
B;
BK
%L=
?A#
'
M:N
#?K
#C
AL>
<#'
GOP
G9
'
O&K
B?A
&'
!"#$%&'
("#$%&'
)''''''' *' +' ,' -' .' /' 0' 1' )2' ))' )*' )+'
34
5'
34
5'
34
5'
34
5'
34
5'
678
9:;
<=>
<?
@AB
C'
'
55
''
55
''
55
''
55
''
55
''
A:
<(9
:='
$;
D:
9C
@<'
#7@
<A
><
>'
E7!
B9!
B9;
>'
&7>
B8
BF
GH:
=@>
'
%7I
>=F
>C
@H;
9>'
#JK
#6
'
A
B C
  
127 
Figure 4 
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Figure 5 
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Chapter 5: General discussion 
Metabolic syndrome (MetS) in an individual reflects the clustering of multiple 
metabolic abnormalities, including central obesity, T2D, dyslipidemia, hypertension, 
as well as NAFLD. MetS is currently considered to be a worldwide epidemic. For 
instance, about 1 in 5 Canadian adults have MetS (Riediger and Clara, 2011), 1 in 10 
adults of the world's population is now obese (WHO, 2012), and 346 million people 
worldwide have diabetes (WHO, 2011).  
In particular, T2D and obesity are more pronounced among indigenous 
peoples than in the rest of the population. This is the case in the CEI of northern 
Quebec, where the age-adjusted prevalence of T2D reached 29% in 2009 (Kuzmina 
et al., 2010 ) and where the prevalence of obesity and overweight is also 2-3 times 
higher than in the general Canadian population. They also suffer from higher rate of 
diabetic complications (Young et al., 2000). This serious problem has been related to 
a sedentary lifestyle and non-traditional diet (Hegele, 2001), a genetic predisposition 
towards obesity (Neel, 1999; Skyler, 2004), and especially due to cultural disconnect 
(Young et al., 2000) of the modern or western pharmaceutical therapies described 
above in the introduction.  
Long before the birth of western medicines, the aboriginal peoples relied on 
traditional healing for many diseases, a knowledge that was verbally taught and 
handed down from generation to generation (Young et al., 2000). Medicinal plants 
played an important role in this holistic approach. Although some of this knowledge 
was lost, anthropologists documented the administration of many plant species 
belonging to aboriginal medicine.  Over 1200 plants worldwide have been used as 
remedies for diabetes (Habeck, 2003; Marles and Farnsworth, 1995) and about 700 
recipes and compounds have been scientifically evaluated for T2D treatment (Singh 
et al., 2011). Several of these medicinal plants are commonly recognized for their 
antidiabetic potentials and significant scientific evidence has been accumulated in 
support of this. These include Trigonella foenum graecum (Fenugreek) (Gupta et al., 
2001); Momordica charantia (bitter melon)(John et al., 2003); Cinnamomum cassia 
(Chinese cinnamon) (Crawford, 2009; Khan et al., 2003); Aloe vera 
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(Bunyapraphatsara et al., 1996) and Ginseng (Sotaniemi et al., 1995; Vuksan et al., 
2008). 
For responding to the primary health care needs of the CEI and to search for 
culturally adapted T2D therapies, our team (CIHR-TAAM) was instated in 2003. 
It was a multipartite project researching the antidiabetic effects of plants used by 
Aboriginals in the Eastern James Bay area of Quebec, Canada. This project required 
a highly coordinated effort between three parts, including the CEI, research scientists, 
and health care professionals. Aide from traditional knowledge keepers and users, the 
multi-disciplinary research team assembled for this project possessed considerable 
expertise not only in pharmacology, but also in phytochemistry, human clinical as 
well as health systems research. A novel ethnobotanical approach (Leduc et al., 2006) 
was used to identify plants for treating several symptoms related to T2D disorder. 17 
plant species were evaluated in several screening studies (Fraser et al., 2007; Harbilas 
et al., 2009; Harris et al., 2011b; Nachar et al., 2013; Nistor Baldea et al., 2010; 
Spoor et al., 2006) using a variety of in vitro bioassays to assess the antidiabetic 
potentials of the ethanol extracts.  
 
5.1 General bioactive compounds and constituents from L. 
laricina 
In a previous study, L. laricina potentiated adipogenesis in 3T3-L1 adipocytes 
(Spoor et al., 2006) acting like the TZD drug rosiglitazone, which is one of the OHAs 
of antidiabetic medication. It also demonstrated antidiabetic potential by increasing 
glucose uptake (comparable to another OHAs medication Metformin) (Spoor et al., 
2006), activating AMPK in C2C12 myotubes and uncoupling mitochondria functions 
(Martineau et al., 2010a). A recent in vivo study also confirmed that L. laricina 
improves insulin resistance and decreases glycemia, using the diet-induced obese 
mouse model (Harbilas et al., 2012). 
Medicinal plants contain numerous compounds and there are more than 200 
pure compounds (Marles and Farnsworth, 1995) from plant sources reported to have 
antidiabetic potential. Thus it is important to use phytochemical methods to screen 
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and isolate bioactive secondary metabolites. Many kinds of natural products and 
constituents, belonging to chemical classes such as terpenoids, alkaloids, flavonoids, 
phenolics, and others, have shown antidiabetic potentials.  
Bioassay-guided fractionation of the stem bark of S. decora (one of the Cree 
plants) resulted the isolation of 3 new pentacycle triterpenes. One of the triterpenes, 
identified as 23,28-dihydroxylupan-20(29)-ene-3β-caffeate, showed significant 
antidiabetic properties as determined by an increase in glucose uptake by C2C12 
cells (Guerrero-Analco et al.). The triterpene dehydrotrametenolic acid isolated from 
dried sclerotia of Poria cocos  Wolf. (Polyporaceae) was shown to have an anti-
hyperglycemic effect in vivo as an insulin sensitizer (Sato et al., 2002). Twelve 
triterpenoid saponins have been isolated from the roots of Gypsophila oldhamiana 
and some showed significant inhibitory activities on α-glucosidase (Luo et al., 2008). 
Corosolic acid (Glucosol), one triterpene isolated from the leaves of Lagerstroemia 
speciosa L. (Lythraceae), significant stimulated glucose transport and showed a 
significant reduction in the blood glucose levels at daily dosages of 32 and 48mg for 
2 weeks in a randomized clinical trial involving T2D (Judy et al., 2003). 
2 new pyrrolidine alkaloids, radicamines were isolated as inhibitors of α-
glucosidase from Lobelia chinensis Lour (Campanulaceae) (Shibano et al., 2001). 
Alkaloids like canthin-6-one was isolated from the methanol root extract of Aerva 
lanata Linn. (Amaranthaceae), a plant used traditionally as an antihyperglycaemic in 
the Ayurvedic system of medicine. The compound is thought to contribute to the 
antihyperglycemia effects observed on streptozotocin-nicotinamide induced T2D in 
rats (Agrawal et al., 2013). 
Several flavonoids were isolated from V. vitis (another of the CEI plants) 
through glucose uptake guided fractionation approach. The flavonoids quercetin and 
quercetin 3-O-glycosides might be responsible for the antidiabetic activity of V. vitis 
crude extract mediated by AMPK (Eid et al.). Glucose uptake activity guided 
fractionation of Sarracenia purpurea  (pitcher plant, S. purpurea), one of the 
identified Cree plants, resulted in the isolation of 11 compounds, including a new 
phenolic glycoside and several flavonoid glycosides. Isorhamnetin-3-O–glucoside, 
kaempferol-3-O-(6″-caffeoylglucoside], and quercetin-3-O–galactoside strongly 
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potentiated glucose uptake (Muhammad et al., 2012). The new compound, namely 6′-
O -caffeoylgoodyeroside, decreased hepatic glucose production by reducing G6Pase 
enzymatic activity, which also contributed to the antidiabetic potential of S. purpurea 
(Muhammad et al., 2012). 
2 new phenolics, 7’-(3’,4’-dihydroxyphenyl)-N-[(4 methoxyphenyl) ethyl] 
propenamide and 7’-(4’-hydroxy-3’-methoxyphenyl)-N-[(4-butylphenyl) ethyl] 
propenamide have been isolated from Cuscuta reflexa Roxb and showed strong α-
glucosidase inhibitory activity with IC50 of 103.58 and 45.67 µM, respectively (Anis 
et al., 2002). Mangiferi was isolated from Anemarrhena asphodeloides Bunge 
rhizome. It improved hyperinsulinemia and, on insulin tolerance test, reduced blood 
glucose levels after oral administration for 3 weeks in mice (Miura et al., 2001). 
As we discussed above, through bioassay-guided fractionation, our team 
isolated several compounds, belonging to terpenoids, alkaloids, flavonoids and 
phenolics from Boreal forest plants. These plants include S. decora (Guerrero-Analco 
et al.), V. vitis (Eid et al.), S. purpurea (Muhammad et al., 2012), A. incana and P. 
balsamifera (Martineau et al., 2010b). And the chapter 2 of this thesis is the first 
report of putative antidiabetic components isolated from L. laricina, increasing 
interest in the medical plants from the Cree pharmacopeia. 
 In that chapter, fractionation of L. laricina extract guided by adipogenesis in 
3T3-L1 cells was carried out to identify putative bioactive compounds. This resulted 
in the isolation of a novel cycloartane triterpene (identified as 23-oxo-
3α-hydroxycycloart-24-en-26-oic acid) and a known diterpene (13-epitorulosol) as 
the possible active principles responsible for the enhancement of adipogenesis. Along 
with other bioactive principles identified by the CIHR-TAAM, the identification of 
such active compounds of L. laricina can serve two main purposes. Firstly, they 
could also help develop methods for the quality control/quality assurance of 
traditional preparations that could be used alongside modern pharmaceuticals to 
provide culturally adapted treatment options for Cree diabetics. Secondly, although 
drug development was not a goal of the CIHR-TAAM initiative, novel putative 
antidiabetic compounds may serve as templates to generate new therapeutic avenues 
for T2D. If so, this should be done in respect of the research agreement that 
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intervenes between academic and Aboriginal partners. This agreement ensures that 
any joint intellectual property generated by the Team will be managed in such a way 
as to benefit Aboriginal communities, notably by adhering to international access and 
benefit sharing principles. 
 
5.2 Antidiabetic activity and mechanisms of action of 
general plants and the CEI plants 
Currently available therapies for T2D include insulin and various OHAs, such 
as α-glucosidase inhibitors, metformin, sulfonylureas and TZDs, which have a 
number of serious adverse effects. Generally speaking, the molecular and cellular 
targets of action of antidiabetic plants that have been investigated thus far also fall 
into one or more of these categories: α-glucosidase inhibitors, insulin secretagogues, 
insulin mimetics and insulin sensitizers. 
As we discussed above, radicamines from Lobelia chinensis Lour 
(Campanulaceae) were shown to suppress α-glucosidase activity (intestinal glucose 
absorption) (Shibano et al., 2001). Two serotonin derivatives isolated from Safflower 
(Carthamus tinctorius) seed were shown to suppress α-glucosidase activity, stronger 
than the positive control acarbose (Takahashi and Miyazawa, 2012). Butyl-isobutyl-
phthalate, an active compound of Laminaria japonica, showed the inhibitory effect 
on α-glucosidase activity in vitro (Bu et al., 2010).  
 Stimulation of insulin secretion constitute the most commonly reported 
mechanism of action of many antidiabetic plants, such as Asparagus racemosus 
(Hannan et al., 2007), Ocimum sanctum (Hannan et al., 2006), Trigonella foenum 
graecum (Fenugreek) (Vijayakumar et al., 2005) and Aloe vera (Ajabnoor, 1990; 
Rajasekaran et al., 2004). The hypoglycemic effect of Aloe vera and its bitter 
component might be mediated by stimulation of synthesis and/or release of insulin 
from the β cells of Langerhans (Ajabnoor, 1990). Aloe vera gel also resulted in 
significant reductions (Rajasekaran et al., 2004) in fasting blood glucose in vivo. 
Insulin mimetics include plants that could activate one or multiple sites to 
enhance insulin signaling. Cinnamomon cassia (cinnamon) was shown to increase 
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tyrosine phosphorylation of insulin receptor and IRS-1 (Qin et al., 2003) in vivo in 
rats and Nigella sativa increased the phosphorylation of Akt in both C2C12 cells and 
H4IIE hepatocytes (Benhaddou-Andaloussi et al., 2010). 
Insulin sensitizers, including popular OHAs biguanides and TZDs and 
varieties of plants, could improve insulin sensitivity in the peripheral tissues, namely 
muscle, adipose tissue and liver. Metformin reduces blood glucose levels by 
suppressing hepatic production and by enhancing glucose uptake in skeletal muscle. 
Through PPARγ activation, TZDs improve insulin sensitivity partly by enhancing 
differentiation of pre-adipocyte to adipocyte to improve lipogenesis and avoid 
lipotoxicity in non-adipose tissue; by reducing lipolysis and hence FFAs in 
circulation; and regulating adipokines of adipose tissue.  Plants belonging to this 
category includes Mitragyna speciosa Korth (Rubiaceae) (Purintrapiban et al., 2011), 
Canna indica root (Purintrapiban et al., 2006), Artemisia princeps (Yamamoto et al., 
2010), Glycyrrhiza uralensis (Kuroda et al., 2003), Cecropia obtusifolia and 
Cecropia peltata (Andrade-Cetto and Vazquez, 2010) and Malmea depressa 
(Andrade-Cetto, 2011). 
In our case, the selected CEI plants were reported to have no effect on glucose 
stimulated insulin secretion by pancreatic β cells in culture (Harbilas et al., 2009; 
Spoor et al., 2006). Interestingly, in general line with the previous study, the findings 
of the present thesis showed that ethanol and hot water extracts of several plant 
products from the pharmacopeia of the CEI have insulin sensitizing and/or insulin 
mimetic effects in vitro. For example, through both ethanol and hot water extractions, 
R. groenlandicum potentiated adipocyte differentiation and adipogenesis (glitazone-
like activity) by activating PPARγ, SREBP-1 and C/EBPα; S. purpurea stimulated 
glucose transport in C2C12 cells by increasing GLUT4 protein content and activating 
phosphorylation of AMPK (for EE) or Akt (for HWE); K. angustifolia suppressed the 
hepatic G6Pase activity by activating phosphorylation of AMPK and Akt. Hence, 
CEI plant extracts, fractions and active principles altogether exert effects through 
both insulin-dependent and –independent biological activities. 
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5.3 Hot water extraction 
As mentioned earlier, most of the initial work of the CIHR-TAAM adopted 
the classical phytochemical approach of using an organic solvent such as ethanol to 
optimally extract plant compounds (especially phenolics) in order to determine their 
biological activities. However, Aboriginal traditional preparations are based much 
more on hot water extraction. The second part of this thesis thus sought to evaluate 
and compare the biological activities of HWE and EE. In comparison to 
corresponding ethanol extracts, the HWE of CEI plants either maintained their 
antidiabetic activity, or exhibited partial or complete loss of the same. Ten of the 17 
plants EE stimulated adipogenesis, hence indicating their antidiabetic potential; only 
3 of the corresponding HWEs (those of R. groenlandicum A. balsamea, and P. glauca) 
still significantly stimulated adipogenesis, albeit at a lower level than their EE 
counterparts. Similarly, 3 species (both Rhododendrons and S. purpurea) either 
partially or fully maintained the capacity of their respective EE to stimulate muscle 
cell glucose transport when more traditional HWE preparations were used. In 
contrast, the inhibition of G6Pase could be observed for both the EE and HWE of 9 
species. All inactive species remained inactive when HWE was used instead of EE. 
Observing such differences in various plant species is not surprising because 
medicinal plants have complex chemical compositions, containing thousands of 
compounds. Hence, different extraction methods (methanol, ethanol, ethyl acetate 
and hot water extraction) might produce different combination of constituents 
(Khatun et al., 2012).  Notably, ethanol is known to be a better solvent than water 
(Jeppesen et al., 2012; Khatun et al., 2012; Motawi et al., 2012) to extract several 
bioactive plant molecules (especially the large class of phenolic compounds). 
However, this does not imply that preparation and usage by the traditional 
method is not efficient. This was discussed in Chapters 3 and 4 and is briefly 
summarized here. Firstly, EE and HWE extracts were tested at identical mg/mL 
concentrations of the crude extracts for purposes of proper pharmacological 
comparison. Future studies should use wide ranges of extract concentrations to better 
compare the pharmacological potential of EE and HWE plant preparations. Secondly, 
numerous parameters might affect the quality of extractions carried out using hot 
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water, such as extraction time, temperature, and water quality. Traditional medicinal 
plant preparations of Aboriginal healers might thus differ from the HWE conditions 
used in this study and could yield more concentrated solutions. Further studies should 
therefore compare crude plant extracts prepared by Cree healers with those prepared 
in the laboratory over a wider range of concentrations. 
Many studies confirmed the biological effects of water extracts of plants for a 
variety of disease. For example, water extract of the Bromelia plumieri exhibited 
hypoglycemic activity in diabetic rats, with stronger effect at dose 350 mg/kg than 
that at 35 mg/kg (Andrade-Cetto and Medina-Hernandez, 2013). Hot water extract of 
Euphorbia formosana selectively inhibited the growth of human leukemic cancer 
cells (Hsieh et al., 2013). High glucose promotes mesangial cell proliferation, and 
water extract of Poria cocos Wolf inhibited this activity (Yoon et al., 2013). 
The water extract of Argyreia speciosa Sweet (Convolvulaceae) attenuated ethanol-
induced gastric ulcer in rats, while the ethanol extract exhibited stronger therapeutic 
potency (Motawi et al., 2012). 
 
5.4 Phytochemical analysis  
The labor-intensive bioassay-guided fractionation is a classic approach to 
isolate the active constituents, but only the most active subtractions are generally 
selected for further fractionation steps and subsequent identification of key active 
principles from a given plant. Other active metabolites may thus exist in the active 
species, and several additional fractionation experiments would be necessary to make 
such determinations. The results of this thesis might provide a novel, additional and 
labor saving way to identify active principles that may be missed by the classic 
bioassay-guided fractionation approach; furthermore for more than one selected 
active plant species at a time. 
Using the optimal UPLC–QTOF/MS, representative fingerprints for all HWE 
and EE of the 17 plants were obtained. This generated a matrix of data comprising 
qualitative (relating to phytochemical compounds, notably retention time and 
accurate mass) and quantitative (signal intensities) components. By applying PCA 
and OPLS-DA on these data for the Cree plants, we evaluated their phytochemical 
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profiles in relation to their biologic activity. The results of the thesis uncovered 
significant differences in the chemical composition of the HWE of plants with 
glucose transport stimulating effects versus inactive plants. This also held true for the 
EE of active versus inactive plants inducing adipogenesis; especially when plant 
species were segregated by their botanical family. Notably, two compounds were 
identified as possessing strong potential to be responsible for the biological activity 
of three active HWE, due to their highest contribution to first separation of clustering. 
One of these, quercetin-3-O-galactoside, was previously identified by our team 
through the classical bioassay-guided fractionation approach and was confirmed to be 
one of the active principles capable of enhancing glucose transport in C2C12 through 
the activation of AMPK (Eid et al.; Muhammad et al., 2012). The second antidiabetic 
compound putatively identified as quercetin 3-O-α-L-arabinopyranoside, has not 
been isolated in prior bioassay-guided fractionation studies by our group or 
associated with this biological activity by others. Hence, other active metabolites may 
exist in the active species and quercetin 3-O-α-L-arabinopyranoside may thus 
contribute to the antidiabetic potential of some CEI plant species. Future studies will 
be needed to carefully assess the biological activity of this compound in the context 
of glucose metabolism and diabetes. 
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Chapter 6: Conclusion and perspective  
The results of this thesis showed that active principles were successfully 
isolated form L. laricina by adipogenesis-guided fractionation and the antidiabetic 
activity, as well as cellular and molecular mechanism of ethanol and hot water 
extracts of 17 Cree plants were evaluated and compared. 
For the fractionation of L. laricina, we isolated several known compounds and 
identified a new active cycloartane triterpene, which strongly enhanced adipogenesis 
in 3T3-L1 cells and was partly responsible for the adipogenic (potentially glitazone-
like insulin sensitizing) activity of the ethanol extract of the bark of L. laricina. 
As discussed in the first article, we hypothesize that a synergistic relationship 
might exist between the isolated compounds that could contribute to the activity of 
the crude extract and to the most active fraction LLE-5. Firstly, the maximal effect of 
this triterpenoid was still less than the most active fraction LLE-5. Secondly, the 
expected activity of the new triterpenoid at the concentration found in LLE-5 only 
accounts for about two thirds of its adipogenic activity. So future work will be 
necessary to search for the synergy effects of these isolated compounds from L. 
laricina.  
Then, in vivo mice model could be used to evaluate the antidiabetic effect of 
the active compound or combination of the active compounds, particularly, reduction 
of glycemia or improvement of insulin resistance. 
We also evaluated the antidiabetic activity and mechanism of the actions of 
ethanol and hot water extracts of 17 Cree plants on lipid and glucose homeostasis in 
vitro. For the adipocyte lipid metabolism, the results confirmed that several EE 
potentiated adipocyte differentiation and adipogenesis, whereas 2 inhibited the same. 
For the glucose homeostasis, results showed that several EE stimulated muscle 
glucose uptake and inhibited hepatic G6Pase activity. Generally, corresponding HWE 
maintained, or exhibited partial or complete loss of such antidiabetic activity in 
comparison to EE. Only one plant (R.groenlandicum) retained similar potential 
between EE and HWE in the glucose metabolism assays.  
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Targeting phosphorylation of AMPK and/or Akt or activation of PPAR γ 
appears to be involved in the mechanism of the active plant species. Indeed, by both 
ethanol and hot water extractions, R. groenlandicum potentiated adipogenesis by 
increasing PPARγ, SREBP-1 and C/EBPα; S. purpurea stimulated glucose uptake in 
C2C12 cells by increasing GLUT4 protein content and activating phosphorylation of 
AMPK (for EE) or Akt (for HWE); K. angustifolia suppressed the hepatic G6Pase 
activity by activating phosphorylation of AMPK and Akt. 
As we discussed previously, to confirm potentially higher biological activities 
of HWE, future studies should use wide ranges of extract concentrations to obtain a 
clearer picture of their full pharmacological potential. Similarly, actual medicinal 
plant recipes prepared by Aboriginal healers according to their traditions should be 
studied in the laboratory and compared with those prepared in the laboratory. 
Finally, by applying PCA and OPLS-DA, we compared the chemical 
composition of some plants. For lipid metabolism part, we uncovered clustering of 
active versus inactive species, notably when segregation by plant family was applied. 
This confirmed significant differences in the chemical profiles of these groups. This 
also suggests that certain compounds or groups thereof may be common to several 
Boreal plant species and underlie some of the potential antidiabetic effects reported 
herein. Indeed, the PCA and OPLS-DA approach enabled us to identify two such 
biomarkers in the HWE of species stimulating muscle cell glucose transport; notably, 
quercetin 3-O-α-L-arabinopyranoside for which our work represents a novel finding. 
Future discriminant analysis should similarly be applied to active and inactive EE 
plants in adipogenesis to identify other biomarkers. Our work supports the notion that 
PCA and OPLS-DA represent a novel and powerful tool to complement the classic 
bioassay-guided fractionation. 
In conclusion, we isolated several known compounds and identified a new 
active triterpene through fractionation of L. laricina. This thesis further provides 
direct evidence for insulin-like or insulin-sensitizing actions of ethanol and/or hot 
water extracts of CEI plants extract at the level of muscle, liver and adipose tissue. 
Part of their action may be related to stimulation of insulin-dependent and -
independent intracellular signaling pathways, as well as to PPARγ activation. Our 
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results indicate that plant species, target tissues or cells, as well as extraction methods 
are all significant determinants of the biological activity of Cree medicinal plants on 
glucose and lipid metabolism.  
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